日本臨牀　65/増刊10　前立腺癌

出版社： 日本臨牀社
発行日： 2007-12-28
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 前立腺癌―基礎・臨床研究のアップデート
電子書籍版： 2007-12-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

14,520 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

14,520 円(税込)

購入する

目次

  • 日本臨牀　65/増刊10　前立腺癌

    ―目次―

    特集　前立腺癌―基礎・臨床研究のアップデート

    ?． 基礎研究 　 　
    　１． 総　論 　 　
    　２． 病　理 　 　
    　３． 発症と予防 　 　
    　４． 遺伝子 　 　
    　５． アンドロゲン非依存性進展 　 　
    　６． バイオマーカー 　 　
    　７． ホルモン抵抗性癌に対する新戦略 　 　

    II． 臨床研究 　 　
    　１． 疫　学 　 　
    　２． 検　診 　 　
    　３． 診　断 　 　
    　４． 治　療 　 　
    　５． 特　論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 基礎研究

P.12 掲載の参考文献
1) Gregory CW, et al : Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61 : 2892-2898, 2001.
PubMed
2) Visakorpi T, et al : In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9 : 401-406, 1995.
PubMed
3) Gaddipati JP, et al : Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54 : 2861-2864, 1994.
PubMed
4) Tricoli J, et al : Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 54 : 178-182, 1999.
PubMed
5) Kibel AS, et al : Loss of heterozygosity at 12p12-13 in primary and metastatic prostate adenocarcinoma. J Urol 164 : 192-196, 2000.
PubMed
6) Yang RM, et al : Low p27 expression predicts poor disease-free survival in patients with prostate caner. J Urol 159 : 941-945, 1998.
 
7) Wang MC, et al : Purification of a human prostate specific antigen. Invest Urol 17 : 159-163, 1979.
PubMed
8) Gutman EB, et al : Am J Cancer 28 : 485-495, 1936.
 
9) Schulman S, et al : J Immunol 93 : 474-480, 1964.
 
10) 原三郎ほか : 日法医誌 26 : 81-84, 1972.
 
11) Haese A, et al : Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 170 : 2269-2273, 2003.
PubMed
12) Gu Z, et al : Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19 : 1288-1296, 2000.
 
13) Ayala G, et al : The prolyl isomerase Pin 1 is a novel prognostic marker in human prostate cancer. Cancer Res 63 : 6244-6251, 2003.
 
14) Hagisawa S, et al : Expression of core 2 β1, 6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology 15 : 1016-1024, 2005.
 
15) Uemura H, et al : Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 10 : 405-410, 2005.
PubMed
P.17 掲載の参考文献
1) 原田昌興 : 前立腺癌の病理診断. 診断病理 17 : 338-344, 2000.
Medical*Online
2) Iczkowski KA, et al : Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies : clinical significance in 33 cases. Am J Surg Pathol 21 : 1489-1495, 1997.
PubMed
3) Haggman MJ, et al : The relationship between prostatic intraepithelial neoplasia and prostate cancer : critical issues. J Urol 158 : 12-22, 1997.
PubMed
4) De Marzo AM, et al : Inflammation in prostate carcinogenesis. Nat Rev Cancer 7 : 256-269, 2007.
PubMed
5) 原田昌興 : 前立腺癌. 病態から見た病理分類. 臨床泌尿器科 50 (増刊号 4) : 153-159, 1996.
 
6) Ro JY, et al : Prostatic duct adenocarcinoma with endometrioid features : immunohistochemical and electron microscopic studies. Semin Diagn Pathol 5 : 301-311, 1988.
PubMed
7) 原田昌興 : 前立腺に発生する神経内分泌腫瘍. 病理と臨床 17 : 1269-1273, 1999.
Medical*Online
8) 原田昌興 : 前立腺癌. 病理・病期. 病理組織学的分類. 日本臨牀 60 (増刊号 11) : 76-81, 2002.
 
9) Gleason DF, VACURG : Histologic grading and clinical staging of prostatic carcinoma. In : Urologic Pathology : The Prostate (ed by Tannenbaum M), p 171-197, Lea & Febiger, Philadelphia, 1977.
 
10) 日本泌尿器科学会, 日本病理学会 (編) : 前立腺癌取扱い規約, 第3版, 金原出版, 2001.
 
11) 原田昌興 : 前立腺癌の組織学的分類-Gleason分類の意義-. 病理と臨床 16 : 1381-1386, 1998.
Medical*Online
12) Gleason DF : Histologic grading of prostate cancer : A perspective. Hum Pathol 23 : 273-279, 1992.
PubMed
13) Epstein JL et al : The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29 : 1228-1242, 2005.
 
14) Kubota Y, et al : Do the worst histological elements in needle biopsy specimens of prostate cancer predict prognosis? Lancet 348 : 822-823, 1996.
PubMed
15) Mostofi FK, et al : Histological typing of prostate tumours. In : WHO International Histological Classification of Tumours, 2nd ed, Springer-Verlag, Berlin, 2002.
 
P.23 掲載の参考文献
1) 小西登ほか : 前立腺癌の多様性-特に分子的観点から. 病理と臨床 16 : 1387-1393, 1998.
Medical*Online
2) 日本泌尿器科学会・日本病理学会 (編) : 前立腺癌取扱い規約, 第3版, 全原出版, 1992.
 
3) Gleason DF, Mellinger GT, and the Veterans Administration Cooperative Urological Research Group : Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 : 58-64, 1974.
 
4) Eble JN, et al : World Health Organization Classification of tumours. In : Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs, IARC Press, Lyon, 2004.
 
5) Mostofi FK, et al : Histological typing of prostate tumors. In : World Health Organization International Histological Classification of Tumours, 2nd ed, Springer-Verlag, Berlin, 2002.
 
6) Partin AW, et al : Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 : 1445-1451, 1997.
PubMed
7) Epstein JI, et al : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 : 368-374, 1994.
PubMed
8) 原田昌興 : 病理組織学的分類. 日本臨牀 60 (増刊号11) : 76-81, 2002.
Medical*Online
9) Masuda M, et al : The worst histologic elements predict prognosis in moderately-differentiated prostate cancer patients with androgen-withdrawal endocrine therapy. Eur Urol 36 : 197-202, 1999.
PubMed
10) Shimada K, et al : Phosphorylation status of Fas-associated death domain containing protein (FADD) is associated with prostate cancer progression. J Pathol 206 : 423-432, 2005.
PubMed
11) Kronz JD, et al : High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Hum Pathol 32 : 389-395, 2001.
PubMed
12) De Marzo AM, et al : Proliferative inflammatory atrophy of the prostate : implications for prostatic carcinogenesis. Am J pathol 155 : 1985-1992, 1999.
PubMed
13) 筧善行 : T1c前立腺癌に対する待機療法の現状と展望. Urology View 1 : 82-87, 2003.
Medical*Online
14) 小西登 : 前立腺癌の病理から何を学ぶか, 全摘標本の組織学的検索. 泌尿器外科 13 : 143-146, 2000.
 
15) Kunz GM Jr, Epstein JI : Should each core with prostate cancer be assigned a separate Gleason score? Hum Pathol 34 : 911-914, 2003.
PubMed
P.28 掲載の参考文献
1) Egevad L, et al : Current practice of Gleason grading among genitourinary pathologists. Hum Pathol 36 : 5-9, 2005.
PubMed
2) Epstein JI, et al ; ISUP Grading Committee : The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29 : 1228-1242, 2005.
 
3) 原田昌興 : 前立腺癌の組織学的分類-Gleason分類の意義-. 病理と臨床 16 : 1381-1386, 1998.
Medical*Online
4) Allsbrook WC, et al : Intraobserver reproducibility of Gleason grading of prostatic carcinoma : general pathologist. Hum Pathol 32 : 81-88, 2001.
 
5) Mikami Y, et al : Accuracy of gleason grading by practicing pathologists and the impact of education on improving agreement. Hum Pathol 34 : 658-665, 2003.
PubMed
6) Oyama T, et al : A comparison of interobserver reproducibility of Gleason grading of prostattic carcinoma in Japan and the United States. Arch Pathol Lab Med 29 : 1004-1010, 2005.
 
7) Epstein JI : Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy : adiagnosis that should not be made. Am J Surg Pathol 24 : 477-478, 2000.
 
8) Kronz JD, et al : Atypical cribriform lesions on prostate biopsy. Am J Surg Pathol 25 : 147-155, 2001.
PubMed
9) Fine SW, Epstein JI : Minute foci of Gleason score 8-10 on prostatic needle biopsy : a morphologic analysis. Am J Surg Pathol 29 : 962-968, 2005.
PubMed
10) Glaessgen A, et al : Interobserver reproducibility of percent Gleason grade 4/5 in prostate biopsies. J Urol 171 : 664-667, 2004.
PubMed
11) 日本泌尿器科学会・日本病理学会 (編) : 前立腺癌取扱い規約, 第3版, 金原出版, 2001.
 
12) Young RH, et al : Tumor of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis, Armed Forces Institute of Pathology, Washington D. C., 2000.
 
13) Epstein JI, Ximing JY : Prostate Biopsy Interpretation, 3rd ed, Lippincott Williams & Wilkins, Philadelphia, 2002.
 
14) Amin MB, et al : Gleason Grading of Prostate Cancer : A Contemporary Approach, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
15) Eble JN, et al : World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs, IARC Press, Lyon, 2004.
 
P.34 掲載の参考文献
1) McNeal JE, Bostwick DG : Intraductal dysplasia : a premalignant lesion of the prostate. Hum Pathol 17 : 64-71, 1986.
PubMed
2) Bostwick DG, Qian J : High-grade prostatic intraepithelial neoplasia. Mod Pathol 17 : 360-379, 2004.
PubMed
3) Nelson WG, et al : Prostate cancer. N Engl J Med 349 : 366-381, 2003.
PubMed
4) Iczkowski KA, et al : Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies : clinical significance in 33 cases. Am J Surg Pathol 21 : 1489-1495, 1997.
PubMed
5) Schlesinger C, et al : High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation : predictive value for cancer in current practice. Am J Surg Pathol 29 : 1201-1207, 2005.
PubMed
6) Borboroglu PG, et al : Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol 166 : 866-870, 2001.
PubMed
7) Iczkowski KA : Current prostate biopsy interpretation : criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med 130 : 835-843, 2006.
PubMed
8) Chan TY, Epstein JI : Patient and urologist driven second opinion of prostate needle biopsies. J Urol 174 : 1390-1394, 2005.
PubMed
9) Epstein JI : Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 17 : 307-315, 2004.
PubMed
10) Haggman MJ, et al : The relationship between prostatic intraepithelial neoplasia and prostate cancer : critical issues. J Urol 158 : 12-22, 1997.
PubMed
11) Epstein JI, Herawi M : Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma : implications for patient care. J Urol 175 : 820-834, 2006.
PubMed
12) Bostwick DG, Meiers I : Atypical small acinar proliferation in the prostate : clinical significance in 2006. Arch Pathol Lab Med 130 : 952-957, 2006.
PubMed
13) Girasole CR, et al : Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy : implications for cancer detection and biopsy strategy. J Urol 175 : 929-933, 2006.
PubMed
14) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン2006年版, p51-52, 金原出版, 2006.
 
15) Carver BS, et al : Race is not a predictor of prostate cancer detection on repeat prostate biopsy. J Urol 172 : 1853-1855, 2004.
 
P.41 掲載の参考文献
1) Giovannucci E, Platz EA : Epidemiology of prostate cancer. In : Comprehensive Textbook of Genitourinary Oncology, 3rd ed (ed by Vogelzang NJ, et al), p9-21, Lippincott Williams & Wilkins, Baltimore, 2005.
 
2) Habuchi T : Common genetic polymorphisms and prognosis of sporadic cancers : prostate cancer as a model. Future Oncol 2 : 233-245, 2006.
 
3) Rubin MA, De Marzo AM : Molecular genetics of human prostate cancer. Mod Pathol 17 : 380-388, 2004.
PubMed
4) Bott SR, et al : Molecular changes in prostatic cancer. Surg Oncol 14 : 91-104, 2005.
PubMed
5) Bradford TJ, et al : Molecular markers of prostate cancer. Urol Oncol 24 : 538-551, 2006.
PubMed
P.47 掲載の参考文献
1) Thompson IM, et al : The influence of finasteride on the development of prostate cancer. N Engl J Med 349 : 215-224, 2003.
PubMed
2) Sugimura Y, et al : Morphogenesis of ductal networks in the mouse prostate. Biol Reprod 34 : 961-971, 1986.
PubMed
3) Cunha GR, et al : Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92 : 221-236, 2004.
PubMed
4) Bosland MC : Sex steroids and prostate carcinogenesis : integrated, multifactorial working hypothesis. Ann NY Acad Sci 1089 : 168-176, 2006.
PubMed
5) Raynaud JP : Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 102 : 261-266, 2006.
 
6) McPherson SJ, et al : Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142 : 2458-2467, 2001.
 
7) Li X, et al : Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase. Endocrinology 142 : 2435-2442, 2001.
PubMed
8) Liehr JG : Role of DNA adducts in hormonal carcinogenesis. Regul Toxicol Pharmacol 32 : 276-282, 2000.
PubMed
9) Platz EA, Giovannucci E : The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92 : 237-253, 2004.
PubMed
10) Bosland MC : The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 27 : 39-66, 2000.
PubMed
11) Hankin JH, et al : Attributable risk of breast, prostate, and lung cancer in Hawaii due to saturated fat. Cancer Causes Control 3 : 17-23, 1992.
PubMed
12) Dorgan JF, et al : Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men : a controlled feeding study. Am J Clin Nutr 64 : 850-855, 1996.
 
13) Schmid HP, et al : Prevention of prostate cancer : more questions than data. Recent Results Cancer Res 174 : 101-107, 2007.
PubMed
14) Williams SA, et al : Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 67 : 312-329, 2007.
 
15) Nakayama M, et al : Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate : a detailed study using laser-capture microdissection. Am J Pathol 163 : 923-933, 2003.
PubMed
16) De Marzo AM, et al : Proliferative inflammatory atrophy of the prostate : implications for prostatic carcinogenesis. Am J pathol 155 : 1985-1992, 1999.
PubMed
17) Wilson MJ, et al : Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat. Exp Mol Pathol 77 : 7-17, 2004.
PubMed
P.52 掲載の参考文献
1) Fleshner N, et al : Dietary fat and prostate cancer. J Urol 171 : S19-S24, 2004.
PubMed
2) Gann PH, et al : Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 : 1118-1126, 1996.
PubMed
3) Zhou JR, Blackbum GL : Bridging animal and human studies : what are the missing segments in dietary fat and prostate cancer? Am J Clin Nutr 66 : 1572S-1580S, 1997.
 
4) Whittemore AS, et al : Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87 : 652-661, 1995.
 
5) Terry P, et al : Fatty fish consumption and risk of prostate cancer. Lancet 357 : 1764-1766, 2001.
PubMed
6) Platz EA, et al : Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 63 : 8542-8548, 2003.
 
7) Freedland SJ, et al : Body mass index as a predictor of prostate cancer : development versus detection on biopsy. Urology 66 : 108-113, 2005.
PubMed
8) Key TJ, et al : Fruits and vegetables and prostate cancer : no association among 1,104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 109 : 119-124, 2004.
 
9) World Cancer Research Fund and American Institute for Cancer Research : Food, Nutrition and the Prevention of Cancer : a Global Perspective, p 216-251, American Institute for Cancer Research, Washington DC, 1997.
 
10) National Cancer Institute (http://www.cancer.gov/).
 
11) Giovannucci E, et al : Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87 : 1767-1776, 1995.
PubMed
12) Kristal AR, Cohen JH : Invited commentary : tomatoes, lycopene, and prostate cancer. How strong is the evidence? Am J Epidemiol 151 : 124-127, 2000.
PubMed
13) Gann PH, et al : Lower prostate cancer risk in men with elevated plasma lycopene levels : results of a prospective analysis. Cancer Res 59 : 1225-1230, 1999.
PubMed
14) The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group : The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 : 1029-1035, 1994.
 
15) Clark LC, et al : Decreased incidence of prostate cancer with selenium supplementation : results of a double-blind cancer prevention trial. Br J Urol 81 : 730-734, 1998.
PubMed
16) Clark LC, et al : Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 : 1957-1963, 1996.
 
17) Klein EA, et al : SELECT : the selenium and vitamin E cancer prevention trial. Urol Oncol 21 : 59-65, 2003.
PubMed
18) Tseng M, et al : Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 81 : 1147-1154, 2005.
PubMed
19) Messina M, et al : Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 55 : 1-12, 2006.
PubMed
20) Kurahashi N, et al ; Japan Public Health Center-Based Prospective Study Group : Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 16 : 538-545, 2007.
PubMed
21) Akaza H, et al : Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 32 : 296-300, 2002.
PubMed
22) Akaza H, et al : Comparisons of percent equol producers between prostate cancer patients and controls : case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 34 : 86-89, 2004.
PubMed
23) Lund TD, et al : Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 70 : 1188-1195, 2004.
PubMed
24) Gupta S, et al : Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98 : 10350-10355, 2001.
PubMed
25) Brusselmans K, et al : Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 106 : 856-862, 2003.
PubMed
26) Bettuzzi S, et al : Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia : a preliminary report from a one-year proof-of-principle study. Cancer Res 66 : 1234-1240, 2006.
PubMed
27) 岩崎基, 津金昌一郎 : 前立腺癌予防の取り組みについて. 日本臨牀 63 : 321-326, 2005.
Medical*Online
P.59 掲載の参考文献
1) Thompson IM, et al : Prevalence of prostate cancer among men with a prostate-specific antigen level <- 4.0ng per milliliter. N Engl J Med 350 : 2239-2246, 2004.
 
2) D'Amico AV, et al : Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 : 125-135, 2004.
PubMed
3) Jiang Z, et al : Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues : A study of 761 cases. Hum Pathol 34 (8) : 792-796, 2003.
PubMed
4) Paul B, et al : Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 65 (10) : 4097-4100, 2005.
PubMed
5) Xu J, et al : Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer hsk. Nat Genet 32 : 321-325, 2002.
 
6) Tsuchiya N, et al : Impact of IGF-I and CYP-19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24 (13) : 1972-1974, 2006.
 
7) Gudmundsson J, et al : Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39 (5) : 631-637, 2007.
PubMed
8) Haiman CA, et al : Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39 (5) : 638-644, 2007.
PubMed
9) Yeager M, et al : Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39 (5) : 645-649, 2007.
PubMed
10) Suzuki H, et al : Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58 : 204-209, 1998.
PubMed
11) Suzuki H, et al : Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Prostate 28 : 318-324, 1996.
PubMed
12) Sato K, et al : Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 91 : 1574-1580, 1999.
PubMed
13) Debes JD, et al : Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 : 1488-1490, 2004.
PubMed
14) Suzuki H, et al : Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46 : 759-765, 1993.
PubMed
15) Suzuki H, et al : Codon 877 mutation in the androgen receptor gene in advanced prostate cancer : relation to antiandrogen withdrawal syndrome. Prostate 29 (3) : 153-158, 1996.
PubMed
16) Deeble PD, et al : Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 67 (8) : 3663-3672, 2007.
PubMed
17) Palayoor ST, et al : Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2. Clin Cancer Res 11 (19 Pt 1) : 6980-6986, 2005.
 
18) Svensson Jp, et al : Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med 3 (10) : e440, 2006.
 
19) Li Yu, et al : Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 4 (3) : 389-398, 2005.
 
20) Yoshino T, et al : Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12 (20 Pt 1) : 6116-6124, 2006.
 
P.64 掲載の参考文献
1) Saunders MA, et al : Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA 104 : 3300-3305, 2007.
PubMed
2) Kimchi-Sarfaty C, et al : A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 : 525-528, 2007.
PubMed
3) Tuzun E, et al : Fine-scale structural variation of the human genome. Nat Genet 37 : 727-732, 2005.
PubMed
4) van der Poel HG : Molecular markers in the diagnosis of prostate cancer. Crit Rev Oncol Hematol 61 : 104-139, 2007.
PubMed
5) Hsing AW, et al : Polymorphic markers in the SRD5A2 gene and prostate cancer risk : a population-based case-control study. Cancer Epidemiol Biomarkers Prev 10 : 1077-1082, 2001.
 
6) Haiman CA, et al : Atetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87 : 204-210, 2000.
PubMed
7) Tsuchiya N, et al : Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24 : 1982-1989, 2006.
PubMed
8) Schildkraut JM, et al : IGF1 (CA) 19 repeat and IGFBP3-202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 14 : 403-408, 2005.
 
9) Tsuchiya N, et al : CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol 26 : 225-231, 2005.
PubMed
10) Kanety H, et al : Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer : correlation with serum prostate-specinc antigen. J Clin Endocrinol Metab 77 : 229-233, 1993.
 
11) Wang L, et al : Insulin-like groWth factor-binding protein-3 gene-202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 63 : 4407-4411, 2003.
 
12) Suzuki H, et al : CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients : potential predictor of prognosis after endocrine therapy. Prostate 51 : 219-224, 2002.
PubMed
13) Habuchi T, et al : Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 60 : 305-308, 2000.
 
14) Wang L, et al : Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 103 : 116-120, 2003.
PubMed
15) Cramer SD, et al : Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels, J Natl Cancer Inst 95 : 1044-1053, 2003.
 
P.68 掲載の参考文献
1) Kononen J, et al : Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 : 844-847, 1998.
PubMed
2) Shergill IS, et al : Tissue microarrays and their relevance to the urologist. J Urol 175 : 19-26, 2006.
 
3) Bubendorf L : High-throughput microarray technologies : from genomics to clinics. Eur Urol 40 : 231-238, 2001.
PubMed
4) Schraml P, et al : Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5 : 1966-1975, 1999.
PubMed
5) Richter J, et al : High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J pathol 157 : 787-794, 2000.
PubMed
6) Rubin MA, et al : Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26 : 312-319, 2002.
PubMed
7) Went PT, et al : Prevalence of KIT expression in human tumors. J Clin Oncol 22 : 4514-4522, 2004.
PubMed
8) Varambally S, et al : The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 : 624-629, 2002.
PubMed
9) Bowen C, et al : Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60 : 6111-6115, 2000.
PubMed
10) Kajdacsy-Balla A, et al : Practical aspects of planning, building, and interpreting tissue microarrays : The Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 38 : 113-121, 2007.
PubMed
11) Inoue T, et al : Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66 : 332-337, 2005.
PubMed
12) Inoue T, et al : High-grade and homone-treated prostate cancer express high levels of thymidylate synthase. BJU Int 98 : 197-200, 2006.
 
13) Shimizu Y, et al : Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 100 : 685-690, 2007.
PubMed
14) Giltnane JM, Rimm DL : Technology insight : Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 1 : 104-111, 2004.
PubMed
P.71 掲載の参考文献
1) Grignon DJ, et al : p53 status and prognosis of locally advanced prostatic adenocarcinoma : a study based on RTOG 8610. J Natl Cancer Inst 89 : 158-165, 1997.
PubMed
2) Bookstein R : Tumor suppressor genes in prostatic oncogenesis. J Cell Biochem Suppl 71 : 217-223, 1993.
 
3) Zhou Z, et al : Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66 : 7889-7898, 2006.
 
4) Wang H, et al : Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model. Urology 68 : 674-681, 2006.
 
5) Konishi N, et al : Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn J Cancer Res 84 (10) : 1050-1054, 1993.
PubMed
6) Dong JT : Prevalent mutations in prostate cancer. J Cell Biochem 97 : 433-447, 2006.
PubMed
7) Tsihlias J, et al : Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58 : 542-548, 1998.
PubMed
8) Kibel AS, et al : CDKNIA and CDKNIB polymorphisms and risk of advanced prostate carcinoma. Cancer Res 63 : 2033-2036, 2003.
 
9) Narla G, et al : A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65 : 1213-1222, 2005.
PubMed
10) Srivastava M, et al : Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7 (+/-) mouse. Proc Natl Acad Sci USA 61 : 14287-14292, 2003.
 
11) Sun X, et al : Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 37 : 407-412, 2005.
PubMed
12) Thompson D, Easton DF : Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 31 : 1358-1365, 2002.
 
13) Edwards SM, et al : Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72 : 1-12, 2003.
PubMed
14) Huusko P, et al : Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36 : 979-983, 2004.
PubMed
15) Ueda T, et al : Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J pathol 149 : 1435-1440, 1996.
PubMed
P.77 掲載の参考文献
1) Russell PJ, Kingsley EA : Human prostate cancer cell lines. Methods Mol Med 81 : 21-39, 2003.
PubMed
2) Sobel RE, Sadar MD : Cell lines used in prostate cancer research : a compendium of old and new lines-part 1. J Urol 173 : 342-359, 2005.
PubMed
3) Sobel RE, Sadar MD : Cell lines used in prostate cancer research : a compendium of old and new lines-part 2. J Urol 173 : 360-372, 2005.
PubMed
4) van Weerden WM, Romijn JC : Use of nude mouse xenograft models in prostate cancer research. Prostate 43 : 263-271, 2000.
PubMed
5) Russell PJ, Voeks DJ : Animal models of prostate cancer. Methods Mol Med 81 : 89-112, 2003.
PubMed
6) Nelson WG, et al : Prostate cancer. N Engl J Med 349 : 366-381, 2003.
PubMed
7) Feinberg AP, et al : The epigenetic progenitor origin of human cancer. Nat Rev Genet 7 : 21-33, 2006.
PubMed
8) Henrique R, et al : Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia : clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4 : 1-8, 2006.
PubMed
9) Yegnasubramanian S, et al : Hypemethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64 : 1975-1986, 2004.
 
10) Shiina H, et al : Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 65 : 2130-2138, 2005.
PubMed
11) Hyytinen ER, et al : Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 75 : 190-195, 1997.
 
12) Kochera M, et al : Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors. Prostate 41 : 7-11, 1999.
PubMed
13) Cher ML, et al : Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56 : 3091-3102, 1996.
PubMed
14) Sato N, et al : Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 58 : 139-146, 1996.
 
15) Taplin ME, et al : Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59 : 2511-2515, 1999.
PubMed
16) Hara T, et al : Novel mutations of androgen receptor : a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63 : 149-153, 2003.
PubMed
17) Marcelli M, et al : Androgen receptor mutations in prostate cancer. Cancer Res 60 : 944-949, 2000.
PubMed
18) Zhu P, et al : Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124 : 615-629, 2006.
PubMed
19) Craft N, et al : Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59 : 5030-5036, 1999.
PubMed
20) Feldman BJ, Feldman D : The development of androgen-independent prostate cancer. Nat Rev Cancer 1 : 34-45, 2001.
PubMed
21) Guo Z, et al : Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10 : 309-319, 2006.
PubMed
22) Chen CD, et al : Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 : 33-39, 2004.
PubMed
23) Yoshida T, et al : Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65 : 9611-9616, 2005.
 
24) Wen Y, et al : HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60 : 6841-6845, 2000.
PubMed
25) Yeh S, et al : From HER2/Neu signal cascade to androgen receptor and its coactivators : a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96 : 5458-5463, 1999.
PubMed
26) Craft N, et al : A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 : 280-285, 1999.
 
27) Lee LF, et al : Neuropeptide-induced androgen independence in prostate cancer cells : roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 21 : 8385-8397, 2001.
PubMed
28) McDonnell TJ, et al : Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52 : 6940-6944, 1992.
PubMed
29) Gleave M, et al : Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5 : 2891-2898, 1999.
PubMed
30) Horie-Inoue K, et al : Identification and functional analysis of consensus androgen response elements in human prostate cancer cells. Biochem Biophys Res Commun 325 : 1312-1317, 2004.
PubMed
31) Migliaccio A, et al : Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19 : 5406-5417, 2000.
 
32) Unni E, et al : Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64 : 7156-7168, 2004.
PubMed
P.84 掲載の参考文献
1) 小宮顕ほか : アンドロゲン受容体. 日本臨牀 63 (増刊号 8) : 476-480, 2005.
 
2) Chang CS, et al : Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240 (4850) : 324-326, 1988.
PubMed
3) 島崎淳 : アンドロゲンの立場から. 第2回性差医学シンポジウム別冊, III. 性ホルモンと受容体, p117-129, 1993.
 
4) Masai M, et al : Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 17 (4) : 293-300, 1990.
PubMed
5) 小宮顕ほか : アンドロゲン作用の分子機序と泌尿器科疾患. Urology View 3 (6) : 21-27, 2005.
Medical*Online
6) Shimbo M, et al : CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. Eur Urol 47 (4) : 557-563, 2005.
PubMed
7) Nakayama T, et al : Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 80 (12) : 1789-1796, 2000.
PubMed
8) Linja MJ, et al : Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61 (9) : 3550-3555, 2001.
PubMed
9) Chen CD, et al : Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (1) : 33-39, 2004.
PubMed
10) Steketee K, et al : Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 100 (3) : 309-317, 2002.
PubMed
11) Sack JS, et al : Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98 (9) : 4904-4909, 2001.
PubMed
12) http://androgendbmcgill.ca/data.htm
 
13) Sun C, et al : Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 25 (28) : 3905-3913, 2006.
PubMed
14) Ueda T, et al : Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277 (9) : 7076-7085, 2002.
PubMed
15) Akakura K, et al : Possible mechanism of dexamethasone therapy for prostate cancer : suppression of circulating level of interleukin-6. Prostate 56 (2) : 106-109, 2003.
PubMed
P.89 掲載の参考文献
1) Miyoshi Y, et al : Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 43 : 225-232, 2000.
PubMed
2) Culig Z, et al : Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92 : 265-271, 2004.
PubMed
3) Rahman M, et al : Androgen receptor coregulators in prostate cancer : mechanisms and clinical implications. Clin Cancer Res 10 : 2208-2219, 2004.
PubMed
4) Miyoshi Y, et al : Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 56 : 280-286, 2003.
PubMed
5) Miyamoto H, et al : Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 95 : 11083-11088, 1998.
PubMed
6) Chen F, et al : Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta, 17beta-diol. J Steroid Biochem Mol Biol 91 : 247-257, 2004.
PubMed
7) Comuzzi B, et al : The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204 : 159-166, 2004.
PubMed
8) Debes JD, et al : p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65 : 5965-5973, 2005.
PubMed
9) Zhou HJ, et al : SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65 : 7976-7983, 2005.
PubMed
10) Fujimoto N, et al : Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 274 : 8316-8321, 1999.
PubMed
11) Kang HY, et al : Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274 : 8570-8576, 1999.
PubMed
12) Ngan ES, et al : Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 22 : 734-739, 2003.
PubMed
13) Halkidou K, et al : Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22 : 2466-2477, 2003.
PubMed
14) Nishimura K, et al : Modulation of androgen receptor transactivation by gelsolin : a newly identified androgen receptor coregulator. Cancer Res 63 : 4888-4894, 2003.
PubMed
P.94 掲載の参考文献
1) Akaza H, et al : Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer : interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 34 : 20-28, 2004.
PubMed
2) Prostate Cancer Trialistsg Collaborative Group : Maximum androgen blockade in advanced prostate cancer : an overview of the randomised trials. Lancet 355 : 1491-1498, 2000.
 
3) Caubet JF, et al : Maximum androgen blockade in advanced prostate cancer : a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49 : 71-78, 1997.
PubMed
4) Lam JS, et al : Secondary hormonal therapy for advanced prostate cancer. J Urol 175 : 27-34, 2006.
PubMed
5) Ryan CJ, et al : Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawa1 : results from a cancer and leukemia group B study. Clin Cancer Res 13 : 2030-2037, 2007.
 
6) Mitamura K, et al : Identification of dehydroepiandrosterone metabolites formed from human prostate homogenate using liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry. J Chromatogr A 961 : 97-105, 2002.
PubMed
7) Mizokami A, et al : The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64 : 765-771, 2004.
PubMed
8) Nishiyama T, et al : The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10 : 7121-7126, 2004.
 
9) Koh E, et al : Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 : 154-159, 2002.
PubMed
10) Harada S, et al : Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 46 : 319-326, 2001.
PubMed
11) Fujimoto N, et al : Different expression of androgen receptor coactivators in human prostate. Urology 58 : 289-294, 2001.
PubMed
P.98 掲載の参考文献
1) Miyake H, et al : Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int J Urol 8 : 337-349, 2001.
PubMed
2) Gleave M, et al : Antisense targets to enhance homlone and cytoxic therapies in advanced prostate cancer. Curr Drug Targets 4 : 209-221, 2003.
 
3) McDonnell TJ, et al : Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52 : 6940-6944, 1992.
PubMed
4) Raffo AJ, et al : Overexpression of bc1-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55 : 4438-4445, 1995.
 
5) Miyake H, et al : Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 59 : 4030-4034, 1999.
PubMed
6) Miyake H, et al : Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 92 : 34-41, 2000.
 
7) Miyake H, et al : Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense Bcl-xL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 86 : 855-862, 2000.
PubMed
8) Yamanaka K, et al : A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4 : 1689-1698, 2005.
PubMed
9) Jones SE, Jomary C : Clusterin. Int J Biochem Cell Biol 34 : 427-431, 2002.
PubMed
10) Miyake H, et al : Enhanced expression of secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep 14 : 1371-1375, 2005.
PubMed
11) Miyake H, et al : Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60 : 2547-2554, 2000.
PubMed
12) Miyake H, et al : Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60 : 170-176, 2000.
PubMed
13) Kiyama S, et al : Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63 : 3575-3584, 2003.
PubMed
14) Miyake M, et al : Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60 : 3058-3064, 2000.
 
15) Rocchi P, et al : Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 65 : 6595-6602, 2005.
 
P.103 掲載の参考文献
1) Inoue T, et al : The roles of androgen-dependent and-independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Rev Endocrinol Metab, 2007. (in press)
 
2) Li J, et al : PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 : 1943-1947, 1997.
PubMed
3) Liaw D, et al : Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 : 64-67, 1997.
PubMed
4) Steck PA, et al : Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers. Nat Genet 15 : 356-362, 1997.
PubMed
5) Stambolic V, et al : Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 : 29-39, 1998.
PubMed
6) Suzuki H, et al : Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58 : 204-209, 1998.
PubMed
7) Dong JT, et al : Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 7 : 304-308, 2001.
PubMed
8) Wang SI, et al : Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 4 : 811-815, 1998.
 
9) Di Cristofano A, et al : Pten is essential for embryonic development and tumour suppression. Nat Genet 19 : 348-355, 1998.
 
10) Podsypanina K, et al : Mutation of Pten/Mmacl in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96 : 1563-1568, 1999.
 
11) Abate-Shen C, et al : Nkx3.1 ; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63 : 3886-3890, 2003.
PubMed
12) Di Cristofano A, et al : Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27 : 222-224, 2001.
PubMed
13) Vivanco I, Sawyers CL : The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 : 489-501, 2002.
PubMed
14) Malik SN, et al : Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8 : 1168-1171, 2002.
PubMed
15) Liao Y, et al : Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer 107 : 676-680, 2003.
PubMed
16) Ayala G, et al : High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10 : 6572-6578. 2004.
PubMed
17) Kreisberg JI, et al : Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64 : 5232-5236, 2004.
PubMed
18) Shimizu Y, et al : Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese Inen. BJU Int 100 : 685-690, 2007.
 
19) Heinlein CA, Chang C : Androgen receptor in prostate cancer. Endocr Rev 25 : 276-308, 2004.
PubMed
20) Majumder PK, et al : Prostate intraepithelial neoplasia induced by prostate restricted Akt activation : the MPAKT model. Proc Natl Acad Sci USA 100 : 7841-7846, 2003.
PubMed
21) Majumder PK, et al : mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 : 594-601, 2004.
PubMed
22) Migliaccio A, et al : Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19 : 5406-5417, 2000.
 
23) Zhoul J, et al : The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res 65 : 9906-9913, 2005.
PubMed
24) Unni E, et al : Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64 : 7156-7168, 2004.
PubMed
25) Nam S, et al : Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65 : 9185-9189, 2005.
PubMed
26) Guo Z, et al : Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10 : 309-319, 2006.
PubMed
27) Nishizuka Y : Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258 : 607-614, 1992.
PubMed
28) Nishizuka Y : Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9 : 484-496, 1995.
PubMed
29) Koivunen J, et al : Protein kinase C (PKC) family in cancer progression. Cancer Lett 235 : 1-10, 2006.
PubMed
30) Goueli SA : Differential regulation of prostatic protein kinase C isozymes by androgens. FEBS Lett 264 : 53-55, 1990.
PubMed
31) Montalvo L, et al : Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells. Biosci Rep 24 : 11-21, 2004.
PubMed
32) Wu D, et al : Protein kinase Cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 62 : 2423-2429, 2002.
PubMed
33) Wu D, Terrian DM : Regulation of caveolin- 1 expression and secretion by a protein kinase Cepsilon signaling pathway in human prostate cancer cells. J Biol Chem 277 : 40449-40455, 2002.
 
34) Inoue T, et al : Requirement of androgen- dependent activation of protein kinase Czeta for androgendependent cell proliferation in LNCaP cells and its roles in transition to androgen-independent cells. Mol Endocrinol 20 : 3053-3069, 2006.
PubMed
35) Garcia-Cao I, et al : Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 6 : 577-583, 2005.
PubMed
36) Sells SF, et al : Commonality of the gene programs induced by effectors of apoptosis in androgendependent and-independent prostate cells. Cell Growth Differ 5 : 457-466, 1994.
PubMed
37) Sells SF, et al : Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 17 : 3823-3832, 1997.
PubMed
38) Berra E, et al : Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade. Mol Cell Biol 17 : 4346-4354, 1997.
PubMed
P.107 掲載の参考文献
1) Watt KW, et al : Human prostate-specific antigen : structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83 : 3166-3170, 1986.
PubMed
2) Yousef GM, Diamandis EP : An overview of the kallikrein gene families in humans and other species : emerging candidate tumour markers. Clin Biochem 36 : 443-452, 2003.
PubMed
3) Mikolajczyk SD, et al : Free prostate-specific antigen is becoming more complex. Urology 59 : 797-802, 2002.
PubMed
4) Stenman UH, et al : A complex between prostate specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer : assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 : 222-226, 1991.
 
5) Mikolajczyk SD, et al : A precursor form of PSA (ppSA) is a component of the free PSA in prostate cancer serum. Urology 50 : 710-714, 1997.
PubMed
6) Mikolajczyk SD, et al : Atruncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 : 6958-6963, 2001.
 
7) Khan MA, et al : Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0ng/ml. J Urol 170 : 723-726, 2003.
 
8) Sokoll LJ, et al : Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range : preliminary analysis. Urology 61 : 274-276, 2003.
 
9) Pollak M, et al : Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17 : 383-390, 1998-1999.
 
10) Krueckl SL, et al : Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64 : 8620-8629, 2004.
 
11) Hellawell GO, et al : Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62 : 2942-2950, 2002.
PubMed
12) Richardsen E, et al : Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Arch 442 : 329-335, 2003.
PubMed
13) Shariat SF, et al : Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and-3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20 : 833-841. 2002.
PubMed
14) Miyata Y, et al : Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues : correlation with histopathologic effects and biochemical recurrence. Urology 63 : 1184-1190, 2004.
PubMed
15) Miyata Y, et al : Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54 : 125-132, 2003.
PubMed
16) Renehan AG, et al : Insulin-1ike growth factor (IGF)-1, IGF binding protein-3, and cancer risk : systematic review and meta-regression analysis. Lancet 363 : 1346-1353, 2004.
 
17) Cottrell S, et al : Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 177 : 1753-1758, 2007.
PubMed
18) Liu X, et al : Association of testis derived transcript gene variants and prostate cancer risk. J Urol 177 : 894-898, 2007.
 
19) Pookot D, et al : The E-cadherin-160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol 176 : 793-796, 2006. Erratum in : J Urol 176 (4 Pt 1) : 1688, 2006.
 
20) Lundin KB, et al : Frequent finding of the androgen receptor A645D variant in normal population. J Clin Endocrinol Metab 91 : 3228-3231, 2006.
PubMed
21) Goetz MP, et al : Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 : 9312-9318, 2005.
PubMed
22) Banez LL, et al : Proteomics in prostate cancer. Curr Opin Urol 15 : 151-156, 2005.
PubMed
23) Solassol J, et al : Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics 3 : 311-320, 2006.
PubMed
24) Flaig TW, et al : Conference report and review : current status of biomarkers potentially associated with prostate cancer outcomes. J Urol 177 : 1229-1237, 2007.
PubMed
P.111 掲載の参考文献
1) 鈴木啓悦 : 前立腺系統的針生検をめぐる諸問題. 癌と化学療法 30 : 16-20, 2003.
 
2) Suzuki H, et al : Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Prostate 28 : 318-324, 1996.
PubMed
3) Soussi T : p53 antibodies in the sera of patients with various types of cancer : A review. Cancer Res 60 : 1777-1788, 2000.
 
4) Suzuki H, et al : Clinical usefulness of serum anti-p53 antibodies for prostate cancer detection : A comparative study with PSA parameters. J Urol 171 : 182-186, 2004.
 
5) 鈴木啓悦ほか : 前立腺癌に対する新しい腫瘍マーカーの可能性. 泌尿器外科 14 : 461-463, 2001.
Medical*Online
6) Stapleton AM, et al : Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3 : 1389-1397, 1997.
PubMed
7) Inahara M, et al : Clinical evaluation of transrectal power Doppler imaging in the detection of prostate cancer. Int Urol Nephrol 36 : 175-180, 2004.
PubMed
8) Suzuki H, et al : Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 67 : 131-136, 2006.
PubMed
P.115 掲載の参考文献
1) Culig Z, et al : Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95 : 497-505, 2005.
PubMed
2) Ueda T, et al : Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277 : 7076-7085, 2002.
PubMed
3) Hobisch A, et al : Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 191 : 239-244, 2000.
 
4) Lee SO, et al : Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67 : 764-773, 2007.
PubMed
5) Shida Y, et al : p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion. Biochem Biophys Res Commun 353 : 744-749, 2007.
PubMed
6) Nakashima J, et al : Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 : 2702-2706, 2000.
PubMed
7) Drachenberg DE, et al : Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41 : 127-133, 1999.
PubMed
8) Twillie DA, et al : Interleukin-6 : a candidate mediator of human prostate cancer morbidity. Urology 45 : 542-549, 1995.
PubMed
9) George DJ, et al : The prognostic significance of plasma interleukin-61evels in patients with metastatic hormone-refractory prostate cancer : results from cancer and leukemia group B 9480. Clin Cancer Res 11 : 1815-1820, 2005.
 
10) Akakura K, et al : Possible mechanism of dexamethasone therapy for prostate cancer : suppression of circulating level of interleukin-6. Prostate 56 : 106-109, 2003.
PubMed
11) Nishimura K, et al : Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93 : 1739-1746, 2001.
PubMed
12) Tannock IF, et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004.
 
13) Domingo-Domenech J, et al : Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12 : 5578-5586, 2006.
PubMed
14) Kuroda K, et al : Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 69 : 113-117, 2007.
PubMed
P.119 掲載の参考文献
1) Gretzer MB, Partin AW : PSA markers in prostate cancer detection. Urol Clin North Am 30 : 677-686, 2003.
PubMed
2) Canto EI, et al : Biochemical staging of prostate cancer. Urol Clin North Am 30 : 263-277, 2003.
PubMed
3) Thompson IM, et al : Prevalence of prostate cancer among men with a prostate-specific antigen level < or=4.0 ng per milliliter. N Engl J Med 350 : 2239-2246, 2004.
 
4) Saito S, et al : Changes in glycolipids in human renal-cell carcinoma and their clinical significance. Int J Cancer 49 : 329-334, 1991.
PubMed
5) Saito S, et al : Common tetrasaccharide epitope NeuAcα2→3Galβ1→3 (NeuAcα2→6) GalNAc, presented by different carrier glycosylceramide or O-linked peptides, is recognized by different antibodies and ligands having distinct specificities. J Biol Chem 269 : 5644-5652, 1994.
 
6) Ito A, et al : A novel ganglioside isolated from renal cell carcinoma. J Biol Chem 276 : 16695-16703, 2001.
PubMed
7) Saito S, et al : RM2 antigen (β1, 4-GalNAc-disialyl Lc4) as a new marker for prostate cancer. Int J Cancer 115 : 105-113, 2005.
 
8) Saito S, et al : Increase of GPX defined by monoclonal antibody RM2 in early prostate cancer. (submitted)
 
9) McNeal JE, et al : Zonal distribution of prostate adenocarcinoma. Correlation with histologic pattern and distribution of spread. Am J Surg Pathol 12 : 897-906, 1988.
PubMed
10) Paul B, et al : Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 65 : 4097-4100, 2005.
PubMed
11) Leman ES, et al : EPCA-2 : A highly specific serum marker for prostate cancer. Urology 69 : 714-720, 2007.
PubMed
P.126 掲載の参考文献
1) Watanabe M, et al : GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol 213 : 1-47, 2002.
PubMed
2) Roberts E : Adventures with GABA : fifty years on. In : GABA in the Nervous System : The View at Fifty Years (ed by Martin DL, Olsen RW), p 1-24, Lippincott Williams and Wilkins, Philadelphia, 2000.
 
3) Gilon P, et al : GABA content and localisation of high-af6nity GABA uptake during the development of the rat pancreas. Cell Mol Biol 33 : 573-585, 1987.
PubMed
4) Maemura K, et al : γ-amino-butyric acid immunoreactivity in intramucosal colonic tumors. J Gastroenterol Hepatol 18 : 1089-1094, 2003.
 
5) Kleinrok Z, et al : GABA content and GAD activity in colon tumors taken from patients with colon cancer or from xenografted human colon cancer cells growing as s. c. tumors in athymic nu/nu mice. J Physiol Pharmacol 49 : 303-310, 1998.
PubMed
6) Matuszek M, et al : GABA content and GAD activity in gastric cancer. Med Sci Monit 7 : 377-381, 2001.
PubMed
7) McCawley IJ, Matrisian LM : Matrix metalloproteinases : multifunctional contributors to tumor progression. Mol Med Today 6 : 149-156, 2000.
 
8) Sternlicht MD, Werb Z : How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 : 463-516, 2001.
PubMed
9) Egeblad M, Werb Z : New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 : 161-174, 2002.
PubMed
10) Azuma H, et al : Transfection of NFkappaB-decoy oligodeoxynucleotides using ethcient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther 10 : 415-425, 2003.
PubMed
11) Gleason DF, Mellinger GT : Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 : 58-64, 1974.
PubMed
12) Chodak GW, et al : Results of conservative management of clinically localized prostate cancer. N Engl J Med 330 : 242-248, 1994.
PubMed
13) Helgesen F, et al : Trends in prostate cancer survival in Sweden, 1960 through 1988 : evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 88 : 1216-1221, 1996.
PubMed
14) Bennett CL, et al : Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer : A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 2 : 4-8, 1999.
PubMed
P.131 掲載の参考文献
1) Kuruma H, et al : High molecular mass proteome of androgen-independent prostate cancer. Proteomics 5 : 1097-1112, 2005.
PubMed
2) Kuruma H, et al : Proteome analysis of prostate cancer. Prostate Cancer Prostatic Dis 8 : 14-21, 2005.
PubMed
3) Adam BL, et al : Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62 : 3609-3614, 2002.
PubMed
P.136 掲載の参考文献
1) Eisenberger MA, Carducci M : Treatment of hormone-refractory prostate cancer. In : Campbell-Walsh Urology, 9th ed (ed by Wein AJ, et al), p 3101-3117, Saunders Elsevier, Philadelphia, 2007.
 
2) Debes JD, Tindall DJ : Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 : 1488-1490, 2004.
PubMed
3) Liao X, et al : Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostatic cancer. Mol Cancer Ther 4 : 505-515, 2005.
PubMed
4) Narayanan BA, et al : RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation : modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5 : 1117-1125, 2006.
PubMed
5) Carducci MA, et al : Eiifect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer : arandomized, phase II, placebo-controlled trial. J Clin Oncol 21 : 679-689, 2003.
 
6) Jimeno A, et al : Atrasentan : a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 5 : 419-427, 2005.
PubMed
7) Hussain M, et al : Ixabepilone (Epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer : ASouthwest Oncology Group Trial S0111. J Clin Oncol 23 : 8724-8729, 2005.
 
8) Weidner N, et al : Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J pathol 143 : 401-409, 1993.
PubMed
9) Duque JL, et al : Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54 : 523-527, 1999.
PubMed
10) Bok RA, et al : Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients : a cancer and leukemia group B study. Cancer Res 61 : 2533-2536, 2001.
 
11) Saad F, et al : A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 94 : 1458-1468, 2002.
 
P.141 掲載の参考文献
1) Sumitomo M, et al : Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression. Hum Gene Ther 10 : 37-47, 1999.
PubMed
2) Matsumoto N, et al : Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 10 : 865-869. 2000.
PubMed
3) Gasparian AV, et al : The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115 : 141-151, 2002.
 
4) Keller E, et al : Inhibition of NF-B activity through maintenance of IκBα levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 271 : 26267-26275, 1996.
 
5) Catz SD, Johnson JL : Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20 : 7342-7351, 2001.
PubMed
6) Herrmann JL, et al : Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res 237 : 101-109, 1997.
PubMed
7) Sumitomo M, et al : An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 161 : 674-679, 1999.
 
8) Nishimura K, et al : Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93 : 1739-1746, 2001.
PubMed
9) Akakura K, et al : Possible mechanism of dexamethasone therapy for prostate cancer : suppression of circulating level of interleukin-6. Prostate 56 : 106-109, 2003.
PubMed
10) Kikuchi E, et al : Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 63 : 107-110, 2003.
PubMed
11) Domingo-Domenech J, et al : Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12 : 5578-5586, 2006.
PubMed
12) Huang S, et al : Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 : 4188-4197, 2001.
PubMed
13) Drake MJ, et al : An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88 : 822-827, 2003.
PubMed
14) Nakashima J, et al : Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 4 : 1743-1748, 1998.
PubMed
15) Nakashima J, et al : Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 : 2702-2706, 2000.
PubMed
16) Michalaki V, et al : Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90 : 2312-2316, 2004.
PubMed
17) George DJ, et al : The prognostic significance of plasma interleukin-6 levels in patients with meta-static hormone-refractory prostate cancer : results from cancer and leukemia group B 9480. Clin Cancer Res 11 : 1815-1820, 2005.
 
18) Akimoto S, et al : Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocr J 45 : 183-189, 1998.
PubMed
19) Kuroda K, et al : Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 69 : 113-117, 2007.
PubMed
20) Nakashima J, et al : Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res 55 : 4881-4885, 1995.
PubMed
21) Strassmann G, et al : Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89 : 1681-1684, 1992.
PubMed
22) Zaki MH, et al : CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111 : 592-595, 2004.
PubMed
23) Kuroda K, et al : Prevention of cancer cachexia by a novel nuclear factor｛kappa｝B inhibitor in prostate cancer. Clin Cancer Res 11 : 5590-5594, 2005.
PubMed
P.146 掲載の参考文献
1) Uemura H, et al : Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 5 : 307-323, 2005.
PubMed
2) Kambayashi Y, et al : Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268 : 24543-24546, 1993.
PubMed
3) Mukoyama M, et al : Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268 : 24539-24542, 1993.
PubMed
4) Matsubara H : Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83 : 1182-1191, 1998.
PubMed
5) Takagi T, et al : Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis. Carcinogenesis 23 : 1235-1241, 2002.
PubMed
6) Schupp M, et al : Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54 : 3442-3452, 2005.
PubMed
7) Feinstein DL, et al : Receptor-independent actions of PPAR thiazolidinedione agonists : is mitochondrial function the key? Biochem Pharmacol 70 : 177-188, 2005.
PubMed
8) Uemura H, et al : Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 66 : 822-830, 2006.
PubMed
9) O'Mahony OA. et al : Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology 146 : 392-398, 2005.
PubMed
10) Uemura H, et al : Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells : a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2 : 1139-1147, 2003.
 
11) Uemura H, et al : Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther 4 : 1699-1709, 2005.
PubMed
12) Kosaka T, et al : Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67 : 41-49, 2007.
PubMed
13) Ishiguro H, et al : Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 67 : 924-932, 2007.
PubMed
14) Yamagishi T, et al : Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. J Urol 173 : 441, 2005.
PubMed
15) Uemura H, et al : Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 10 : 405-410, 2005.
PubMed
P.151 掲載の参考文献
1) Feldman BJ, Feldman D : The development of androgen-independent prostate cancer. Nat Rev Cancer 1 : 34-45, 2001.
PubMed
2) Debes JD, Tindall DJ : Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 : 1488-1490, 2004.
PubMed
3) Eder IE, et al : Targeting the androgen receptor in hormone-refractory prostate cancer-new concepts. Future Oncol 1 : 93-101, 2005.
PubMed
4) Reddy GP, et al : Regulatory processs affecting androgen receptor expression, stability. and function : potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98 : 1408-1423, 2006.
 
5) Terasawa K, et al : Constantly updated knowledge of Hsp90. J Biochem (Tokyo) 137 : 443-447, 2005.
PubMed
6) Solit DB, et al : Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30 : 709-716. 2003.
PubMed
7) Zhang H, Burrows F : Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82 : 488-499, 2004.
PubMed
8) Lattouf JB, et al : Mechanisms of disease : the role of heat-shock protein 90 in genitourinary Inalignancy. Nat Clin Pract Urol 3 : 590-601, 2006.
PubMed
9) Thomas SA, et al : Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br J Urol 77 : 367-372, 1996.
PubMed
10) Kurahashi T, et al : Expression of major heat shock proteins in prostate cancer : correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol 177 : 757-761, 2007.
PubMed
11) Kamal A, et al : A high-affinity conformation of Hsp90 collfers tumour selectivity on Hsp90 inhibitors. Nature 425 : 407-410, 2003.
 
12) Pacey S, et al : Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 172 : 331-358, 2006.
PubMed
13) Solit DB, et al : 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8 : 986-993, 2002.
PubMed
14) Banerji U, et al : Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23 : 4152-4161, 2005.
PubMed
15) Solit DB, et al : Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13 : 1775-1782, 2007.
PubMed
P.156 掲載の参考文献
1) van der Bruggen P, et al : A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 : 1643-1647, 1991.
PubMed
2) Wang RF, Rosenberg SA : Human tumor antigens for cancer vaccine development. Immunol Rev 170 : 85-100, 1999.
PubMed
3) Rosenberg SA, et al : Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4 : 321-327, 1998.
PubMed
4) Miller AM, Pisa P : Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 56 : 81-87, 2005.
PubMed
5) Yamada A, et al : Peptide-based vaccine for cancer immunotherapy. Current Topics in Peptide & Protein Research 6 : 71-80, 2004.
 
6) Noguchi M, et al : Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57 : 80-92, 2003.
PubMed
7) Harada M, et al : Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+prostate cancer patients. Prostate 57 : 152-159, 2003.
PubMed
8) Noguchi M, et al : Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 60 : 32-45, 2004.
PubMed
9) Noguchi M, et al : Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 95 : 77-84, 2004.
PubMed
10) Mine T, et al : Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10 : 929-937, 2004
PubMed
11) Noguchi M, et al : Immunological evaluation of individualized peptide vaccination with low dose of estramustine for HLA-A24+ HRPC patients. Prostate 63 : 1-12, 2005.
PubMed
12) Noguchi M, et al : Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients : an analysis of prognostic factors in the treatment. Oncol Res 16 : 341-349, 2007.
PubMed
13) Noguchi M, et al : Percentage of the positive area of bone metastasis is an independent predictor of the disease death in advanced prostate cancer. Br J Cancer 88 : 195-201, 2003.
PubMed
P.162 掲載の参考文献
1) Rosenberg J, Small EJ : Prostate cancer update. Curr Opin Oncol 15 : 217-221, 2003.
PubMed
2) Tannock IF, et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004.
 
3) Petrylak DP, et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004.
PubMed
4) Gleave ME, Monia BP : Antisense therapy for cancer. Nat Rev Cancer 5 : 468-479, 2005.
PubMed
5) Miyake H, et al : Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer : Vancouver experience from discovery to clinic. Int J Urol 12 : 785-794, 2005.
PubMed
6) Rocchi P, et al : Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64 : 6595-6602, 2004.
 
7) Wu H, et al : Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 279 : 17181-17189, 2004.
PubMed
8) Henry SP, et al : Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 12 : 409-420, 1997.
 
9) Monia BP, et al : Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268 : 14514-14522, 1993.
PubMed
10) Reed JC : Bcl-2 and the regulation of programmed cell death. J Cell Biol 124 : 1-6, 1994.
PubMed
11) Jansen B, et al : bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4 : 232-234, 1998.
PubMed
12) Chi KN, et al : A phase II study of oblimersen sodium (G3139) and docetaxel (D) in patients with metastatic hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 22 : 393, 2003.
 
13) Jansen B, et al : Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 : 1728-1733, 2000.
PubMed
14) Chi KN, et al : A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 : 1287-1296, 2005.
PubMed
15) Rocchi P, et al : Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65 : 11083-11093, 2005.
PubMed

II 臨床研究

P.170 掲載の参考文献
1) Parkin DM, et al : Age-standardized (world) incidence (per 100, 000) and cumulative (0-74) incidence (percent) rates and standard errors prostate (C61). In : Cancer Incidence in Five Continents, Vol VIII (ed by Parkin DM, et al), p 633-635, International Agency for Research on Cancer, Lyon, 2002.
 
2) Jemal A, et al : Cancer statistics, 2007. CA Cancer J Clin 57 : 43-66, 2007.
PubMed
3) Roberts RO, et al : Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 161 : 529-533, 1999.
 
4) Meyer F, et al : Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 161 : 1189-1191, 1999.
 
5) 中田誠司ほか : 本邦における前立腺癌の疫学動向と国際比較. 日本臨牀 60 (増刊号11) : 44-48, 2002.
Medical*Online
6) Bray F : Chapter 8. Age standardization. In : Cancer Incidence in Five Continents, Vol VIII (ed by Parkin DM, et al), p 87-89, International Agency for Research on Cancer, Lyon, 2002.
 
7) 厚生省大臣官房統計情報部 : 基準人口 (昭和60年モデル人口). 平成9年 人口動態統計 上巻 (厚生省大臣官房統計情報部編), p59, 財団法人厚生統計協会, 1999.
 
8) Marugame T, et al : Cancer incidence and incidence rates in Japan in 2000 : Estimates based on data From 11 population-based cancer registries. Jpn J Clin Oncol 36 : 668-675, 2006.
PubMed
9) 大野ゆう子ほか : 日本のがん罹患の将来推計-ベイズ型ポワソン・コウホートモデルによる解析に基づく2020年までの予測-. がん・統計白書-罹患/死亡/予後-2004 (大島明ほか編), p 201-217, 篠原出版新社, 2004.
 
10) 厚生労働省大臣官房統計情報部 : 死亡, [主な死因] 悪性新生物 表5-24 悪性新生物の主な部位別にみた性・年次別死亡数及び率 (人口10万対). 平成17年 人口動態統計 上巻 (厚生労働省大臣官房統計情報部編), p 294-295, 財団法人厚生統計協会, 2007.
 
11) 黒石哲生ほか : 日本のがん死亡の将来予測. がん・統計白書-罹患/死亡/予後-2004 (大島明ほか編), p219-234, 篠原出版新社, 2004.
 
12) 厚生労働省大臣官房統計情報部 : 死亡, 第1表-1 死亡数, 性・年齢 (5歳階級) ・死因に三桁基本分類) 別. 平成12年 人口動態統計 下巻 (厚生労働省大臣官房統計情報部編), p142, 財団法人厚生統計協会, 2002.
 
13) 中田誠司 : 前立腺癌の疫学・危険因子. 前立腺癌スクリーニングAtoZ (市川智彦, 鈴木和浩編), p17-25, メジカルビュー社, 2006.
 
14) 中田誠司ほか : 日本および世界における前立腺癌死亡と食摂取様式の相関分析. 癌の臨床 40 : 831-836, 1994.
Medical*Online
P.176 掲載の参考文献
1) Yatani R, et al : Geographic pathology of latent prostatic carcinoma. Int J Cancer 29 (6) : 611-616, 1982.
PubMed
2) Marugame T, Mizuno S : Comparisoll of prostate cancer mortality in five countries : France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol 35 (11) : 690-691, 2005.
PubMed
3) Etzioni R, et al : 0ver diagnosis due to prostate-specific antigen screening : lessons from U. S. prostate cancer incidence trends. J Natl Cancer Inst 94 (13) : 981-990, 2002.
 
4) Giovannucci E, et al : Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121 (7) : 1571-1578, 2007.
PubMed
5) Akaza H, et al : Comparisons of percent equol producers between prostate cancer patients and controls : case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 34 (2) : 86-89, 2004.
PubMed
6) Cancer Registration Committee of the Japanese Urological Association : Clinicopathological statistics on registered prostate cancer patients in Japan : 2000 reports from the Japanese Urological Association. Int J Urol 12 (1) : 46-61, 2005.
PubMed
7) Cooperberg MR, et al : The changing face of low-risk prostate cancer : trends in clinical presentation and primary management. J Clin Oncol 22 (11) : 2141-2149, 2004.
PubMed
P.180 掲載の参考文献
1) Collins VP, et al : Observation on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 76 : 988-1000, 1956.
PubMed
2) Yatani R, et al : Geographic pathology of latent prostatic carcinoma. Int J Cancer 29 : 611-616, 1982.
PubMed
3) McNeal JE, et al : Pattern of progression in prostate cancer. Lancet i : 60-63, 1986.
PubMed
4) Stamey TA, et al : Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 (Suppl 3) : 933-938, 1993.
 
5) 矢谷隆一 : ヒト前立腺癌の発生と進展-地理病理学的・分子病理学的アプローチ. 日病会誌 86 : 47-62, 1997.
 
6) McNeal JE, et al : Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66 : 1225-1233, 1990.
PubMed
7) Johansson JE, et al : Natural history of early localized prostate cancer. JAMA 291 : 2713-2719, 2004.
PubMed
8) Whitmore WF, et al : Expectant management of localized prostatic cancer. Cancer 67 : 1091-1096, 1990.
 
9) Albertsen PC, et al : 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 : 2095-2101, 2005.
PubMed
10) Bill-Axelson A, et al : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 : 1977-1984, 2005.
PubMed
11) Zhang L, et al : Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 176 : 1392-1398, 2006.
PubMed
12) Ochiai A, et al : The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy : implication for expectant management. J Urol 174 : 2164-2168, 2005.
PubMed
P.186 掲載の参考文献
1) 大竹伸明ほか : 本邦における家族性前立腺癌の最新知見. 日本臨牀 60 (増刊号11) : 469-473, 2002.
Medical*Online
2) Carter BS, et al : Hereditary prostate cancer : Epidemiologic and clinical features. J Urol 150 : 797-802, 1993.
PubMed
3) Walsh PC, Partin AW : Family history facilitates the early diagnosis of prostate cancer. Cancer 80 : 1871-1874, 1997.
PubMed
4) Sarma AV, Schottenfield D : Prostate cancer incidence, mortality and survival trends in the United States : 1981-2001. Semin Urol Oncol 20 : 3-9, 2002.
 
5) Sim HG, Cheng CW : Changing demography of prostate cancer in Asia. Eur J Cancer 41 (6) : 834-845, 2005.
 
6) Gronberg H : Prostate cancer epidemiology. Lancet 361 : 859-864, 2003.
PubMed
7) Bai Y, et al : Risk of prostate cancer and family history of cancer : apopulation-based study in China. Prostate Cancer Prostatic Dis 8 : 60-65, 2005.
 
8) Johns LE, Houlston RS : A systematic review and meta-analysis of familial prostate cancer risk. Br J Urol Int 91 : 789-794, 2004.
 
9) Spangler E, et al : Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors. Int J Cancer 113 : 471-474, 2005.
PubMed
10) Narain V, et al : Biochemical recurrence after radical prostatectomy in black and white American men with a positive or negative family history of prostate cancer. J Urol 165 : 474-477, 2001.
PubMed
11) Paiss T, et al : Association between the clinical presentation and epidemiologic features of familial prostate cancer in patients selected for radical prostatectomy. Eur Urol 43 : 615-621, 2003.
PubMed
12) Kimberly AR, et al : Characteristics of patients with familial versus sporadic prostate cancer. J Urol 176 : 2438-2442, 2006.
 
13) Kotsis SV, et al : Early onset prostate cancer : predictors of clinical grade. J Urol 167 : 1659-1663, 2003.
 
14) Lee KL, et al : Positive family history of prostate cancer not associated with worse outcome after radical prostatectomy. Urology 65 : 311-315, 2005.
 
15) King TM, et al : Accuracy of family history of cancer as reported by men with prostate cancer. Urology 59 : 546-550, 2002.
PubMed
P.192 掲載の参考文献
1) 広域研究「日本における前立腺がん検診の広域研究」・対照研究「前立腺がん検診の死亡率減少効果に関する検証研究」, 平成14年度 年次報告書 (主任研究者 : 田中啓幹), 2006.
 
2) 伊藤一人, 山中英壽 : 前立腺がん検診. 厚生労働省老人保健事業推進費等補助金「新たながん検診手法の有効性の評価」, 平成12年度報告書 (主任研究者 : 久道茂), p363-402, 2001.
 
3) 厚生省がん研究補助金「前立腺がん集団検診の妥当性に関する研究」, 平成6・7年度研究成果報告書 (主任研究者 : 渡邉泱).
 
4) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン2006年版, 疫学, 金原出版, 2006.
 
5) Aus G, et al : Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 51 : 659-664, 2007.
PubMed
P.198 掲載の参考文献
1) Sirovich BE, et al : Screening men for prostate and colorectal cancer in the United States : does practice reflect the evidence? JAMA 289 : 1414-1420, 2003.
PubMed
2) Jemal A, et al : Cancer statistics, 2007. CA Cancer J Clin 57 : 43-66, 2007.
PubMed
3) Jemal A, et al : Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14 : 590-595, 2005.
PubMed
4) Roberts RO, et al : Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 161 : 529-533, 1999.
 
5) Oliver SE, et al : Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355 : 1788-1789, 2000.
PubMed
6) Lu-Yao G, et al : Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325 : 740-745, 2002.
PubMed
7) Bartsch G, et al : Prostate cancer mortality Eifter introduction of pros tate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 : 417-424, 2001.
 
8) Bartsch G, et al : Tyrolean screening study : update 2005-stage migration and decrease of mortality. J Urol 175 (Suppl) : 153-154, 2006.
 
9) Labrie F, et al : Screening decreases prostate cancer death : first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38 : 83-91, 1999.
PubMed
10) Labrie F, et al : Screening decreases prostate cancer mortality : 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59 : 311-318, 2004.
PubMed
11) Aus G, et al : Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 51 : 659-664, 2007.
PubMed
P.202 掲載の参考文献
1) Stamey TA, et al : Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 : 909-916, 1987.
PubMed
2) Arcangeli CG, et al : Prostate-specific antigen as a screening test for prostate cancer. The United States experience. Urol Clin North Am 24 : 299-306, 1997.
PubMed
3) 鈴木和浩 : 我が国における前立腺癌検診の現状と展望. 日本臨牀 65 (増刊号10) : 187-193, 2007.
Medical*Online
4) 小松和人ほか : 金沢市医師会「すこやか検診」による前立腺癌検診-平成12-平成15年度のまとめ-. 泌尿器外科 18 : 929-932, 2005.
Medical*Online
5) http://www.city.kanazawa.ishikawa.jp/toukei/b01/be_00001.xls
 
6) Thompson IM, et al : Prevalence of prostate cancer among men with a prostate-specific antigen level <- 4.0 ng per milliliter. N Engl J Med 350 : 2239-2246. 2004.
 
7) Demura T, et al : Ratio of free and total prostate-specific antigen : Amethod of detecting prostate cancer in the cases with PSA levels of 10 ng/ml or lower. J Urol l55 : 368A, 1996.
 
P.206 掲載の参考文献
1) Ito K, Schroder FH : Informed consent for PSA-based screening-European view. Urology 61 : 20-22, 2003.
 
2) Antenor JA, et al : Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 66 : 156-160, 2005.
PubMed
3) Catalona WJ, et al : Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer : an alternative model. Urology 54 : 220-224, 1999.
 
4) Partin AW, et al : Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 : 843-848, 2001.
PubMed
5) Thompson IM, et al : Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 : 2239-2246, 2004.
 
6) Ito K, et al : Correlation of prostate-specific antigen before prostate cancer detection and clinicopathological features : evaluation of mass screenillg populations. Urology 55 : 705-709, 2000.
PubMed
7) Ito K, et al : Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 56 : 278-282, 2000.
PubMed
8) 大井勝ほか : 前立腺がん集団検診における年齢階層別PSA基準値の導入-80歳以上のPSA基準値引き上げに関する検討-. 日本がん検診・診断学会誌 10 : 123-125, 2003.
 
P.212 掲載の参考文献
1) 前立腺研究財団 (編) : 前立腺がん検診 市町村別実施状況 (2006年10月調査), 財団法人前立腺研究財団, 2007.
 
2) 伊藤一人ほか : 群馬県における前立腺集団検診形態の変遷-18年間の総括および現況・問題点-. 泌尿器外科 13 (8) : 997-1001, 2000.
 
3) Bartsch G, et al : Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austha. Urology 58 (3) : 417-424, 2001.
PubMed
4) Labrie F, et al : Screening decreases prostate cancer death : first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38 : 83-91, 1999.
PubMed
5) 武智浩之ほか : 前立腺がん検診暴露率と発見がん症例の臨床的特徴の関係. 泌尿器外科 18 (8) : 997-999, 2005.
Medical*Online
6) Kubota Y, et al : Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 50 : 262-269, 2002.
PubMed
7) Ito K, et al : Lead time of prostate cancer detected in population based screening for prostate cancer in Japan. J Urol 178 : 1258-1263 ; discussion 1263-1264, 2007.
 
8) Roemeling S, et al : Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Prostate 66 : 1076-1081, 2006.
 
9) Aus G, et al : Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 51 : 659-664, 2007.
PubMed
10) Sirovich BE, et al : Screening men for prostate and colorectal cancer in the United States : does practice renect the evidence? JAMA 289 : 1414-1420, 2003.
PubMed
11) Jemal A, et al : Cancer statistics, 2007. CA Cancer J Clin 57 : 43-66, 2007.
PubMed
12) Mullan R, et al : Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000. BJU Int 95 : 951-955, 2005.
PubMed
13) Jemal A, et al : Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14 (3) : 590-595, 2005.
PubMed
P.215 掲載の参考文献
1) 赤座英之 : 前立腺癌の診断・治療における最新の進歩. 日本臨牀 63 : 237-240, 2005.
Medical*Online
2) Jemal A, et al : Cancer statistics, 2007. CA Cancer J Clin 57 : 43-66, 2007.
PubMed
3) がん研究振興財団 : がんの統計2005年版, 2005.
 
4) Steyerberg EW, et al : Prediction of indolent prostate cancer : validation and updating of a prognostic nomogram. J Urol 177 : 107-112, 2007.
PubMed
5) D'Amico AV, et al : Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 : 125-135, 2004.
PubMed
6) Klotz L, et al : Active surveillance for prostate cancer : for whom? J Clin Oncol 23 : 8165-8169, 2005.
PubMed
P.218 掲載の参考文献
1) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン2006年版, p29-60, 金原出版, 2006.
 
2) Sobin LH, Wittekind Ch (ed) : Urological tumours : Prostate. In : TNM CIassific. ation of Malignant Tumours, 6th ed, p 184-187, John Wiley & Sons, Hoboken, New Jersey, 2002.
 
3) Pederson KV, et al : Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 300 : 1041-1044, 1990.
 
4) Ellis WJ, et al : Diagnosis of prostatic carcinoma : the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 152 : 1520-1525, 1994.
PubMed
5) Aoki H, et al : Experience of the treatment with GDC (gemcitabine, docetaxel, carboplatin) chemotherapy for patients with small cell carcinoma of the prostate. Int J Urol 13 : 1254-1258, 2006.
PubMed
P.222 掲載の参考文献
1) 財団法人がん研究振興財団 : 悪性新生物罹患数, 罹患率および年齢階級別罹患率) 平成11年 <平成10年～12年値>). がんの統計'05, p46-47, 2005.
 
2) 財団法人がん研究振興財団 : 悪性新生物罹患数, 罹患率および・年齢階級別罹患率) 平成10年 <平成9年～11年値>). がんの統計'03, p46-47, 2003.
 
3) 平山雄 : 前立腺ガンの疫学. 予防ガン学-その新しい展開, p148-157, メディサイエンス社, 1987.
 
4) Gutman AB, Gutman EB : An acid phosphatase occurring in serum of patiens with metastasizing carcinoma of the prostate gland. J Clin Invest 17 : 473-478, 1938.
 
5) Hara M, et al : Some physico-chemical characteristics of "gamma-seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nihon Hoigaku Zasshi 25 : 322-324, 1971.
 
6) Wang MC, et al : Purification of a human prostate specific antigen. Invest Urol 17 : 159-163, 1979.
PubMed
7) Kuriyama M, et al : Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41 : 3874-3876, 1981.
PubMed
8) Kuriyama M, et al : Quantitation of prostatic specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 40 : 4658-4662, 1980.
PubMed
9) Chodak GW : Early detection and screening for prostatic cancer. Urology 34 : 10-12, 1989.
PubMed
10) Pedersen KV, et al : Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 300 : 1041-1044, 1990.
 
11) Haas GP, et al : The state of prostate cancer screening in the United States. Eur Urol 23 : 337-347, 1993.
PubMed
12) Carter HB. et al : Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277 (18) : 1456-1460, 1997.
PubMed
13) Babaian RI, et al : The incidence of prostate cancer in a screening population with a serum prostate spcific antigen between 2.5 and 4.0 ng/ml : relation to biopsy strategy. J Urol 165 : 757-760, 2001.
 
P.234 掲載の参考文献
1) Lilja H, et al : Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 37 : 1618-1625, 1991.
 
2) Stenman UH, et al : A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer : assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 : 222-226, 1991.
 
3) Stamey T : Second conference on international standardization of prostate-specific antigen immunoassays : September 1 and 2, 1994. Urology 46 : 173-184, 1995.
 
4) NCCLS : Primary Reference Preparations Used to Standardize Calibration of Immunochemical Assays for Serum Prostate Specific Antigen (PSA) ; Approved Guideline. NCCLS document I/LA 19-A, NCCLS, Pennsylvania, 1997.
 
5) 加野象次郎ほか : わが国における血清総PSA測定の現状と方法間差の要因. 泌尿器外科 11 : 942-949, 1998.
Medical*Online
6) 加野象次郎ほか : 血清総PSA測定における標準化の現状 日本泌尿器科学会PSA ad hoc委員会による "2000年サーベイ" の結果. 臨床病理 49 : 967-973, 2001.
 
7) 加野象次郎 : 血清中総PSA測定の標準化に関する考え方 PSA検査標準化専門委員会作業部会による試案. 臨床泌尿器科 57 (増刊号) : 316-322, 2003.
 
8) 桑克彦 : 標準物質に関する用語とその意味. 臨床検査 41 : 1613-1619, 1997.
 
9) Kano S, et al : Successful Preparation of Serum-Based Secondary Reference Material for Standardization of Total Prostate-Specific Antigen (PSA) Immunoassays. Proceedings of the 15th IFCC-FFSCC European Congress of Clinical Chemistry and Laboratory Medicine, p 507-511, 2003.
 
10) 加野象次郎 : 前立腺特異抗原 (PSA) の標準化に関する活動報告. 日本臨床検査標準協議会会誌 21 (1) : 9-47, 2006.
 
P.238 掲載の参考文献
1) Benson MC, et al : An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol 11 : 206-213, 1993.
 
2) Bazinet M, et al : Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 43 : 44-51, 1994.
PubMed
3) Catalona WJ, et al : Comparison of prostate 9. pecific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer : receiver operating characteristic curves. J Urol 152 : 2031-2036, 1994.
 
4) Kalish J, et al : Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43 : 601-606, 1994.
PubMed
5) Djavan B, et al : Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 160 : 411-418, 1998.
PubMed
6) Kikuchi E, et al : Prostate specific antigen adjusted for transition zone volume : the most powerful method for detecting prostate carcinoma. Cancer 89 : 842-849, 2000.
PubMed
7) Maeda H, et al : Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology 54 : 225-228, 1999.
PubMed
8) Ohi M, et al : Diagnostic significance of PSA density adjusted by transition zone volume in males with PSA levels between 2 and 4 ng/ml. Eur Urol 45 : 92-96, 2004.
 
9) Singh H, et al : Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol 171 : 1850-1854, 2004.
PubMed
10) Horinaga M, et al : Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy : the usefulness of complexed prostate specific antigen adjusted for transition zone volume. J Urol 168 : 986-990, 2002.
PubMed
11) Ohigashi T, et al : Prostate specific antigen adjusted for transition zone epithelial volume : the powerful predictor for the detection of prostate cancer on repeat biopsy. J Urol 173 : 1541-1545, 2005.
PubMed
12) Canto EL et al : Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63 : 905-910, 2004.
 
13) Khan MA, et al : Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 64 : 1160-1164, 2004.
PubMed
14) Horiguchi A, et al : Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate 56 : 23-29, 2003.
PubMed
15) Freedland SJ, et al : Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy : results from the search data base. J Urol 169 : 969-973, 2003.
 
P.242 掲載の参考文献
1) Gretzer MB, Partin AW : PSA markers in prostate cancer detection. Urol Clin North Am 30 : 677-686, 2003.
PubMed
2) Mikolajczyk SD, Rittenhouse HG : ProPSA : a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 52 : 86-91, 2003.
PubMed
3) Balk SP, et al : Biology of ptostate-specific antigen. J Clin Oncol 21 : 383-391, 2003.
PubMed
4) Bjork T, et al : Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha1-antichymotrypsin from serum. Urology 51 : 57-62, 1998.
PubMed
5) Bjork T, et al : Alpha1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 43 : 427-434, 1994.
PubMed
6) Catalona WJ, et al : Use of the percentage of free prostate-specitic antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 279 : 1542-1547, 1998.
 
7) Roddam AW, et al : Use of prostate-specific antigen (PSA) isoforms for detection of prostate cancer in men with a PSA level of 2-10 ng/ml : systematic review and meta-analysis. Eur Urol 48 : 386-399, 2005.
 
8) Stenman UH, et al : Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl 216 : 64-81, 2005.
PubMed
9) Thompson IM, et al : Prevalence of prostate cancer among men with a prostate-specific antigen level≦4.0 ng per milliliter. N Engl J Med 350 : 2239-2246, 2004.
 
10) Catalona WJ, et al : Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination : enhancement of specificity with free PSA measurements. JAMA 277 : 1452-1455, 1997.
 
11) 石戸谷滋人ほか : 平成16年度前立腺がん検診の成績 : 生検基準にF/T比を導人した南北海道東北地区共同プロジェクト. 腎泌予防医誌 15 : 65-66, 2007.
 
12) Pannek J, et al : Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol l59 : 449-453, 1998.
 
13) 日本泌尿器科学会 (編) : 2. 診断. 前立腺癌診療ガイドライン2006年版, p35-36, 金原出版, 2006.
 
14) Catalona WJ, et al : Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170 : 2181-2185, 2003.
 
15) Catalona WJ, et al : Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 : 2239-2244, 2004.
 
P.247 掲載の参考文献
1) Mikolajczyk SD, et al : A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50 (5) : 710-714, 1997.
PubMed
2) Mikolajczyk SD, et al : Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50 : 1017-1025, 2004.
PubMed
3) Peter J. et al : Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61 : 957-962, 2001.
PubMed
4) Mikolajczyk SD, et al : A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 : 6958-6963, 2001.
PubMed
5) Mikolajczyk SD, et al : Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 45 : 271-276, 2000.
PubMed
6) Catalona WJ, et al : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease : a prospective multicenter clinical trial. JAMA 279 : 1542-1547, 1998.
PubMed
7) Brawer MK, et al : Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 163 : 1476-1480, 2000.
PubMed
8) Parsons JK, et al : Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0ng/mL range of total PSA. BJU Int 94 : 47-50, 2004.
 
9) Horninger W, et al : Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 60 : 31-35, 2002.
PubMed
10) Lein M, et al : A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 170 : 1175-1179, 2003.
PubMed
11) Okihara K, et al : Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 167 : 2017-2023, 2002.
PubMed
12) Partin AW, et al : Complexed prostate specific antigen improves specificity for prostate cancer detection : results of a prospective multicenter clinical trial. J Urol 170 : 1787-1791, 2003.
PubMed
13) Okegawa T, et al : Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0ng/mL. Urology 55 : 700-704, 2000.
 
14) Catalona WJ, et al : Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 : 2239-2244, 2004.
 
15) Lein M, et al : A multicenter clinical trial on the use of (-5,-7) pro prostate specific antigen. J Urol 174 : 2150-2153, 2005.
PubMed
16) Khan MA, et al : Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 64 : 1160-1164, 2004.
PubMed
P.252 掲載の参考文献
1) 揖靖ほか : 前立腺spectroscopyの臨床への展開. 画像診断 24 : 1119-1128, 2004.
 
2) Sato C, et al : Differentiation of noncancerous tissue and cancer lesions by apparent diffUsion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 21 : 258-262, 2005.
PubMed
3) Shimofusa R, et al : Diffusion-weighted imaging of prostate cancer, J Comput Assist Tomogr 29 : 149-153, 2005.
PubMed
4) Hara T, et al : PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 : 990-995, 1998.
PubMed
5) Maeda T, et al : Distant metastasis of prostate cancer : early detection of recurrent tumor with dual-phase carbon-11 choline positron emission tomography/computed tomography in two cases. Jpn J Clin Oncol 36 : 598-601, 2006.
PubMed
6) Yamaguchi T, et al : Prostate cancer : a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 32 : 742-748, 2005.
 
P.257 掲載の参考文献
1) 渡辺泱 : 超音波断層法による前立腺診断. 日泌尿会誌 59 : 273-279, 1968.
 
2) McNeal JE, et al : Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 : 897-906, 1988.
PubMed
3) Nakanouchi T, et al : Possible use of transrectal power Doppler imaging as an indicator of microvascular density of prostate cancer. Urology 58 : 573-577, 2001.
PubMed
4) Kimura G, et al : Power Doppler ultrasound enhances the specificity of the diagnostic parameters related to prostate specific antigen in early prostate cancer detection. J Urol 167 : AUA 99th annual meeting abstract 1294, 2002.
 
5) Okihara K, et al : The role of power Doppler-guided prostatic biopsy in the diagnosis of prostate cancer. Acta Urol Jpn 45 : 559-563, 1999.
 
6) Unal D, et al : Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional examination methods : the value of diagnostic predictors of prostate cancer. Br J Urol 86 : 58-64, 2000.
 
7) Loch T, et al : Artificial neural network analysis (ANNA) of prostatic transrectal ultrasound. Prostate 39 : 198-204, 1999.
PubMed
8) Ronco AL, et al : Improving ul. trasonographic diagnosis of prostate cancer with neural networks. Ultrasound Med Biol 25 : 729-733, 1999.
 
9) Halpern EJ, et al : Directed biopsy during contrast-enhanced sonography of the prostate. AJR Am J Roentgenol 178 : 915-919, 2002.
PubMed
10) Ekici S, et al : A comparison of transrectal ultrasonography and endorectal magnetic resonance imaging in the local staging of prostatic carcinoma. Br J Urol 83 : 786-800, 1999.
 
11) 日本泌尿器科学会, 日本病理学会 (編) : 前立腺癌取扱い規約, 第3版, p12-14, 金原出版, 2001.
 
12) Ukimura O, et al : Prostate cancer staging : correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol 159 : 1251-1259, 1998.
PubMed
13) Ukimura O, et al : Real-time transrectal ultrasonography during laparoscopic radical prostatectomy. J Urol 172 : 112-118, 2004.
PubMed
14) Ukimura O, Gill IS : Real-time transrectal ultrasound guidance during nerve sparing laparoscopic radical prostatectomy : pictorial essay. J Urol 175 : 1311-1319, 2006.
PubMed
15) Ukimura O, et al : Real-time transrectal ultrasound guidance during laparoscopic radical prostatectomy : impact on surgical margins. J Urol 175 : 1304-1310, 2006.
PubMed
P.261 掲載の参考文献
1) van den Brink JS, et al : Implications of SENSE MR in routine clinical practice. Eur J Radiol 46 : 3-27, 2003.
PubMed
2) Rouviere O, et al : Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 13 : 931-942, 2003.
PubMed
3) Sato C, et al : Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 21 : 258-262, 2005.
PubMed
4) Kurha newicz J, et al : Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 198 : 795-805, 1996.
 
5) Zakian KL, et al : Transition zone prostate cancer : metabolic characteristics at 1H MR spectroscopic imaging-initial results. Radiology 229 : 241-247, 2003.
PubMed
6) Kaji Y, et al : Anatomical and metabolic assessment of prostate using a 3-Tesla MR scanner with a custom-made external transceive coil : healthy volunteer study. J Magn Reson Imaging 25 : 517-526, 2007.
PubMed
7) Futterer JJ, et al : Prostate cancer : local staging at 3-T endorectal MR imaging-early experience. Radiology 238 : 184-191, 2006.
PubMed
8) Beyersdorff D. et al : MRI of prostate cancer at 1.5 and 3.0 T : comparison of image quality in tumor detection and staging. AIR Am J Roentgenol 185 : 1214-1220, 2005.
 
9) Gibbs P, et al : DiffUsion imaging of the prostate at 3.0 tesla. Invest Radiol 41 : 185-188, 2006.
 
10) Prando A, et al : Helical CT of prostate cancer : early clinical experience. AJRAm J Roentgenol 175 : 343-346, 2000.
 
11) Wolf JS Jr, et al : The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 153 : 993-999, 1995.
PubMed
P.267 掲載の参考文献
1) 久保敦司, 木下文雄 : 核医学ノート, 第4版, 金原出版, 2001.
 
2) Hricak H, et al : Imaging prostate cancer : a multidisciplinary perspective. Radiology 243 : 28-53, 2007.
PubMed
P.271 掲載の参考文献
1) Hodge KK, et al : Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142 : 71-75, 1989.
PubMed
2) Barringer BS : Prostatic carcinoma. J Urol 47 : 306-310, 1942.
 
3) Franzen S, et al : Cytological diagnosis of prostatic tumours by transrectal aspiration biopsy : a preliminary report. Br J Urol 32 : 193-196, 1960.
PubMed
4) 小川修ほか : 限局性前立腺癌の診断と治療における超音波ガイド下前立腺生検の有用性. 泌尿紀要 42 : 805-810, 1996.
 
5) 石戸谷哲ほか : 前立腺超音波生検技術の進歩と前立腺癌発見率. 日本臨牀 56 : 108-113, 1998.
 
6) McNeal JE, et al : Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 : 897-906, 1988.
PubMed
7) Eskew LA, et al : Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157 : 199-202 ; discussion 202-203, 1997.
 
8) Ramey JR, et al : Ultrasonography and biopsy of the prostate. In : Campbell-Walsh Urology (ed by Wein AJ), p 2883-2895, Saunders Elsevier, Philadelphia, 2007.
 
9) Terris MK. et al : Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 157 : 204-219, 1997.
 
10) 松田公志ほか : 前立腺生検方法「経直腸的か, 経会陰的か」. Urology View 3 : 92-104, 2005.
 
11) Vis AN, et al : Detection of prostate cancer : a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 56 : 617-621, 2000.
PubMed
12) Emiliozzi P, et al : Best approach for prostate cancer detection : a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology 61 : 961-966, 2003.
PubMed
13) Miller J, et al : Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg 75 : 48-50, 2005.
PubMed
14) 賀本敏行 : 経直腸的前立腺生検法. Urologic Surgeryシリーズ6「前立腺の手術」 (荒井陽一, 村井勝編), p44-47, メジカルビュー社, 2001.
 
15) Yun TJ, et al : Does the intrarectal instillation of lidocaine gel before periprostatic neurovascular bundle block during transrectal ultrasound guided prostate biopsies improve analgesic efficacy? A prospective, randomized trial. J Urol 178 : 103-106, 2007.
 
16) 鳴海善文ほか : 非イオン性ヨード造影剤およびガドリニウム造影剤の重症副作用および死亡例の頻度調査. 日本医放会誌 65 : 300-301, 2005.
 
17) Kapoor DA, et al : Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 52 : 552-558, 1998.
PubMed
P.275 掲載の参考文献
1) Hodge KK, et al : Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142 : 71-75, 1989.
PubMed
2) Eskew LA, et al : Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157 : 199-203, 1997.
PubMed
3) Presti JC Jr, et al : The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies : results of a prospective clinical trial. J Urol 163 : 163-166, 2000.
PubMed
4) Ravery V, et al : Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 164 : 393-396, 2000.
PubMed
5) Igel TC, et al : Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. J Urol l65 : 1575-1579, 2001.
 
6) Satoh T, et al : Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology 66 : 114-118, 2005.
PubMed
7) Furuno T, et al : Difference of cancer core distribution between first and repeat biopsy : In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate 58 : 76-81, 2004.
PubMed
8) Demura T, et al : Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy. Cancer 103 : 1826-1832, 2005.
PubMed
9) Vis AN, et al : Detection of prostate cancer : a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 56 : 617-621, 2000.
PubMed
10) Emilliozzi P, et al : Best approach for prostate cancer detection : a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology 61 : 961-966, 2003.
PubMed
11) Stamey TA, et al : The prostate specific antigen era in the United States is over for prostate cancer : what happened in the last 20 years? J Urol 172 : 1297-1301, 2004.
PubMed
P.279 掲載の参考文献
1) Kawakami S, et al : Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. Int J Clin Oncol 11 : 127-132, 2006.
PubMed
2) Kawakami S, et al : Optimal sampling sites for repeat prostate biopsy : arecursive partitioning analysis of three-dimensional26-core systematic biopsy. Eur Urol 51 : 675-683, 2007.
 
3) Ito K, et al : The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL. Cancer 95 : 2112-2119, 2002.
 
4) Watanabe M, et al : Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection. Int J Urol 12 : 959-963, 2005.
PubMed
5) 矢野雅隆ほか : 前立腺多部位 (26ヵ所), 立体生検法 : インフォームドコンセントのためのビデオ. Audio-Video Journal of JUA 11 (1) : 11-14, 2005.
 
6) Kawakami S, et al : Direct comparison of cancer detectability between transrectal versus transperineal extended prostate biopsy. Int J Urol 14 : 719-724, 2007.
 
7) Numao N, et al : Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy. Eur Urol. (in press)
 
8) Numao N, et al : A prostate biopsy scheme optimal for both cancer detectability and grade accuracy. Eur Urol Suppl 6 : 120, 2007.
 
9) D'Amico AV, et al : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 : 969-974, 1998.
 
10) Partin AW, et al : Contemporary update of prostate cancer staging nomogram (Partin table) for the new millennium. Urology 58 : 843-848, 2001.
PubMed
11) Grossfeld GD, et al : Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy : results from the Cancer of the Prostate Strategic Urologic Research Endeavor Database. J Urol 165 : 851-856, 2001.
 
12) D'Amico AV, et al : Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 : 1164-1172, 2000.
PubMed
13) 川上理ほか : 26ヶ所立体生検所見に基づくlow volume/low grade癌の予測モデル. 泌尿器外科. (印刷中)
 
14) Kojima M, et al : Transperineal 12-core systematic biopsy in the detection of prostate cancer. Int J Urol 8 : 301-307, 2001.
PubMed
15) Kawakami S, et al : Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. Int J Urol ll : 613-618, 2004.
 
16) Demura T, et al : Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy. Cancer 103 : 1826-1832, 2005.
PubMed
17) Takenaka A, et al : Transperineal extended biopsy improves the clinically significant prostate cancer detection rate : a comparative study of 6 and 12 biopsy cores. Int J Urol 13 : 10-14, 2006.
 
18) Noguchi M, et al : A questionnaire survey of patient preparation and techniques for prostate biopsy among urologists in the Kyushu and Okinawa regions of Japan. Int J Clin Oncol 11 : 390-395, 2006.
PubMed
P.283 掲載の参考文献
1) Djavan B, et al : Prospective evaluation of prostate cancer detection on biopsies 1, 2, 3and 4 : When should we stop? J Urol 166 : 1679-1683, 2001.
 
2) Svetec D, et al : Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol 159 : 1606-1608, 1998.
PubMed
3) Chen ME, et al : Optimization of prostate biopsy strategy using computer based analysis. J Urol 158 : 2168-2175, 1997.
PubMed
4) Rabbani F, et al : Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 159 : 1247-1250, 1998.
PubMed
5) Stroumbakis N, et al : Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 49 (Suppl 3A) : 113-118, 1997.
 
6) Takashima R, et al : Anterior distribution of stage T1c nonpalpable tumors in radical prostatectomy specimens. Urology 59 : 692-697, 2002.
PubMed
7) Fink KG, et al : Evaluation of transition zone and lateral sextant biopsies for prostate cancer detection after initial sextant biopsy. Urology 61 : 748-753, 2003.
PubMed
8) Djavan B, et al : Optimal predictors of prostate cancer on repeat prostate biopsy : A prospective study of 1,051 men. J Urol 163 : 1144-1149, 2000.
 
9) Keetch DW, et al : Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151 : 1571-1574, 1994.
PubMed
10) Mian BM, et al : Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 60 : 836-840, 2002.
PubMed
11) Iczkowski KA, et al : Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. Urology 60 : 851-854, 2002.
PubMed
12) Lopez-Corona E, et al : A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 170 : 1184-1188, 2003.
 
13) Stewart CS, et al : Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166 : 86-92, 2001.
PubMed
14) Steiner H, et al : Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening Population. Prostate 58 : 277-282, 2004.
 
15) Miyake H, et al : Clinicopathological features of prostate cancer in Japanese men diagnosed on repeat transrectal ultrasound-guided biopsy. Int J Clin Oncol 10 : 30-34, 2005.
PubMed
P.288 掲載の参考文献
1) Cagiannos I, et al : Analysis of clinical T2 prostate cancer. Do current subclassifications represent an improvement? JClin Oncol 20 : 2025-2039, 2002.
 
2) Sobin LH, Wittekind CH : TNM Classification of Malignant Tumors, 6th ed, Wiley-Liss, New York, 2002.
 
3) 日本泌尿器科学会, 日本病理学会 (編) : 前立腺癌取扱い規約, 第3版, 金原出版, 2001.
 
4) Ohori M, et al : Do impalpable (T1c) cancers visible on ultrasound differ from those not visible? J Urol 169 : 964-968, 2003.
 
5) Tiguert R, et al : Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors. J Urol 163 : 1486-1490, 2000.
PubMed
6) Spigelman SS, et al : Rectal examination in volume determination of carcinoma of the prostate : clinical and anatomical correlations. J Urol 136 : 1228-1230, 1986.
PubMed
7) Lee N, et al : Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 54 : 490-494, 1999.
 
8) Heenan SD : Magnetic resonance imaging in prostate cancer. Prostate Cancer Prostatic Dis 7 : 282-288, 2004.
PubMed
9) Partin AW, et al : Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 : 843-848, 2001.
PubMed
P.296 掲載の参考文献
1) Partin AW, et al : Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (18) : 1445-1451, 1997.
PubMed
2) Partin AW, et al : Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 : 843-848, 2001.
PubMed
3) Blute ML, et al : Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 164 : 1591-1595, 2000.
PubMed
4) Penson D, et al : How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol 167 (4) : 1653-1658, 2002.
 
5) Augustin H, et al : Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol 171 : 177-181, 2004.
PubMed
6) 権藤立男ほか : 日本版と米国版「前立腺癌病理病期予測ノモグラム」の比較と検証. 日泌尿会誌 98 (2) : 278, 2007.
 
7) 坂本昇ほか : 日本版病理病期予測ノモグラムの検証. 日泌尿会誌 98 (2) : 283, 2007.
 
8) Ohori M, et al : Predicting the presence and side of extracapsular extension : anomogram for staging prostate cancer. J Urol 171 (5) : 1844-1849, 2004.
 
9) Koh H, et al : A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 170 : 1203-1208, 2003.
 
10) Cagiannos I, et al : A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170 : 1798-1803, 2003.
PubMed
11) Kattan MW, et al : Counseling men with prostate cancer : A nomogram for predicting the presence of indolent (small, well-moderately differentiated, confined) tumors. J Urol 170 (5) : 1792-1797, 2003.
 
P.300 掲載の参考文献
1) Partin AW, et al : Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 : 1445-1451, 1997. [erratum appears in JAMA 278 (2) : 118, 1997]
 
2) Partin AW, et al : Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 : 843-848, 2001.
PubMed
3) Augustin H, et al : Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol 171 : 177-181, 2004.
PubMed
4) Blute ML, et al : Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 164 : 1591-1595, 2000.
PubMed
5) Eskicorapci SY, et al : Validation of 2001 Partin tables in Turkey : a multicenter study. Eur Urol 47 : 185-189, 2005.
 
6) Graefen M, et al : Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol 43 : 6-10 ; discussion 11, 2003.
PubMed
7) Penson DF, et al : How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol 167 : 1653-1657 ; discussion 1657-1658, 2002.
 
8) Epstein JI ; ISUP Grading Committee : The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29 : 1228-1242, 2005.
 
P.305 掲載の参考文献
1) Huggins C, Hodges CV : The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 : 293-297, 1941.
 
2) Walsh PC : Anatomic radical prostatectomy : evolution of the surgical technique. J Urol 160 : 2418-2424, 1998.
PubMed
3) Han M, et al : Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166 : 416-419, 2001.
PubMed
4) Hull GW, et al : Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167 : 528-534, 2002.
PubMed
5) Pilepich MV, et al : Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 : 1285-1290, 2005.
PubMed
6) Bolla M, et al : Lo ng-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) : a phase III randomized trial. Lancet 360 : 103-108, 2002.
 
7) Pollack A, et al : Prostate cancer radiation dose response : results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 : 1097-1105, 2002.
 
8) Zelefsky MJ, et al : High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 : 876-881, 2001.
PubMed
9) Kupelian PA, et al : Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >-72 Gy, permanent seed implantation, or combined seed/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 : 25-33, 2004.
 
10) Stock RG, et al : Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64 : 810-816, 2006.
PubMed
11) Zelefsky MJ, et al : Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 : 327-333, 2007.
PubMed
12) Sylvester JE, et al : 15-year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy ; Seattle experience. Int J Radiat Oncol Biol Phys 67 : 57-64, 2007.
PubMed
13) Akaza H, et al : Efficacy of primary hormone therapy for localized or locally advanced prostate cancer : results of a 10-year follow-up. BJU Int 98 : 573-579, 2006.
 
14) Kakehi Y : Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol 33 : 1-5, 2003.
PubMed
15) Bill-Axelson A, et al : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 : 1977-1984, 2005.
PubMed
P.310 掲載の参考文献
1) Partin AW, et al : Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 : 843-848, 2001.
PubMed
2) Holmberg L, et al : A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 : 781-789, 2002.
 
3) Rozet F, et al : Extraperitoneal laparoscopic radical prostatectomy : aprospective evaluation of 600 cases. J Urol 174 : 908-911, 2005.
 
4) Bhandari A, et al : Perioperative complications of robotic radical prostatectomy after the learning curve. J Urol 174 : 915-918, 2005.
PubMed
5) Jolesz FA : Future perspectives for intraoperative MRI. Neurosurg Clin N Am 16 : 201-213, 2005.
PubMed
6) Walsh PC, et al : Importance following radical prostatectomy : insight into etiology and prevention. J Urol 128 : 492-497, 1982.
 
7) 荒井陽一ほか : EDと骨盤内悪性腫瘍手術. 治療 84 : 135-139, 2003.
 
8) Pound CR, et al : Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 281 : 1591-1597, 1999.
 
9) D'Amico A, et al : Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 : 1376-1386, 2003.
 
10) 藤元博行 : 本邦, 前立腺癌症例に対する根治的前立腺全摘の可能性と限界. 臨床放射線 50 : 593-601, 2005.
 
P.316 掲載の参考文献
1) 荒井陽一 : 泌尿器科教育施設における診療実態. 教育ワークショップ2006調査報告. 日泌会誌 98 (Suppl) : 61-70, 2006.
 
2) Bill-Axelson A, et al ; Scandinavian Prostate Cancer Group Study No. 4 : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (19) : 1977-1984, 2005.
 
3) Kamat AM, et al : Validation of criteria used to predict extraprostatic cancer extension : a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol 174 (4 Pt 1) : 1262-1265, 2005.
 
4) Kaiho Y, et al : Intraoperative electrophysiological confirmation of urinary continence after radical prostatectomy. J Urol 173 : 1139-1142, 2005.
PubMed
5) Walsh PC, et al : Cancer control and quality of life following anatomical radical retropubic prostatectomy : results at 10 years. J Urol 152 (5 Pt 2) : 1831-1836, 1994.
 
6) Talcott JA, et al : Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 89 : 1117-1123, 1997.
PubMed
7) Namiki S, et al : Intraoperative electrophysiological confirmation of neurovascular bundle preservation during radical prostatectomy : long-term assessment of urinary and sexual function. Jpn J Clin Oncol 35 : 660-666, 2005.
PubMed
8) Takenaka A, et al : Anatomical analysis of the neurovascular bundle supplying penile cavernous tissue to ensure a reliable nerve graft after radical prostatectomy. J Urol 172 : 1032-1035, 2004.
PubMed
9) Kaul S, et al : Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing : an analysis of 154 consecutive patients. BJU Int 97 : 467-472, 2006.
PubMed
10) Mulhall J, et al : The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2 : 532-540 ; discussion 540-542, 2005.
 
11) Bumett AL, Lue TF : Neuromodulatory therapy to improve erectile function recovery outcomes after pelvic surgery. J Urol 176 : 882-887, 2006.
 
12) Arai Y : Letter to the editor, Re : Nerve sparing open radical retropubic prostatectomy-does it have an impact on urinary continence? J Urol 177 : 798-799, 2007.
 
13) Namiki S, et al : Impact of unilateral sural nerve graft on recovery of potency and continence following radical prostatectomy : 3-year longitudinal study. J Urol 178 : 212-216 ; discussion 216, 2007.
PubMed
P.320 掲載の参考文献
1) Young H : The early diagnosis and radical cure of carcinoma of the prostate : being a study of 40 cases and presentation of a radical operation which was carried out in four cases. Bull Johns Hopkins Hosp 16 : 315-321, 1905.
 
2) Cornum R, et al : Is there really a difference between the perineal and retropubic prostatectomy? J Urol 157 : 393, 1997.
 
3) Lance R, et al : A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int 87 : 61-65, 2001.
 
4) Weldon V, et al : Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 153 : 1565-1569, 1995.
PubMed
5) Hiraoka Y, et al : Radical perineal prostatectomy : development of a new surgical technique that divides the dorsal vein complex. Urol Int 73 : 113-116, 2004.
PubMed
6) Saito S, Murakami G : Radical perineal prostatectomy : a novel approach for lymphadenectomy from perineal incision. J Urol 170 : 1298-1300, 2003.
PubMed
7) Lassen P, Kearse W Jr : Rectal injuries during radical perineal prostatectomy. Urology 45 : 266-269, 1995.
PubMed
8) Leventhal I, et al : Rhabdomyolysis and acute renal failure as a complication of urethral surgery. Urology 26 : 59-61, 1985.
PubMed
9) Reddy P, Kaye K : Deep posterior compartment syndrome : a serious complication of the lithotomy position. J Urol 132 : 144-145, 1984.
PubMed
10) Bruce R, et al : Rhabdomyolysis and acute renal failure following radical perineal prostatectomy. Urology 47 : 427-430, 1996.
PubMed
11) Price D, et al : Transient lower extremity neurapraxia associated with radical perineal prostatectomy : a complication of the exaggerated lithotomy position. J Urol 160 : 1376-1378, 1998.
PubMed
12) Keller H : Letter to the editor. RE : Paper#15. 162 : 171, 1999.
 
13) Namiki S, et al : Changes in quality of life in first year after radical prostatectomy by retropubic, laparoscopic, and perineal approach : multi-institutional longitudinal study in Japan. Urology 67 : 321-327, 2006.
PubMed
14) Bishoff J, et al : Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol 160 : 454-458, 1998.
 
15) Gibbons RP : Radical perineal prostatectomy. In : Campbell's Urology (ed by Walsh PC, et al), p3131-3146, WB Saunders, Philadelphia, 2002.
 
P.324 掲載の参考文献
1) Guillonneau B, Vallancien G : Laparoscopic radical prostatectomy : the Montsouris technique. J Urol 1643-1649, 2000.
PubMed
2) Alejandro RR, et al : Laparoscopic extraperitoneal radical prostatectomy in complex surgical cases. J 177 : 1765-1770, 2007.
 
3) Rhee HK, et al : Transperitoneal laparoscopic radical prostatectomy : descending technique. J Endourol 18 : 601-604, 2004.
PubMed
4) Terachi T, Usui Y : Clinical outcomes and problems in laparoscopic radical prostatectomy. Nippon : 267-270, 2005.
 
5) Guillonneau B, et al : Laparoscopic radical prostatectomy : the lessons learned. J Endourol 15 : 441-448, 2001.
 
6) Goeman L, et al : Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to a prospective evaluation of 550 patients. World J Urol 24 : 281-288, 2006.
PubMed
7) Stolzenburg JU, et al : Endoscopic extraperitoneal radical prostatectomy : oncological and functional results after 700 procedures. J Urol 174 : 1271-1275, 2005.
PubMed
8) Rozet F, et al : Extraperitoneal laparoscopic radical prostatectomy : aprospective evaluation of 600 cases. J Urol 174 : 908-911, 2005.
 
9) Trabulsi EJ, Guillonneau B : Laparoscopic radical prostatectomy. J Urol 173 : 1072-1079, 2005.
PubMed
10) 田中正利ほか : 日本の腹腔鏡下前立腺全摘除術における合併症の調査 (日本Endourology and ESWL学会学術委員会. 報告). Japanese Journal of Endourology and ESWL 16 : 72-77, 2003.
Medical*Online
11) Salomon L, et al : Open versus laparoscopic radical prostatectomy : part I. BJU Int 94 : 23. 8-243, 2004.
 
12) Remzi M, et al : Morbidity of laparoscopic extraperitoneal versus transperitoneal radical prostatectomy verus open retropubic radical prostatectomy. Eur Urol 8 : 83-89, 2005.
PubMed
13) Mibani W, et al : Is laparoscopic radical prostatectomy better than traditional retropubic radical prostatectomy? An analysis of peri-operative morbidity in two contemporary series in Italy. Eur Urol 44 : 401-406, 2003.
 
14) Nadu A, et al : Early removal of the catheter after laparoscopic radical prostatectomy. J Urol 166 : 1662-1664, 2001.
PubMed
15) Hara I, et al : Comparison of quality of life following laparoscopic and open prostatectomy for prostate cancer. J Urol 169 : 2045-2048, 2003.
PubMed
16) Namiki S, et al : Changes in quality of life in first year after radical prostatectomy by retropubic, laparoscopic, and perineal approach : Multi-institutional longitudinal study in Japan. Urology 67 : 321-327, 2006.
PubMed
17) Roumeguere T, et al : Radical prostatectomy : aprospective comparison of oncological and functional results between open and laparoscopic approaches. World J Urol 20 : 360-366, 2003.
 
18) Salomon L, et al : Urinary continence and erectile function : a prospective evaluation of functional results after radical laparoscopic prostatectomy. Eur Urol 42 : 338-343, 2002.
PubMed
19) Rassweiler J, et al : Laparoscopic radical prostatectomy with the Heilbronn technique : oncological results in the first 500 patients. J Urol 173 : 761-764, 2005.
PubMed
20) Katz R, et al : Positive surgical margins in laparoscopic radical prostatectomy : the impact of apical dissection, bladder neck remodeling and nerve preservation. J Urol 169 : 2049-2052, 2003.
PubMed
21) Salomon L, et al : Location of positive surgical margins after retropubic, perinea1, and laparoscopic radical prostatectomy for organ-confined prostate cancer. Urology 61 : 386-390, 2003.
PubMed
22) Guillonneau B, et al : Laparoscopic radical prostatectomy : oncological evaluation after 1,000 cases a Montsouris Institute. J Urol 169 : 1261-1266, 2003.
 
23) Ates M, et al : Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis. J Urol 177 : 1771-1776, 2007.
PubMed
24) Anderson JK, et al : Cost comparison of laparoscopic versus radical retropubic prostatectomy. Urology 66 : 557-560, 2005.
PubMed
25) Menon M, et al : Vattikuti Institute prostatectomy, a technique of robotic radical prostatectomy for management of localized carcinoma of the prostate : experience of over 1100 cases. Urol Clin North Am 31 : 701-717, 2004.
PubMed
P.330 掲載の参考文献
1) 木原和徳ほか : ミニマム創内視鏡下泌尿器手術 (木原和徳編), 医学書院, 2002.
 
2) 木原和徳 : ミニマム創内視鏡下手術とは何か. 泌尿器外科 19 : 771-782, 2006.
 
3) 木原和徳 : ミニマム創内視鏡下手術の原理と手術器具の開発と目標の達成度. Urology View 14 : 28-37, 2006.
 
4) 木原和徳 : イラストレーテッド・ミニマム創内視鏡下泌尿器手術, 医学書院. (印刷中)
 
5) 木原和徳 : ミニマム創内視鏡下前立腺全摘除術. Urology View 2 : 48-56, 2004.
 
6) 横山みなと, 木原和徳 : ミニマム創内視鏡下手術の標準化と教育. 泌尿器外科 19 : 783-792, 2006.
 
7) 木原和徳ほか : ミニマム創内視鏡下泌尿器腫瘍手術の先進医療認定. 泌尿器外科 20 : 211-217, 2007.
 
8) 木原和徳 : 準ミニマム創/ミニマム創/アドバンスミニマム創・内視鏡下泌尿器手術 : 全ての開放手術の低侵襲化. 泌尿器外科 20 : 219-227, 2007.
 
P.334 掲載の参考文献
1) Klotz LH, et al : CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy : 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 53 (4) : 757-763, 1999.
PubMed
2) Gleave ME, et al : Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy : biochemical and pathological effects. J Urol 166 (2) : 500-506, 2001.
PubMed
3) Aus G, et al : Three-month neoadjuvant hormonal therapy before radical prostatectomy : a 7-year follow-up of a randomized controlled trial. BJU Int 90 : 561-566, 2002.
PubMed
4) Takashima R, et al : Anterior distribution of Stage T1c nonpalpable tumors in radical prostatectomy specimens, Urology 59 : 692-697, 2002.
PubMed
5) 中川徹ほか : 前立腺全摘除術. 新 癌の外科-手術手技シリーズ2 泌尿器癌 (垣添忠生監, 藤元博行編), p89-107, メジカルビュー社, 2001.
 
6) 藤元博行 : 非神経温存前立腺広汎切除術における排尿機能. Urology View 5 (2) : 51-57, 2007.
Medical*Online
P.347 掲載の参考文献
1) Cambio AJ, Evans CP : Minimising Postoperative incontinence following radical prostatectomy : considerations and evidence. Eur Urol 50 : 903-913, 2006.
PubMed
2) Sacco E, et al : Urinary incontinence after radical prostatectomy : incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 97 : 1234-1241, 2006.
 
3) Burgio KL, et al : Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence : a randomized, controlled trial. J Urol 175 : 196-201, 2006.
PubMed
4) Burkhard FC, et al : Nerve sparing open radical retropubic prostatectomy-does it have an impact on urinary continence? J Urol 176 : 189-195, 2006.
PubMed
5) Egawa S, et al : Delayed recovery of urinary continence after laparoscopic radical prostatectomy. Int J Urol 10 : 207-212, 2003.
PubMed
6) Takenaka A, et al : Preservation of the puboprostatic collar and puboperineoplasty for early recovery of urinary continence after robotic prostatectomy : anatomic basis and preliminary outcomes. Eur Urol 51 : 433-440, 2007.
PubMed
7) Gaker DL, et al : Radical prostatectomy with preservation of urinary continence. J Urol 156 : 445-449, 1996.
PubMed
8) Seaman EK, Benson MC : Improved continence with tubularized bladder neck reconstruction following radical retropubic prostatectomy. Urology 47 : 532-535, 1996.
PubMed
9) Hollabaugh RS, et al : Preservation of putative continence nerves during radical retropubic prostatectomy leads to more rapid return of urinary continence. Urology 51 : 960-967, 1998.
PubMed
10) Moinzadeh A, et al : Urinary incontinence after radical retropubic prostatectomy : the outcome of a surgical technique. BJU Int 92 : 355-359, 2003.
PubMed
11) Rocco F, et al : Restoration of posterior aspect of rhabdosphincter shortens continence time after radical retropubic prostatectomy. J Urol 175 : 2201-2206, 2006.
PubMed
12) Lowe BA : Preservation of the anterior urethral ligamentous attachments in maintaining post-prostatectomy urinary continence : a comparative study. J Urol 158 : 2137-2141, 1997.
PubMed
13) Sugimura Y, et al : An anterior urethral stitch improves urinary incontinence following radical prostatectomy. Int J Urol 8 : 153-157, 2001.
PubMed
14) 杉村芳樹 : 排尿機能温存のためのDVC処理の工夫. Urology View 5 : 28-33, 2007.
Medical*Online
15) Feneley MR, Walsh PC : Incontinence after radical prostatectomy. Lancet 353 (9170) : 2091-2092, 1999.
PubMed
P.351 掲載の参考文献
1) Walsh PC : Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life : a structured debate. J Urol 163 : 1802」807, 2000.
 
2) Rabbani F, et al : Factors predicting recovery of erections after radical prostatectomy. J Urol 164 : 1929-1934, 2000.
PubMed
3) Stanford JL, et al : Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer. JAMA 283 : 354-360, 2000.
PubMed
4) Noh C, et al : Outcomes after radical retropubic prostatectomy. Urology 61 : 412-416. 2003.
PubMed
5) Kundu SD, et al : Potency, continence and complications in 3477 consecutive radical retropubic prostatectomies. J Urol 172 : 2227-2231, 2004.
 
6) Chuang MS, et al : Early release of the neurovascular bundles and optical loupe magnification lead to improved and earlier return of potency following radical retropubic prostatectomy. J Urol 173 : 537-539, 2005.
PubMed
7) Montorsi F, et al : Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy. Eur Urol 48 : 938-945, 2005.
PubMed
8) Horninger W, et al : Radical retropubic prostatectomy : apical preparation and curtain dissection of the neurovascular bundle. BJU Int 95 : 911-923, 2005.
PubMed
9) Benoit G, et al : Supra and infralevator neurovascular pathways to the penile corpora cavernosa. J Anat 195 : 605-615, 1999.
 
10) Secin FP, et al : Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy. Eur Urol 51 : 1229-1235, 2007.
PubMed
11) Rogers CG, et al : Preservation of accessory pudendal arteries during radical retropubic prostatectomy : surgical technique and results. Urology 64 : 148-151, 2004.
PubMed
12) Hoznek A, et al : Laparoscopic radical prostatectomy. The Creteil experience. Eur Urol 40 : 38-45, 2001.
PubMed
13) Anastasiadis AG, et al : Radical retropubic versus laparoscopic prostatectomy : aprospective comparison of functional outcome. Urology 62 : 292-297, 2003.
 
14) Su LM, et al : Nerve-sparing laparoscopic radical prostatectomy : Replicating the open surgical technique. Urology 64 : 123-127, 2004.
PubMed
15) Rozet F, et al : Extraperitoneal laparoscopic radical prostatectomy : aprospective evaluation of 600 cases. J Urol 174 : 908-911, 2005.
 
16) Stolzenburg JU, et al : Endoscopic extraperitoneal radical prostatectomy : oncological and functional results after 700 procedures. J Urol 174 : 1271-1275, 2005.
PubMed
17) Menon M, et al : Vattikuti institute prostatectomy : asingle-team experience of 100 cases. J Endourol 17 : 785-790, 2003.
 
18) Bentas W, et al : Robotic technology and the translation of open radical prostatectomy to laparoscopy : the early Frankfurt experience with robotic radical prostatectomy and one year follow-up. Eur Urol 44 : 175-181, 2003.
PubMed
19) Kaul S, et al : Robotic radical prostatectomy with preservation of the prostatic fascia : a feasibility study. Urology 66 : 1261-1265, 2005.
PubMed
20) Ahlering TE, et al : Impact of cautery versus cautery-free preservation of neurovascular bundles on early return of potency. J Endourol 20 : 586-589, 2006.
PubMed
21) Joseph JV, et al : Robotic extraperitoneal radical prostatectomy : an alternative approach. J Urol 175 : 945-951, 2006.
PubMed
22) Tewari A, et al : Anatomical foundations for nerve preservation during prostatectomy-trizonal concept and athermal robotic technique. Contemp Urol. (in press)
 
23) Takenaka A, et al : Pelvic autonomic nerve mapping around the prostate by intraoperative electrical stimulation with simultaneous measurement of intracavernous and intraurethral pressure. J Urol 177 : 225-229, 2007.
PubMed
24) Terada N, et al : Intraoperative electrical stimulation of cavernous nerves with monitoring of intracorporeal pressure to confirm nerve sparing during radical prostatectomy : early clinical results. Int J Urol 10 : 251-256, 2003.
PubMed
25) Tsujimura A, et al : Significance of electrostimulation in detecting neurovascular bindle during radical prostatectomy. Int J Urol 13 : 926-931, 2006.
 
26) Kim ED, et al : Bilateral nerve graft during radical retropubic prostatectomy : 1-year followup. J Urol 165 : 1950-1956, 2001.
PubMed
27) Saito S, et al : Impact of unilateral interposition sural nerve graft on the recovery of sexual function after radical prostatectomy in Japanese men : a preliminary study. Int J Urol 14 : 133-139, 2007.
 
28) Secin FP, et al : Bilateral cavernous nerve interposition grafting during radical retropubic prostatectomy : Memorial Sloan-Kettering Cancer Center experience. J Urol 177 : 664-668, 2007.
PubMed
29) Martinez-Salamanca JI, et al : Nerve advancement with end-to-end reconstruction during robotic radical prostatectomy : a new challenge. J Endourol. (in press)
 
30) Padma-Nathan H : PDE-5 inhibitor therapy for erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy. Rev Urol 7 : s33-s38, 2005.
PubMed
31) Raina R, et al : Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 63 : 960-966, 2004.
PubMed
32) Dall'Era JE, et al : Penile rehabilitation after radical prostatectomy : important therapy or wishful thinking? Rev Urol 8 : 209-215, 2006.
PubMed
P.359 掲載の参考文献
1) Pound CR, et al : Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 : 1591-1597, 1999.
PubMed
2) Freedland SJ, et al : The search database study group. Improved clinical staging system combining biopsy laterally and TNM stage for men with T1c and T2 prostate cancer : results from the SEARCH database. J Urol 169 : 2129-2135, 2003.
 
3) Freedland SJ, et al : Comparison of preoperative prostate specific antigen for predicting recurrence after radical prostatectomy : results from the search data base. J Urol 169 : 969-973, 2003.
 
4) Grossfield GD, et al : Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169 : 157-163, 2003.
 
5) Graefen M, et al : Early prostate-specific antigen relapse after radical retropubic prostatectomy : prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 36 : 21-30, 1999.
PubMed
6) Grossfeld GD, et al : Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies : results from CaPSURE. Urology 59 : 560-565, 2002.
PubMed
7) Cheng L, et al : The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol 23 : 2911-2917, 2005.
PubMed
8) Kupelian P, et al : Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48 : 249-260, 1996.
PubMed
9) Freedland SJ, et al : Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease : pT2a versus pT2b. Cancer 100 : 1646-1649, 2004.
PubMed
10) Haukaas SA, et al : Is preoperative serum prostate-specific antigen level signhicantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? BJU Int 97 : 51-55, 2006.
PubMed
11) Jhaveri FM, et al : Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer : 10-year results. Urology 54 : 884-890, 1999.
 
12) Freedland SJ, et al : Risk of prostate cancer-specific mortality following biological recurrence after radical prostatectomy. JAMA 294 : 433-439, 2005.
PubMed
13) Hachiya T, et al : Prostate-specific antigen failure within 2 year of radical prostatectomy predicts overall survival. Int J Urol 13 : 362-367, 2006.
 
14) Hachiya T, et al : Long-term survival following radical prostatectomy in Japanese men with clinically localized prostate cancer : a single institutional study. Int J Urol 11 : 862-869, 2004.
PubMed
15) Patel A, et al : Recurrence pattems after radical retropubic prostatectomy : clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 : 1441-445, 1997.
 
P.365 掲載の参考文献
1) http://www.nci.nih.gov/cancertopics/pdq/levels-evidence-adult-treatment/HealthProfessional/page3
 
2) Amling CL, et al : Defining prostate specific antigen progression after radical prostatectomy : what is the most appropriate cut point? J Urol 165 (4) : 1146-1151, 2001.
 
3) Freedland SJ, et al : Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61 (2) : 365-369, 2003.
PubMed
4) Stephenson AJ, et al : Defining biochemical recurrence of prostate cancer after radical prostatectomy : a proposal for a standardized definition. J Clin Oncol 24 (24) : 3973-3978, 2006.
PubMed
5) Shen S, et al : Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 173 (3) : 777-780, 2005.
PubMed
6) Bolla M, et al ; European Organization for Research and Treatment of Cancer : Postoperative radiotherapy after radical prostatectomy : a randomised controlled trial (EORTC trial 22911). Lancet 366 (9485) : 572-578, 2005.
PubMed
7) Terai A, et al : Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int 96 (7) : 1009-1013, 2005.
PubMed
P.369 掲載の参考文献
1) Jhaveri FM, et al : Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer. Urology 54 : 884-890, 1999.
 
2) Pound CR, et al : Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 : 1591-1597, 1999.
PubMed
3) vander Kooy MJ, et al : Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 49 : 65-70, 1997.
PubMed
4) Forman JD, et al : Therapeutic irradiation for patients with elevated post-prostatectomy prostate specific antigen level. J Urol 158 : 1436-1470, 1997.
 
5) Cox JD, et al : American Society for Therapeutic Radiology and Oncology Consensus Panel : Consensus statements on radiation therapy of prostate cancer : guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 17 : 1155-1163, 1999.
PubMed
6) Boccon-Gibod L, et al : Management of prostate-specific antigen relapse in prostate cancer : a European Consensus. Int J Clin Pract 58 : 382-390, 2004.
PubMed
7) Cadeddu JA, et al : Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159 : 173-178, 1998.
PubMed
8) Ward JF, et al : Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172 : 2244-2248, 2004.
PubMed
9) Numata K, et al : Predictor of response to salvage radiotherapy in patients with PSA recurrence after radical prostatectomy : the usefulness of PSA doubling time. Jpn J Clin Oncol 35 : 256-259, 2005.
PubMed
10) Stephenson N, Slawin KM : The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat Clin Pract Urol 63 : 90-96, 2004.
 
11) Moul JW, et al : Early versus delayed hormonal therapy for PSA-only recurrence of prostate cancer after prior radical prostatectomy. J Urol 171 : 1141-1147, 2004.
PubMed
12) Iversen P, et al : Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer : 6.3 years of followup. J Urol 164 : 1579-1582, 2000.
PubMed
13) Boccardo F, et al : Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients : results of an Italian Prostate Cancer Project study. J Clin Oncol 17 : 2027-2038, 1999.
PubMed
14) Kurek R, et al : Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35 : 27-31, 1999.
PubMed
15) Yokomizo A, et al : Randomized controlled trial to evaluate radiotherapy±endocrine therapy alone for PSA failure after radical prostatectomy : Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol 35 : 34-36, 2005.
 
P.374 掲載の参考文献
1) Nagata Y, et al : CT simulator : a new 3-D planning and simulating system for radiotherapy : Part 2. Clinical application. Int J Radiat Oncol Biol Phys 18 : 505-513, 1990.
PubMed
2) Kupelian PA, et al : Radical prostatectomy, external beam radiotherapy〈72 Gy, external beam radiotherapy > or=72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 : 25-33, 2004.
 
3) Pollack A, et al : Prostate cancer radiation dose response : results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 : 1097-1105, 2002.
 
4) Zelefsky MJ, et al : High-dose intensity modulated radiation therapy for prostate cancer : early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 : 1111-1116, 2002.
PubMed
5) Zietman AL, et al : Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate : a randomized controlled trial. JAMA 294 : 1233-1239, 2005.
PubMed
6) Ishikawa H, et al : Carbon ion radiation therapy for prostate cancer : results of a prospective phase II study. Radiother Oncol 81 : 57-64, 2006.
PubMed
7) Yoshioka Y, et al : High-dose-rate brachytherapy as monotherapy for localized prostate cancer : a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56 : 213-220, 2003.
PubMed
P.379 掲載の参考文献
1) Zagars GK, et al : Prostate cancer and radiation therapy-the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 33 : 23-35, 1995.
PubMed
2) Swanson GP, et al : Predominant treatment failure in postprostatectomy patients is local : analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (16) : 2225-2229, 2007.
PubMed
3) Pollack A, et al : External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48 : 507-512, 2000.
PubMed
4) Jani AB, Hellman S : Early prostate cancer. Clinical decision-making. Lancet 361 : 1045-1053, 2003.
PubMed
5) Abhell SO, et al : Elective pelvic irradiation in stage A2, B carcinoma of the prostate : analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15 : 1307-1316, 1988.
PubMed
6) Abhell SO, et al : Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG#77-06, aphase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40 : 769-. 782, 1998.
 
7) Duncan W, et al : Carcinoma of the prostate : results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 26 (2) : 203-210, 1993.
PubMed
8) Garzotto M, et al : Outcome assessment of external beam radiation therapy for clinically localized prostate cancer. AUA Update Series 19 lesson 27, 2000.
 
9) Bagshaw MA, et al : Prostate cancer. Radiation therapy for localized disease. Cancer 71 : 939-952, 1993.
PubMed
10) Zietman AL, et al : Radical radiation therapy in the management of prostatic adenocarcinoma : the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151 (3) : 640-645, 1994.
PubMed
11) Lawton CA, et al : Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate : analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21 : 935-939, 1991.
PubMed
12) Smit WG, et al : Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18 : 23-29, 1990.
PubMed
13) Zelefsky MJ, et al : Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 : 491-500, 1998.
PubMed
14) Hanks GE, et al : Dose escalation with 3D conformal treatment : five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 : 501-510, 1998.
PubMed
15) Nguyen LN, et al : Late effects after radiotherapy for prostate cancer in a randomized dose-response study : results of a self-assessment questionnaire. Urology 51 : 991-997, 1998.
 
16) Pollack A, et al : Prostate cancer radiation dose response : results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 : 1097-1105, 2002.
 
17) Lukka H, et al : Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 : 6132-6138, 2005.
PubMed
18) Yeoh EE, et al : Evidence for efficacy without increases toxicity of hypofractionated radiotherapy for prostate carcinoma : early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 55 : 943-955, 2003.
PubMed
19) Pilepich MV, et al : Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 : 1285-1290, 2005.
PubMed
20) Bolla M, et al : Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) : a phase III randomized trial. Lancet 360 : 103-108, 2002.
PubMed
21) D'Amico AV, et al : 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer : a randomized controlled trial. JAMA 292 : 821-827, 2004.
PubMed
22) Zelefsky MJ, et al : High-dose intensity modulated radiation therapy for prostate cancer : early toxicity and biochemical outcome in 772 patient. Int J Radiat Oncol Biol Phys 53 : 1111-1116, 2002.
PubMed
23) Bolla M, et al ; European Organization for Research and Treatment of Cancer : Postoperative radiotherapy after radical prostatectomy : a randomized controlled trial (EORTC trial 22911). Lancet 366 : 572-578, 2005.
PubMed
24) Kupelian PA, et all Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >- 72 Gy, permanent seed implantation, or combined seed/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 : 25-33, 2004.
 
25) National Comprehensive Cancer Network : Practice Guidelines in Oncology-v. 2.2007/Prostate cancer ; (Accessed May 5, 2007). http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf
 
P.384 掲載の参考文献
1) Kupelian PA, et al : Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy> or=72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (1) : 25-33, 2004.
 
2) Zelefsky MJ, et al : High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (3) : 876-881, 2001.
PubMed
3) Pollack A, et al : Prostate cancer radiation dose response : results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (5) : 1097-1105, 2002.
 
4) Intensity Modulated Radiation Therapy Collaborative Working Group : Intensity-modulated radiotherapy : current status and issues of interest. Int J Radiat Oncol Biol Phys 51 (4) : 880-914, 2001.
 
5) 溝脇尚志 : 強度変調放射線治療 (IMRT). 医学のあゆみ 212 (12) : 1057-1062, 2005.
Medical*Online
6) Shirato H, et al : Real-time tumour-tracking radiotherapy. Lancet 353 (9161) : 1331-1332, 1999.
PubMed
7) Kupelian P, et al : Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer : the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61 (2) : 415-419, 2005.
PubMed
8) Zelefsky MJ, et al : Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (4 Pt 1) : 1415-1419, 2006.
 
9) 溝脇尚志ほか : 強度変調放射線治療 (IMRT). 泌尿器外科 18 (11) : 1327-1333, 2005.
Medical*Online
10) 溝脇尚志ほか : 前立腺癌に対する3D-CRT/IMRT. 臨床放射線 50 : 610-617, 2005.
 
11) Ling CC, et al : Towards multidimensional radiotherapy (MD-CRT) : biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47 (3) : 551-560, 2000.
PubMed
12) Mohan R, et al : Radiobiological considerations in the design of fractionation strategies for intensitymodulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 46 (3) : 619-630, 2000.
PubMed
13) Roach M, et al : Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66 (3) : 647-653, 2006.
PubMed
14) Mizowaki T, et al : Towards integrating functional imaging in the treatment of prostate cancer with radiation : the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys 54 (5) : 1558-1564, 2002.
PubMed
P.389 掲載の参考文献
1) Shimizu S, et al : Fluoroscopic real-time tumor-tracking radiation treatment (RTRT) can reduce internal margin (IM) and set-up margin (SM) of planning target. Proceedings of the 42nd Annual ASTRO Meeting, p 166-167, 2000.
 
2) Shirato H, et al : Real-time tumour-tracking radiotherapy. Lancet 353 (9161) : 1331-1332, 1999.
PubMed
3) Shirato H, et al : Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys 56 (1) : 240-247, 2003.
 
4) Shimizu S, et al : Use of an implanted marker and real-time tracking of the marker for the positioning of prostate and bladder cancers. Int J Radiat Oncol Biol Phys 48 (5) : 1591-1597, 2000.
PubMed
5) Kitamura K, et al : Three-dimensional intrafractional movement of prostate measured during realtime tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys 53 (5) : 1117-1123, 2002.
PubMed
6) Onimaru R, et al : Calculation of rotational setup error using the real-time tracking radiation therapy (RTRT) system and its application to the treatment of spinal schwannoma. Int J Radiat Oncol Biol Phys 54 (3) : 939-947, 2002.
 
7) Kitamura K, et al : Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer : preliminary results of a phase I/II study. Cancer J 9 (4) : 268-276, 2003.
PubMed
8) Kitamura K, et al : The relationship betWeen technical parameters of external beam radiation therapy and complications for localized prostate cancer. Jpn J Clin Oncol 30 (5) : 225-229, 2000.
PubMed
P.395 掲載の参考文献
1) Partin AW, et al : Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (6) : 843-848. 2001.
PubMed
2) Hanks GE, et al : Dose escalation with 3D conformal treatment : five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (3) : 501-510, 1998.
PubMed
3) Pollack A, et al : Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (23) : 3904-3911, 2000.
PubMed
4) Zietman AL, et al : The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor : an in vitro and in vivo study. Cancer J Sci Am 3 (1) : 31-36, 1997.
 
5) Pollack A, et al : Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res 57 (12) : 2493-2500, 1997.
PubMed
6) Laverdiere J, et al : Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (2) : 247-252, 1997.
PubMed
7) Pilepich MV, et al : Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (5) : 1243-1252, 2001.
PubMed
8) Shipley WU, et al : Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy : a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 54 (5) : 1302-1310, 2002.
 
9) D'Amico AV, et al : 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer : arandomized controlled trial. JAMA 292 (7) : 821-827, 2004.
 
10) Pilepich MV, et al : Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy : report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (3) : 1013-1021, 1997.
PubMed
11) Lawton CA, et al : Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-3 levaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (4) : 937-946, 2001.
 
12) Horwitz EM, et al : Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 49 (4) : 947-956, 2001.
PubMed
13) Lawton CA, et al : Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate : updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 23 (4) : 800-807, 2005.
PubMed
14) Bolla M, et al : Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) : a phase III randomised trial. Lancet 360 (9327) : 103-106, 2002.
PubMed
15) Hanks GE, et al ; Radiation Therapy Oncology Group : Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate : the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (21) : 3972-3978, 2003.
PubMed
16) Messing EM, et al : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (24) : 1781-1788, 1999.
PubMed
17) Tollefson MK, et al : Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer : impact on prostate cancer specific survival. J Urol 175 (2) : 1337-1340, 2006.
 
18) Zapatero A, et al : Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer : Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23 (27) : 6561-6568, 2005.
PubMed
P.400 掲載の参考文献
1) Paulson DF : Management of prostate malignancy. In : Genitourinary Cancer Management (ed by deKernion JB, Paulson DF), p 107-160, Lea and Febiger, Philadelphia, 1987.
 
2) Babaian RJ, et al : Radiation therapy of stage C prostate cancer : significance of Gleason grade to survival. Semin Urol 8 : 225-231, 1990.
 
3) del Regato JA, et al : Twenty years follow-up of patients with inoperable cancer of the prostate (stage C) treated by radiotherapy : report of a national cooperative study. Int J Radiat Oncol Biol Phys 26 : 197-201, 1993.
 
4) Pollack A, et al : Treatment of prostate cancer with regional lylnph node (N1) metastasis. Semin Radiat Oncol 13 : 121-129, 2003.
PubMed
5) Pilepich MV, et al : Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 : 1285-1290, 2005.
PubMed
6) Bolla M, et al : Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) : aphase III randomised trial. Lancet 360 : 103-106, 2002.
 
7) Roach M 3rd, et al : Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression : Radiation Therapy Oncology Group 9413. J Clin Oncol 21 : 1904-1911, 2003.
PubMed
8) Pollack A : A call for more with a desire for less : pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer. J Clin Oncol 21 : 1899-1901, 2003.
 
9) Vicini FA, et al : Defining a dose-response relationship with radiotherapy for prostate cancer ; is more really better? Int J Radiat Oncol Biol Phys 51 : 1200-1208, 2001.
PubMed
10) Kuban DA, et al : Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 : 915-928, 2003.
PubMed
11) Speight JL, et al : Radiotherapy in the management of clinically localized prostate cancer ; evolving standards, consensus, controversies and new directions. J Clin Oncol 23 : 8176-8185, 2005.
PubMed
12) D'Amico AV, et al : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 : 969-974, 1998.
 
13) Blasko JC, et al : Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. Semin Radiat Oncol 3 : 240-249, 1993.
PubMed
14) Nag S, et al : American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 : 789-799, 1999.
PubMed
15) Copp H, et al : Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Urology 65 : 1146-1151, 2005.
PubMed
16) Kupelian PA, et al : Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era ; a large single-institutional experience with radical prostatectomy and externaLbeam radiotherapy. J Clin Oncol 20 : 3376-3385, 2002.
 
17) Dearnaley DP, et al : Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer : a randomised trial. Lancet 353 : 267-272, 1999.
PubMed
18) Zelefsky MJ, et al : Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiat Oncol 55 : 241-249, 2000.
 
19) Lange PH, et al : Radiation therapy as adjuvant treatment after radical prostatectomy. NCI Monogr : 141-149, 1988.
PubMed
20) Ray GR, et al : Extemal beam radiation salvage for residual or recurrent local tumor following radical prostatectomy. J Urol 132 : 926-930, 1984.
PubMed
21) Bolla M, et al : Postoperative radiotherapy after radical prostatectomy : arandomized controlled trial (EORTC22911). Lancet 366 : 572-578, 2005.
 
22) Swanson GP, et al : Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG8794). Int J Radiat Oncol Biol Phys 63 (Suppl 1) : S1, 2005.
 
P.406 掲載の参考文献
1) Sylvester JE, et al : 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy ; Seattle experience. Int J Radiat Oncol Biol Phys 67 : 57-64, 2007.
PubMed
2) Ciezki JP, et al : A retrospective comparison of androgen deprivation vs. no androgen deprivation among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys 60 : 1347-1350, 2004.
PubMed
3) 斉藤史郎 : 前立腺癌小線源療法 : 日本の現状と今後の進展. Jpn J Endourol ESWL 16 : 206-212, 2003.
 
4) Nag S, et al : American Brachytherapy Society (ABS) recommendation for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 : 789-799, 1999.
PubMed
5) Stock RG, et al : Biologically effective dose values for prostate brachytherapy : effects on PSA failureand posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 : 527-533, 2006.
 
6) Critz FA, et al : Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer, J Urol 163 : 1085-1089, 2000.
PubMed
7) Stock RG, et al : Prostate speciflc antigen bounce after prostate seed implantation for localized prostate cancer : description and implication. Int J Radiat Oncol Biol Phys 56 : 448-453, 2003.
 
8) 水野隆一ほか : 密封小線源療法施行前内分泌療法による前立腺体積縮小効果. 日泌尿会誌 97 : 835-838, 2006.
 
P.411 掲載の参考文献
1) Mate TP, et al : High dose-rate afterloading 1921ridium prostate brachytherapy : feasibility report. Int J Radiat Oncol Biol Phys 41 (3) : 525-533, 1998.
PubMed
2) Rodriguez RR, et al : High dose rate brachytherapy for prostate cancer : assessment of current clinical practice and the recommendation of the American Brachytherapy Society. J Brachytherapy Int 17 : 265-282, 2001.
 
3) Yoshioka Y, et al : High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer : Treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 48 : 675-681, 2000.
PubMed
4) Syed AM, et al : High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. Cancer Control 8 : 511-521, 2001.
PubMed
5) Galalae RM, et al : Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52 : 81-90, 2002.
PubMed
6) Martinez AA, et al : Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53 : 316-327, 2002.
PubMed
7) Hiratsuka J, et al : Clinical results of combined treatment conformal high-dose-rate Iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59 : 684-690, 2004.
PubMed
8) Galalae RM, et al : Long-term outcome by risk factors using conformal high-dose rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 : 1048-1055, 2004.
 
9) Demanes DJ, et al : High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer : California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61 : 1306-1316, 2005.
PubMed
10) Hsu IC, et al : Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost : potential for dose escalation. Int J Radiat Oncol Biol Phys 46 : 851-858, 2000.
PubMed
11) Vergas CE, et al : High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost : results of a phase I to II study. Int J Radiat Oncol Biol Phys 66 : 416-423, 2006.
 
12) Michalski JM, et al : Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 62 : 706-713, 2005.
 
13) Tsuji H, et al : Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 63 : 1153-1160, 2005.
PubMed
P.415 掲載の参考文献
1) Akakura K, et al : Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58 : 252-258, 2004.
PubMed
2) Tsuji H, et al : Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 63 (4) : 1153-1160, 2005.
PubMed
3) Ishikawa H, et al : Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 66 : 1084-1091, 2006.
PubMed
4) Storey MR, et al : Complications from dose escalation in prostate cancer : preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 : 635-642, 2000.
PubMed
5) Kupelian PA, et al : Hypofractionated intensity-modulated radiotherapy (70 Gy at 2. 5Gy per fraction) for localized prostate cancer : long-term outcomes. Int J Radiat Oncol Biol Phys 63 : 1463-1468, 2005.
 
6) Schulte RW, et al : Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther Onkol 176 : 3-8, 2000.
PubMed
7) Hanks GE, et al : Dose escalation for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46 : 823-832, 2000.
 
P.419 掲載の参考文献
1) Sisterson J : World wide charged particle patient totals. Particles 36 : 10-11. 2005.
 
2) Hishikawa Y, et al : Usefulness of positron-emission tomographic images after proton therapy. Int J Radiat Oncol Biol Phys 53 : 1388-1391, 2002.
PubMed
3) Cella L, et al : Potential role of intensity modulated proton beams in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 49 : 217-223, 2001.
PubMed
4) Kry MS, et al : The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62 : 1195-1203, 2005.
 
5) Schneider U, et al : The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 68 : 892-897, 2007.
PubMed
6) Shipley WU, et al : Advanced prostate cancer : the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32 : 3-12, 1995.
PubMed
7) Slater JD, et al : Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 42 : 299-304, 1998.
PubMed
8) Slater JD, et al : Conformal proton therapy for early-stage prostate cancer. Urology 53 : 978-984, 1999.
PubMed
9) Slater JD, et al : Proton therapy for prostate cancer : the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 59 : 348-352, 2004.
 
10) Zietman AL, et al : Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate a randomized controlled trial. JAMA 294 : 1233-1239, 2005.
PubMed
11) Nihei K, et al : Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy : first clinical trial of proton beam therapy for prostate cancer in Japan. Jpn J Clin Oncol 35 : 745-752, 2005.
PubMed
12) Mayahara H, et al : Acute morbidity of proton therapy for prostate cancer : The Hyogo Ion Beam Medical Center Experience. Int J Radiat Oncol Biol Phys 69 : 434-443, 2007.
PubMed
P.424 掲載の参考文献
1) http://www.jcog.jp/SHIRYOU/CTCAEver_3/CTCAEv3J_070308.pdf
 
2) http://www.rtog.org/members/toxicity/late.html
 
3) Emami B, et al : Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 : 109-122, 1991.
PubMed
4) Fowler JF : The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 : 679-694, 1989.
PubMed
5) Intemational Commission on Radiation Units and Measurements : Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). ICRU report 62, 1998.
 
6) Garg AK, et al : Radiation proctopathy in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 66 : 1294-1305, 2006.
PubMed
7) Vargas C, et al : Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 62 : 1297-1308, 2005.
PubMed
8) Soejima T, et al : Case of radiation-induced esophageal ulcer worsened after endoscopic biopsy. Dis Esophagus 15 (3) : 266-268, 2002.
PubMed
9) Heemsbergen WD, et al : Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients : consequential late damage. Int J Radiat Oncol Biol Phys 66 : 3-10, 2006.
PubMed
10) Kupelian PA, et al : Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer : preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 51 : 9. 88-993, 2001.
 
11) Peeters ST, et al : Acute and late complications after radiotherapy for prostate cancer : results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 : 1019-1034, 2005.
PubMed
12) Cozzarini C, et al : Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 55 : 688-694, 2003.
 
13) Peeters Svr, et al : Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 64 : 1151-1161, 2006.
 
14) Waterman FM, Dicker AP : Probability of late rectal morbidity in 1251 prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 : 342-353, 2003.
 
P.430 掲載の参考文献
1) Pound CR, et al : Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 : 1591-1597, 1999.
PubMed
2) Naito S : Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Jpn J Clin Oncol 35 : 365-374, 2005.
PubMed
3) Terai A, et al : Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int 96 : 1009-1013, 2005.
PubMed
4) Scattoni V, et al : Diagnosis of local recurrence after radical prostatectomy. BJU Int 93 : 680-688, 2004.
PubMed
5) Schwarz R, et al : Therapy of recurrent disease after radical prostatectomy in 2007. World J Urol 25 : 161-167, 2007.
PubMed
6) Cox JD, et al : Consensus statements on radiation therapy of prostate cancer : guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17 : 1155-1163, 1999.
 
7) Kalapurakal JA, et al : Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys 54 : 1047-1054, 2002.
PubMed
8) Pazona JF, et al : Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy : 10-year outcome estimates. J Urol 174 : 1282-1286, 2005.
PubMed
9) Brooks JP, et al : Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J Urol 174 : 2204-2208, 2005.
PubMed
10) Sasaki T, et al : Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer. Anticancer Res 26 : 2367-2374, 2006.
PubMed
11) Stockdale AD, et al : Management of biochemical failure following radical prostatectomy : salvage radiotherapy-a case series. Prostate Cancer Prostatic Dis 10 : 205-209, 2007.
PubMed
12) Stephenson AJ, et al : Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 : 2035-2041, 2007.
PubMed
13) Stephenson AJ, et al : Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 : 1325-1332, 2004.
PubMed
14) Hu JC, et al : The effect of postprostatectomy external beam radiotherapy on quality of life. Results from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer 107 : 281-288, 2006.
PubMed
15) Yokomizo A, et al : Randomized controlled trial to evaluate radiotherapy±endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy : Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol 35 : 34-36, 2005.
 
P.437 掲載の参考文献
1) Akaza H : Trends in primary androgen depletion therapy for patients With localized and locally advanced prostate cancer : Japanese perspective. Cancer Sci 97 : 243-247, 2006.
PubMed
2) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン2006年版, 金原出版, 2006.
 
3) Mulrow C, et al : Integrating heterogeneous pieces of evidence in systematic reviews. Ann Intern Med 127 : 989-995, 1997.
PubMed
4) Fleming C, et al : Adecision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 269 : 2650-2658, 1993.
 
5) Miller DC, et al : Incidence of initial local therapy among men with lower-risk prostate cancer in the 98 : 1134-1141, 2006.
PubMed
6) Loblaw DA, et al : Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer : 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25 : 1596-1605, 2007. (Epub 2007 Apr 2)
 
7) Albertsen PC, et al : 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 : 2095-2101, 2005.
PubMed
8) Ankerst DP, Thonpson IM : New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. Arch Ital Urol Androl 78 : 154-156, 2006.
 
P.441 掲載の参考文献
1) Schally AV, et al : Gonadotropin-releasing hormone : one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173 : 1036-1038, 1971.
PubMed
2) Auclair C, et al : Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin. Biochem Biophys Res Commun 76 : 855-862, 1977.
PubMed
3) Labrie F, et al : Antifertility effects of LHRH agonists in the male. J Androl 1 : 209-228, 1980.
 
4) Redding TW, et al : Long-acting delivery systems for peptides : inhibition of rat prostate tumors by controlled release of [D-Trp6] luteinizing hormone-releasing hormone from injectable microcap sules. Proc Natl Acad Sci USA 81 : 5845-5848, 1984.
 
5) Parmar H, et al : Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet ii : 1201-1205, 1985.
 
6) Huben RP, Murphy GP : A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 62 : 1881-1887, 1988.
PubMed
7) Soloway MS, et al : Zoladex versus orchiectomy in treatment of advanced prostate cancer : a randomized trial. Zoladex Prostate Study Group. Urology 37 : 46-51, 1991.
 
8) Seidenfeld J, et al : Single-therapy androgen suppression in men with advanced prostate cancer : a systematic review and meta-analysis. Ann Intern Med 132 : 566-577, 2000.
PubMed
9) Hanks GE, et al : Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate : The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 : 3972-3978, 2003.
PubMed
10) Bolla M, et al : Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) : a phase III randomized trial. Lancet 360 : 103-106, 2002.
PubMed
11) Brawer MK : The evolution of hormonal therapy for prostatic carcinoma. Rev Urol 3 : S1-S9, 2001.
PubMed
P.445 掲載の参考文献
1) Cancer Registration Committee of the Japanese Urological Association : Clinicopathological statistics on registered prostate cancer patients in Japan : 2000 report from the Japanese Urological Association. Int J Urol 12 : 46-61, 2005.
PubMed
2) Akaza H, et al : Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan : J-CaP surveillance. Jpn J Clin Oncol 34 : 329-336, 2004.
PubMed
3) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン2006年版, 金原出版, 2006.
 
4) Trachtenberg J, et al : A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 167 : 1670-1674, 2002.
PubMed
5) Prostate Cancer Trialists' Collaborative Group : Maximum androgen blockade in advanced prostate cancer : an overview of the randomised trials. Lancet 355 : 1491-1498, 2000.
 
6) Akaza H, et al : A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group. Jpn J Clin Oncol 23 : 178-185, 1993.
 
7) Boccoll-Gibod L, et al : Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 32 : 391-395, 1997.
 
8) Kaisary AV, et al : A randomized comparison of monotherapy with casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Eur Urol 28 : 215-222, 1995.
PubMed
9) Tyrrell CJ, et al : A randomized comparison of 'casodex'(TM) (Bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33 : 447-456, 1998.
 
10) Wirth M, et al : Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58 : 146-151, 2001.
 
11) Iversen P, et al : Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer : 5. 3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 172 : 1871-1876, 2004.
 
12) See WA : Bicalutamide adjuvant to radical prostatectomy. Rev Urol 6 (Suppl 2) : S20-28, 2004.
 
13) Ozono S, et al : A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer. Jpn J Clin Oncol 30 : 389-396, 2000.
PubMed
14) Ozono S, et al : Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis 5 : 128-131, 2002.
PubMed
15) Kojima M, et al : Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer : a preliminary study. Int J Urol 9 : 42-46, 2002.
PubMed
P.449 掲載の参考文献
1) Huggins C, Hodgers CV : Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 : 293-297, 1941.
 
2) Labrie F, et al : Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 7 : 67-74, 1986.
PubMed
3) Mizokami A, et al : The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64 : 765-771, 2004.
PubMed
4) Labrie F, et al : Combination therapy with flutamide and castration (LH-RH agonist or orchiectomy) in advanced prostate cancer : a marked improvement in response and survival. J Steroid Biochem 23 : 833-841, 1985.
 
5) 中里晴樹ほか : 進行性前立腺癌におけるFlutamideによる副腎性アンドロゲン抑制効果の臨床的検討. 日泌尿会誌 92 : 6-12, 2001.
 
6) Prostate Cancer Trialists' Collaborative Group : Maximum androgen blockade in advanced prostate cancer : an overview of the randomized trials. Lancet 355 : 1491-1498, 2000.
 
7) Klotz L, et al : Are-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 93 : 1177-1182, 2004.
PubMed
8) Labrie F, et al : Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60 : 115-119, 2002.
 
9) Akaza H, et al : Efficacy of primary hormone therapy for localized or locally advanced prostate cancer : results of a 10-year follow-up. BJU Int 98 : 573-579, 2006.
 
10) Ueno S, et al : Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer : a retrospective multicenter study, Int J Urol 13 : 1494-1500, 2006.
PubMed
P.453 掲載の参考文献
1) Kelly WK, Scher HI : Prostate specific antigen decline after antiandrogen withdrawal : the fiutamide withdrawal syndrome. J Urol 149 : 607-609, 1993.
 
2) 秋元晋 : アンチアンドロゲン除去症候群. 日本臨牀 56 (8) : 187-191, 1998.
 
3) 西山勉, 照沼正博 : 進行性前立腺癌におけるアンチアンドロゲン除去症候群. 癌治療と宿主 10 (1) : 62-69, 1998.
 
4) 赤倉功一郎 : アンチアンドロゲン除去症候群. 前立腺癌のすべて, p260-262, メジカルビュー社, 1999.
 
5) 鈴木啓悦 : アンチアンドロゲン除去症候群とアンドロゲンリセプター. 日本臨牀 58 (増刊号 : 前立腺癌の診断と治療) : 434-436, 2000.
 
6) 赤倉功一郎, 伊藤晴男 : 前立腺癌における増殖因子およびアンドロゲンレセプターの役割. Biotherapy 16 (5) : 487-492, 2002.
 
7) Paul R, Breul J : Antiandrogen withdrawal syndrome associated with prostate cancer therapies : incidence and clinical significance. Drug Saf 23 : 381-390, 2000.
PubMed
8) Miyamoto H, et al : Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 91 : 3-12, 2004.
PubMed
9) Veldscholte J, et al : Amutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173 : 534-540, 1990.
 
10) Veldscholte J, et al : The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41665-669, 1992.
 
11) Suzuki H, et al : Codon 877 mutation in the androgen receptor gene in advanced prostate cancer : relation to antiandrogen withdrawal syndrome. Prostate 29 : 153-158, 1996.
PubMed
12) Hara T, et al : Novel mutations of androgen receptor : apossible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63 : 149-153, 2003.
 
13) Akakura K, et al : Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45 : 700-705, 1995.
PubMed
14) Nishiyama T, Terunuma M : Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawa1 : a case report. Int J Urol 1 : 355-356, 1994.
PubMed
15) Miyake H, et al : Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96 : 791-795, 2005.
PubMed
16) Kojima S, et al : Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171 (2 Pt 1) : 679-683, 2004.
 
17) Okihara K, et al : Clinical efficacy of alternative antiandrogen deprivation therapy in Japanese men with relapsed prostate cancer after first line hormonal therapy. Int J Urol 14 : 128-132, 2007.
 
P.456 掲載の参考文献
1) Labrie F, et al : Neoadjuvant hormonal therapy : the Canadian experience. Urology 49 (3A Suppl) 56-64, 1997.
 
2) AusG, et al : Three-month neoadjuvant hormonal therapy before radical prostatectomy : a 7-year follow-up of a randomized controlled trial. BJU Int 90 : 561-566, 2002.
 
3) Soloway MS, et al : Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer : 5-year results. J Urol 167 : 112-116, 2002.
PubMed
4) Goldenberg SL, et al : Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 156 : 873-877, 1996.
 
5) Klotz LH, et al : Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170 : 791-794, 2003.
 
6) Bono AV, et al : Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer : progress pathology report of the Italian PROSIT study. Urology 57 : 117-121, 2001.
PubMed
7) Gleave ME, et al : Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy : biochemical and pathological effects. J Urol 166 : 500-506, 2001.
PubMed
8) Prezioso D, et al : Neoadjuvant hormone treatment with leuprolide acetate depot 3. 75 mg and cyproterone acetate, before radical prostatectomy : a randomized study. Urol Int 72 : 189-195, 2004.
PubMed
9) Schulman CC, et al : 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38 : 706-713, 2000.
 
10) Homma Y, et al : Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation : Five-year results. Int J Urol 11 : 295-303, 2004.
 
11) Powell U, et al : Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate : 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol 168 : 2016-2019, 2002.
 
12) Ward JF, et al : Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing : 15-year outcome. BJU Int 95 : 751-756, 2005.
PubMed
13) 藤元博行 : 局所進行前立腺癌に対するホルモン療法と手術療法の併用療法. 日本臨牀 63 : 271-278, 2005.
Medical*Online
P.460 掲載の参考文献
1) Kojima S, et al : Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171 : 679-683, 2004.
PubMed
2) Huggins C, Hodges CV : Studies on prostatic cancer : I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 : 293-297, 1941.
 
3) Lam JS, et al : Secondary hormonal therapy for advanced prostate cancer. J Urol 175 : 27-34, 2006.
PubMed
4) Small EJ, Ryan CJ : The case for secondary hormonal therapies in the chemotherapy age. J Urol 176 : S66-71, 2006.
 
5) Ryan CJ, Small EJ : Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 62 (Suppl 1) : 87-94, 2003.
 
6) Scher HI, Kolvenbag GJ : The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur Urol 31 (Suppl 2) : 3-7 ; discussion 24-27, 1997.
 
7) Fowler JE, et al : Prostate spec近c antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 154 : 448-453, 1995.
 
8) Joyce R, et al : High dose bicalutamide for androgen independent prostate cancer : effect of prior hormonal therapy. J Urol 159 : 149-153, 1998.
PubMed
9) Scher HI, et al : Bicalutamide for advanced prostate cancer : the natural versus treated history of disease. J Clin Oncol 15 : 2928-2938, 1997.
 
10) Okihara K, et al : Clinical ef6cacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 14 : 128-132, 2007.
PubMed
11) Miyake H, et al : Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96 : 791-795, 2005.
PubMed
12) Kucuk O, et al : Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed : a Southwest Oncology Group study (SWOG 9235). Urology 58 : 53-58, 2001.
 
13) Desai A, et al : Nilutamide : possible utility as a second-line hormonal agent. Urology 58 : 1016-1020, 2001.
PubMed
14) Kassouf W, et al : Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169 : 1742-1744, 2003.
 
P.466 掲載の参考文献
1) Huggins C, Hodges CV : Studies on prog. tatic cancer. 1 ; The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 : 293-297, 1941.
 
2) Bruchovsky N : Intermittent therapy for prostate cancer. Endocr Relat Cancer 4 : 153-177, 1997.
 
3) Noble RL : Hormonal control of growth and progression in tumors of Nb rats and theory of action. Cancer Res 37 : 82-94, 1977.
PubMed
4) Vahlensieck W, et al : Comparison between continuous and intermittent administration of Estracyt in the treatment of carcinoma of the prostate. Urol Res 13 : 209-212, 1985.
PubMed
5) Klotz LH, et al : Intermittent endocrine therapy for advanced prostate cancer. Cancer 58 : 2546-2550, 1986.
PubMed
6) Akakura K, et al : Effects of intermittent androgen suppression on androgen-dependent tumors ; apotosis and serum prostate-specific antigen. Cancer 71 : 2782-2790, 1993.
 
7) Goldenberg SL, et al : Intermittent androgen suppression in the treatment of prostate cancer ; a preliminary report. Urology 45 : 839-845, 1995.
PubMed
8) Higano CS, et al : Intermittent androgen suppression with leuprolide and flutamide for prostate cancer ; a pilot study. Urology 48 : 800-804, 1996.
PubMed
9) Grossfeld GD, et al : Intermittent androgen deprivation for clinically localized prostate cancer ; initial experience. Urology 51 : 137-144, 1998.
PubMed
10) Kurek R, et al : Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35 : 27-31. 1999.
PubMed
11) de Leval J, et al : Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer ; results of a prospective randomized trial. Clin Prostate Cancer 1 : 163-171, 2002.
PubMed
12) Sato N, et al : Intermittent androgen suppression for locally advanced and metastatic prostate cancer ; preliminary report of a prospective multi-center study. Urology 64 : 341-345, 2004.
 
13) 赤倉功一郎ほか : 前立腺癌の間欠的内分泌療法-導入の手引きと最適なプロトコール (赤倉功一郎編), p32-61, メジカルビュー社, 2005.
 
P.471 掲載の参考文献
1) Koutsilieris M, et al : Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer : case report. Prostate 38 : 313-316, 1999.
PubMed
2) Nishimura K, et al : Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93 : 1739-1746, 2001.
PubMed
3) Nishimura K, et al : Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89 : 2570-2576, 2000.
PubMed
4) Ebert BL, et al : An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone : identification of dexamethasone-responsive genes by microarray. Blood 105 : 4620-4626, 2005.
PubMed
5) Weitzman AL, et al : Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163 : 834-837, 2000.
PubMed
6) Chang CY, et al : Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61 : 8712-8717, 2001.
 
7) Zhao XY, et al : Glucocorticoids can promote androgen-independent groWth of prostate cancer cells through a mutated androgen receptor. Nat Med 6 : 703-706, 2000.
PubMed
8) Small EJ, et al : Suramin therapy for patients with symptomatic hormone-refractory prostate cancer : results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18 : 1440-1450, 2000.
PubMed
9) Kantoff PW, et al : Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer : results of the cancer and leukemia group B 9182 study. J Clin Oncol 17 : 2506-2513, 1999.
 
10) Fossa SD, et al : Flutamide versus prednisone in patients with prostate cancer symptomatically pro-gressing after androgen-ablative therapy : a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19 : 62-71, 2001.
 
11) Sartor O, et al : Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52 : 252-256, 1998.
PubMed
12) Tannock I, et al : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer : a Canadian randomized trial with palliative end points. J Clin Oncol 14 : 1756-1764, 1996.
 
13) Srinivas S, et al : Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. Urology 67 : 1001-1006, 2006.
PubMed
14) Storlie JA, et al : Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76 : 96-100, 1995.
PubMed
P.475 掲載の参考文献
1) Lee HH, et al : Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 83 : 438-448, 1999.
PubMed
2) Scott WW, Boyd HL : Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate : a retrospective study based upon 25 years of experience. J Urol 101 : 86-92, 1969.
PubMed
3) van Poppel H, et al : Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer : interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 154 : 429-434, 1995.
 
4) Goldenberg SL, et al : Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 156 : 873-877, 1996.
PubMed
5) Hugosson J, et al : The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 29 : 413-419, 1996.
PubMed
6) Soloway MS, et al : Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer : 5-year results. J Urol 167 : 112-116, 2002.
PubMed
7) Gleave ME, et al : Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy : biochemical and pathological effects. J Urol 166 : 500-506, 2001.
PubMed
8) D'Amico AV, et al : Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 : 2163-2172, 2003.
 
9) Chodak GW, et al : Results of conservative management of clinically localized prostate cancer. N Engl J Med 330 : 242-248, 1994.
PubMed
10) Poppel HV, et al : Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 38 : 372-379, 2000.
 
11) Powell IJ, et al : Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate : 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol 168 : 2016-2019, 2002.
 
12) Miyake H, et al : The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men. Urol Int 77 : 122-126, 2006.
PubMed
13) Miyake H, et al : Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3Nl prostate cancer. Int J Urol 11 : 397-401, 2004.
PubMed
14) Febbo PG, et al : Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 : 5233-5240, 2005.
PubMed
P.480 掲載の参考文献
1) Huggins C, Hodges CV : Studies on prostate cancer. I. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of prostate. Cancer Res 1 : 293-297, 1941.
 
2) Arai Y, et al : Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy. Int J Urol 5 : 550-555, 1998.
PubMed
3) Vassilikos EJ, et al : Relapse and cure rates of prostate cancer patients after radical prostatectolny and 5 years of follow-up. Clin Biochem 33 : 115-123, 2000.
PubMed
4) Shen S, et al : Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 173 : 777-780, 2005.
PubMed
5) Sakai I, et al : Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Urol Int 76 : 227-231, 2006.
PubMed
6) Nakamura M, et al : Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol 12 : 1050-1054, 2005.
PubMed
7) 木下秀文ほか : 前立腺全摘術術後のPSA (prostate specific antigen) 再発とPSA nadir. 泌尿器外科 18 : 986-989, 2005.
 
8) Taylor JA 3rd, et al : The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int 98 : 540-543, 2006.
PubMed
9) 田中祝江 : 内分泌療法中前立腺癌における高感度PSAの検討. 日泌尿会誌 93 : 602-607, 2002.
 
10) 田中祝江 : 内分泌療法中前立腺癌における再生検と高感度PSAについての検討. 泌尿器外科 18 : 1048-1049, 2005.
Medical*Online
P.483 掲載の参考文献
1) Smith MR, et al : Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91 : 2238-2245, 2001.
PubMed
2) Orwoll ES, et al : Androgen receptors in osteoblast-like cell lines. Calcif Tissue Int 49 : 183-187, 1991.
PubMed
3) Tanaka S, et al : 1, 25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 137 : 1860-1869, 1996.
PubMed
4) Smith EP, et al : Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331 : 1056-1061, 1994.
 
5) Carani C, et al : Effect of testosterone arnd estradiol in a man with aromatase deficiency. N Engl J Med 337 : 91-95, 1997.
 
6) Marcus R, et al : The contribution of testosterone to skeletal development and maintenance : lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab 85 : 1032-1037, 2000.
PubMed
7) Mason RA, Morris HA : Effects of dihydrotestosterone on bone biochemical markers in sham and oophorectomized rats. J Bone Miner Res 12 : 1431-1437, 1997.
 
8) Murphy S, et al : Sex hormones and bone mineral density in elderly men. Bone Miner 20 : 133-140, 1993.
PubMed
9) Greenspan SL, et al : Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90 : 6410-6417, 2005.
PubMed
10) Morote J, et al : Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69 : 500-504, 2007.
PubMed
11) Kiratli BJ, et al : Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57 : 127-132, 2001.
PubMed
12) Weston R, et al : Testosterone recovery and changes in bone mineral density after stopping longtem luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer. BJU Int 95 : 776-779, 2005.
 
13) Shahinian VB, et al : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 : 154-164, 2005.
PubMed
14) Smith MR, et al : Gonadotropin-releasing hormone agonists and fracture risk : a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23 : 7897-7903, 2005.
 
15) Poor G, et al : Age-related hip fractures in Inen : clinical spectrum and short-term outcomes. Osteoporos Int 5 : 419-426, 1995.
 
16) Fransen M, et al : Excess mortality or institutionalization after hip fracture : men are at greater risk than women. J Am Geriatr Soc 50 : 685-69. 0, 2002.
 
17) Smith MR, et al : Pamidronate to prevent bonやloss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 : 948-955, 2001.
 
18) Polascik TJ, et al : Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-s ensitive prostate cancer and bone metastases. Urology 66 : 1054-1059, 2005.
 
19) Smith MR, et al : Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer : a randomized controlled trial. J Clin Endocrinol Metab 89 : 3841-3846, 2004.
PubMed
20) Taneja SS, et al : Toremifene-a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs 15 : 293-305, 2006.
PubMed
P.488 掲載の参考文献
1) Yagoda A, Petrylak D : Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 : 1098-1109, 1993.
PubMed
2) Tannock IF, et al : Chemotherapy with nlitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer : a Canadian randomized trial with palliative end points. J Clin Oncol 14 : 1756-1764, 1996.
 
3) Kantoff PW, et al : Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer : results of the cancer and leukemia group B 9182 study. J Clin Oncol 17 : 2506-2513, 1999.
 
4) Hudes G, et al : Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer : A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17 : 3160-3166, 1999.
 
5) Petrylak DP, et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004.
PubMed
6) Tannock IF, et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004.
 
7) 住吉義光ほか : ホルモン不応性前立腺癌に対するプレドニゾロン併用によるドセタキセルの第2相臨床試験 (抄録). 日泌尿会誌 98 : 362, 2007.
 
8) Febbo PG, et al : Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 : 5233-5240, 2005.
PubMed
9) Beekman KW, et al : Second-line chemotherapy for prostate cancer : patient characteristics and survival. Clin Prostate Cancer 4 : 86-90, 2005.
PubMed
P.492 掲載の参考文献
1) Murphy GP, et al : A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive radiation. J Urol 118 : 288-291, 1977.
 
2) Soloway MS, et al : Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125 : 664-667, 1981.
PubMed
3) Soloway MS, et al : A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cls-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. J Urol 129 : 56-61, 1983.
PubMed
4) Nishimura K, et al : Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology 60 : 49-54, 2001.
PubMed
5) Miyake H, et al : Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer. Oncol Rep 14 : 673-676, 2005.
PubMed
6) Pienta KJ, et al : Inhibition of prostate cancer growth by estramustine and etoposide. Cancer 75 (Suppl) : 1920-1926, 1995.
 
7) Pienta KJ, et al : A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50 : 401-406, 1997.
PubMed
8) Dimopoulos MA, et al : Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 50 : 754-758, 1997.
PubMed
9) Smith DC, et al : Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17 : 1664-1671, 1999.
PubMed
10) Tannock IF, et al : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer : a Canadian randomized trial with palliative end points. J Clin Oncol l4 : 1756-1764, 1996.
 
11) Kantoff PW, et al : Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer : results of the cancer and leukemia group B 9182 study. J Clin Oncol 17 : 2506-2513, 1999.
 
12) Petrylak DP : Chemotherapy for the treatment of hormone-refractory prostate cancer. Eur Urol Suppl 1 : 15-23, 2002.
 
13) Latif T, et al : Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily×5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 23 : 79-84, 2005.
 
14) Sternberg CN, et al : Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 : 2-9, 2005.
PubMed
15) Carles J, et al : Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol 37 : 187-191, 1998.
PubMed
16) Sweeney CJ, et al : A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol 13 : 435-440, 2002.
 
17) Mackler NJ, et al : Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer 106 : 2617-2623, 2006.
PubMed
P.497 掲載の参考文献
1) Hudes GR, et al : Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15 : 3156-3163, 1997.
PubMed
2) Petrylak DP, et al : Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17 : 958-967, 1999.
PubMed
3) Tannock IF, et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004.
 
4) Petrylak DP, et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004.
PubMed
5) Iversen P, et al : Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer : DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol 157 : 929-934, 1997.
 
6) Pienta KJ, et al : Phase I evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12 : 2005-2012, 1994.
PubMed
7) Dimopoulos MA, et al : Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 50 : 754-758, 1997.
PubMed
8) Pienta KJ, et al : A phase II trial of estramustine and etoposide in hormone refractory prostate cancer : A Southwest Oncology Group trial (SWOG 9407). Prostate 46 : 257-261, 2001.
 
9) Speicher LA, et al : Combined antimicrotubule activity of estramustine and taxol on prostate cancer cell lines. Cancer Res 52 : 4433-4440, 1992.
PubMed
10) Savarese DM, et al : Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with horrnone-refractory prostate cancer : a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19 : 2509-2516, 2001.
 
11) Berry DL, et al : Quality of life and pain in advanced stage prostate cancer : results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24 : 2828-2835, 2006.
 
12) Vordos D, et al : Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 94 : 524-527, 2004.
PubMed
13) Petrylak DP : Future directions in the treatment of androgen-independent prostate cancer. Urology 65 : 8-12, 2005.
PubMed
P.502 掲載の参考文献
1) Smith DC, et al : Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 98 : 269-276, 2003.
PubMed
2) Kreis W, et al : Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 79 : 196-202, 1997.
PubMed
3) Berry W, et al : Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 (Suppl 15) : 8-15, 2001.
 
4) Kojima T, et al : Weekly administration of docetaxel in patients with hormone-refractory prostate cancer : a pilot study on Japanese patients. Jpn J Clin Oncol 34 : 137-141, 2004.
PubMed
5) 島居徹, 赤座英之 : 再燃前立腺癌におけるドセタキセル療法の現状と展望. 臨床泌尿器科 60 : 177-187, 2006.
 
6) Petrylak DP, et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004.
 
7) Tannock IF, et al : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer : a Canadian randomized trial with palliative end points. J Clin Oncol 14 : 1756-1764, 1996.
 
8) Shimazui T, et al : Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer-retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol 37 : 603-608, 2007.
PubMed
9) Tannock I, et al : Treatment of metastatic prostatic cancer with low-dose prednisone : evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7 : 590-597, 1989.
PubMed
10) Fossa SD, et al : Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer : A Randomized Phase II Study. Eur Urol, 2007. (Epub ahead of print)
 
11) Petrylak DP, et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004.
PubMed
12) Li Y, et al : Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 4 : 389-398, 2005.
PubMed
13) Dreicer R, et al : Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 : 1138-1142, 2004.
PubMed
14) Febbo PG, et al : Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 : 5233-5240, 2005.
PubMed
P.511 掲載の参考文献
1) Tanllock IF, et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004.
 
2) Petrylak DP, et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004.
PubMed
3) Urakami S, et al : Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168 : 2444-2450, 2002.
PubMed
4) Urakami S, et al : Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chernotherapy-resistant hormone-refractory prostate cancer : a pilot study. Urology 65 : 543-548, 2005.
PubMed
5) Kikuno N, et al : Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 51 : 1252-1258, 2007.
PubMed
6) Yoshino T, et al : Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12 : 6116-6124, 2006.
PubMed
7) Wang Q, Wieder R : All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 23 : 426-433, 2004.
PubMed
8) Shiina H, et al : Estramustine-binding protein to dihydrotestosterone ratio in human prostatic carci-noma : a new marker for predicting disease progression. Br J Urol 77 : 96-101, 1996.
 
9) Mosca A, et al : The neuroendocrine phenotype in prostate cancer : basic and clinical aspects. J Endocrinol Invest 28 : 141-145, 2005.
PubMed
10) Yang CP, et al : Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst 86 : 723-725, 1994.
PubMed
11) Maeda S, et al : Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 95 : 679-684, 2004.
PubMed
12) He Q, et al : Steroid hormones induce HMGI overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 97 : 5768-5772, 2000.
 
13) Di Maio M, et al : Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25 : 1377-1382, 2007.
PubMed
14) Lin AM, et al : Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 61 : 243-254, 2007.
PubMed
15) Cabrespine A, et al : Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. J Urol 175 : 1347-1352, 2006.
PubMed
P.516 掲載の参考文献
1) Isaacs JT : The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5 : 1-17, 1984.
 
2) Murphy GP, et al : Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormone alone. Cancer 51 : 1264-1272, 1983.
PubMed
3) Murphy GP, et al : Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28 : 36-40, 1986.
PubMed
4) Osborne CK, et al : Combined versus sequential chemo-endocrine therapy in advanced prostate cancer : final results of a randomized Southwest Oncology Group study. J Clin Oncol 8 : 1675-1682, 1990.
 
5) Huben RP, Murphy GP : A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 62 : 1881-1887, 1988.
PubMed
6) Sagaster P, et al : Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer. J Cancer Res Clin Oncol 122 : 171-176, 1996.
PubMed
7) de Reijke TM, et al : Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis : the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol 162 : 1658-1664, 1999.
 
8) Janknegt RA, et al : Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer : a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 49 : 411-420, 1997.
 
9) Roessler W, et al : Experience in advanced prostate cancer : orchiectomy and flutamide versus orchiectomy and estramustine phosphate. Urology 43 (Suppl 2) : 57-60, 1994.
 
10) Noguchi M, et al : Chemohormonal therapy as primary treatment for metastatic prostate cancer : a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11 : 103-109, 2004.
PubMed
11) Pummer K, et al : Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32 (Suppl 3) : 81-85, 1997.
 
12) Kuriyama M, et al : Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31 : 18-24, 2001.
PubMed
13) Sakai H, et al : Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group. Cancer Chemother Pharmacol 35 (Suppl) : S23-S26, 1994.
 
14) Kubota Y, et al : Chemo-endocrine therapy in patients with stage D2 prostate cancer. Prostate 26 : 50-54, 1995.
PubMed
15) 酒井英樹ほか : 進行前立腺癌に対する初期化学内分泌療法の無作為比較臨床試験. 西日泌尿 61 : 401-404, 1999.
 
P.520 掲載の参考文献
1) Egawa S, et al : Treatment outcome by risk group after radical prostatectomy in Japanese men. Int J Urol 8 : 295-300, 2001.
PubMed
2) Donohue JF, et al : Poorly differentiated prostate cancer treated with radical prostatectomy : long-term outcome and incidence of pathological downgrading. J Urol 176 : 991-995, 2006.
PubMed
3) Aiuti A : Advances in gene therapy for ADA-deficient SCID. Curr Opin Mol Ther 4 : 515-522, 2002.
PubMed
4) Eager R, et al : GM-CSF gene-transduced tumor vaccines. Mol Ther 12 : 18-27, 2005.
PubMed
5) Raper SE, et al : Fatal systemic inflammatory response syndrome in a ornithine transcarbam) 'las. edeficient patient following adenoviral gene transfer. Mol Genet Metab 80 : 148-158, 2003.
 
6) Kubo H, et al : Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14 : 227-241, 2003.
PubMed
7) 後藤章暢ほか : ホルモン抵抗性前立腺癌転移巣に対する治療法について. 泌尿器科紀要 51 : 75-79, 2005.
 
8) Hinata N, et al : Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer : Initial expeHence at Kobe University. Int J Urol 8 : 834-837, 2006.
PubMed
9) 後藤章暢 : 泌尿器科癌に対する遺伝子治療. 臨床泌尿器科 60 : 265-271, 2006.
 
10) Rodriguez R, et al : Prostate attenuated replication competent adenovirus (ARCA) CN706 : a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57 : 2559-2563, 1997.
PubMed
11) Freytag SO, et al : Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res 63 : 7497-7506, 2003.
PubMed
P.527 掲載の参考文献
1) Cross D, Burmester JK : Gene therapy for cancer treatment : past, present and future. Clin Med Res 4 : 218-227, 2006.
PubMed
2) Freytag SO, et al : Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15 : 636-642, 2007.
PubMed
3) Simons JW, et al : Phase I/II trial of an allogeneic cellular immunotherapy in hormone-natve prostate cancer. Clin Cancer Res 12 : 3394-3401, 2006.
 
4) Herman JR, et al : In situ gene therapy for adenocarcinoma of prostate : a phase I clinical trial. Hum Gene Ther 10 : 1239-1249, 1999.
PubMed
5) Miles BJ, et al : Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12 : 1955-1967, 2001.
PubMed
6) Teh BS, et al : Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58 : 1520-1529, 2004.
 
7) Nasu Y, et al : Suicide gene therapy with adenoviral delivery of HSV-TK gene for patient with local recurrence of prostate cancer after hormonal therapy. Mol Ther 15 : 834-840, 2007.
PubMed
8) van der Linden RR, et al : Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol 48 : 153-161, 2005.
PubMed
9) Freytag SO, et al : Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy for the treatment of locally recurrence prostate cancer. Cancer Res 62 : 4968-4976, 2002.
PubMed
10) Freytag SO, et al : Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conforrnal radiation therapy for the treatment of newly diagnosed, intermediate to high-risk prostate cancer. Cancer Res 63 : 7497-7506, 2003.
PubMed
11) Kubo H, et al : Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14 : 227-241, 2003.
PubMed
12) Belldegrun A, et al : Interleukin 2 gene therapy for prostate cancer : phase I ciinical trial and basic biology. Hum Gene Ther 12 : 883-892, 2001.
 
13) Trudel S, et al : A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 10 : 755-763, 2003.
PubMed
14) Pantuck AJ, et al : Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 27 : 240-253, 2004.
PubMed
15) Simons JW, et al : Induction of immunity to prostate cancer antigens : results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59 : 5160-5168, 1999.
PubMed
16) China OK's gene therapy drug. Genetic Engineering News 2003 ; 6.
 
17) Lupold SE, Rodriguez R : Adenovirus gene therapy, radiation and prostate cancer. Rev Urol 7 : 193-202, 2005.
 
18) Tetzlaff MT, et al : Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat 5 : 23-36, 2006.
PubMed
P.532 掲載の参考文献
1) Petrylak DP, et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004.
PubMed
2) Nishizaki M, et al : Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 7 : 2887-2897, 2001.
PubMed
3) Bubendorf L, et al : Metastatic patterns of prostate cancer : an autopsy study of 1, 589 patients. Hum Pathol 31 : 578-583, 2000.
PubMed
4) Shirakawa T, et al : Tissue-specinc promoters in gene therapy for the treatment of prostate cancer. Mol Urol 4 : 73-82, 2000.
 
5) Nasu Y, et al : Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 15 : 834-840, 2007.
PubMed
6) Moolten FL, Wells JM : Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82 (4) : 297-300, 1990.
PubMed
7) Rainov NG : A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11 (17) : 2389-2401, 2000.
PubMed
8) Fujita T, et al : Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 65 : 84-90, 2006.
PubMed
9) Lang SH, et al : Stimulation of human prostate cancer cell lines by factors present in human osteoblast-like cells but not in bone marrow. Prostate 27 : 287-293, 1995.
PubMed
10) Bubley GJ, et al : Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer : recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 : 3461-3467, 1999.
 
11) Ayala G, et al : Biological response determinants in HSV-tk十ganciclovir gene therapy for prostate cancer. Mol Ther 13 : 716-728, 2006.
 
P.536 掲載の参考文献
1) Tarassoff CP, et al : Therapeutic vaccines for prostate cancer. Oncologist 11 : 451-462, 2006.
PubMed
2) Simons JW, et al : Induction of immunity to prostate cancer antigens : results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte macrophage colony stimulating factor using ex vivo gene transfer. Cancer Res 59 : 5160-5168, 1999.
PubMed
3) Hara I, et al : Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 7 : 83-90, 2000.
PubMed
4) Furukawa J, et al : Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol 176 : 1198-1203, 2006.
PubMed
5) Schendel DJ, et al : Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 7 : 2007-2014, 2000.
 
6) Simons JW, et al : Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 12 : 3394-3401, 2006.
PubMed
7) Steinman RM : The dendritic cells system and its role in immunogenicity. Annu Rev Immunol 9 : 271-296, 1991.
PubMed
8) Banchereau J, Palucka AK : Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 : 296-306, 2005.
PubMed
9) Nakamura M, et al : Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res 8 : 2742-2749, 2002.
PubMed
10) Heiser A, et al : Human dendritic cells transfected with RNA encoding PSA stimulate prostate-specific CTL responses in vitro. J Immunol 164 : 5508-5514, 2000.
PubMed
11) Mukouyama H, et al : Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res 10 : 1421-1429, 2004.
PubMed
12) Su Z, et al : Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174 : 3798-3807, 2005.
PubMed
13) Gilboa E, Vieweg J : Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199 : 251-263, 2004.
PubMed
14) Heiser A, et al : Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109 : 409-417, 2002.
PubMed
15) Ojima T, et al : The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int J Oncol 28 : 947-953, 2006.
PubMed
P.540 掲載の参考文献
1) Uchida T, et al : Transrectal high-intensity focused ultrasound for localized prostate cancer. Urology 59 : 394-399, 2002.
PubMed
2) Uchida T, et al : Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 13 : 228-233, 2006.
PubMed
3) Uchida T, et al : The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy. BJU Int 98 : 770-773, 2006.
PubMed
4) D'Amico AV, et al : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 : 969-974, 1998.
 
5) Roach M III, et al : Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer : recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 : 965-974, 2006.
 
6) 日本泌尿器科学会, 日本病理学会 (編) : 泌尿・器科・病理 前立腺癌取扱い規約, 第3版, p95-97, 金原出版, 2001.
 
P.545 掲載の参考文献
1) Soanes WA, et al : Apparatus and technique for cryosurgery of the prostate. J Urol 96 (4) : 508-511, 1966.
PubMed
2) Reuter HJ : Endoscopic cryosurgery of prostate and bladder tumors. J Urol 107 (3) : 389-393, 1972.
PubMed
3) Bonney WW, et al : Cryosurgery in prostatic cancer : survival. Urology 19 (1) : 37-42, 1982.
 
4) Onik GM, et al : Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 72 (4) : 1291-1299, 1993.
PubMed
5) Shinohara K : Prostate cancer : cryotherapy. Urol Clin North Am 30 (4) : 725-736, viii, 2003.
PubMed
6) Tatsutani K, et al : Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology 48 (3) : 441-447, 1996.
PubMed
7) Onik G, et al : Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer : a new approach to preserving potency. Urology 60 (1) : 109-114, 2002.
PubMed
8) Bahn I) K, et al : Focal prostate cryoablation : initial results show cancer control and potency preservation. J Endourol 20 (9) : 688-692, 2006.
 
9) Koppie TM, et al : The efficacy of cryosurgical ablation of prostate cancer : the University of California, San Francisco experience. J Urol 162 (2) : 427-432, 1999.
PubMed
10) Long J P, et al : Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 57 (3) : 518-523, 2001.
PubMed
11) Bahn DK, et al : Targeted cryoablation of the prostate : 7-year outcomes in the primary treatment of prostale cancer. Urology 60 (2 Suppl 1) : 3-11, 2002.
 
12) De La Taille A, et al : Cryoablation for clinically localized prostate cancer using an argon-based system : complication rates and biochemical recurrence. BJU Int 85 (3) : 281-286, 2000.
PubMed
13) Han KR, et al : Treatment of organ confined prostate cancer with third generation cryosurgery : preliminary multicenter experience. J Urol 170 (4 Pt 1) : 1126-1130, 2003.
 
14) Bahn DK, et al : Prostate cancer : US-guided percutaneous cryoablation. Work in progress. Radiology 194 (2) : 551-556, 1995.
PubMed
15) Shinohara K, et al : Cryosurgical treatment of localized prostate cancer (stages T1 to T4) : preliminary results. J Urol 156 (1) : 115-120 ; discussion 120-121, 1996.
 
P.550 掲載の参考文献
1) Fleisch H : Development of bisphosphonates. Breast Cancer Res 4 : 30-34, 2002.
PubMed
2) Purohit OP, et al : A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72 : 1289-1293, 1995.
PubMed
3) Saad F, et al ; Zoledronic Acid Prostate Cancer Study Group : A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 : 1458-1468, 2002.
 
4) Saad F, et al ; Zoledronic Acid Prostate Cancer Study Group : Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 : 879-882, 2004.
 
5) Roodman GD : Mechanisms of bone metastasis. N Engl J Med 350 : 1655-1664, 2004.
PubMed
6) Hughes DE, et al : Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 : 1478-1487, 1995.
PubMed
7) 小中弘之ほか : 進行性前立腺癌に対するビスフォスフォネート併用療法の検討. 泌尿器外科 19 : 587-593, 2006.
Medical*Online
8) Asahi H, et al : Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol 169 : 281-282, 2003.
PubMed
9) Kunzmann V, et al : Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340 : 737-738, 1999.
PubMed
10) Giraudo E, et al : An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114 : 623-633, 2004.
PubMed
11) Boissier S, et al : Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60 : 2949-2954, 2000.
PubMed
12) Eastham JA, et al : Consensus guidelines : the use of IV bisphosphonate in the management of bone complication for patients with advanced prostate cancer. Am J Urol Rev 2 : 5-40, 2004.
 
13) Mason MD, et al ; Medical Research Council PRO4 Collaborators : Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial : Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 99 : 765-776, 2007.
 
14) Smith MR, et al : Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 : 2008-2012, 2003.
PubMed
15) 田中郁子ほか : アレンドロネートの服用継続率の検討 : クリニックにおける骨粗鬆症診療実体調査. Osteoporosis Jpn 11 : 252-255, 2003.
 
P.555 掲載の参考文献
1) The Medical Research Council Prostate Cancer Working Party Investigators Group : Immediate versus deferred treatment for advanced prostatic cancer : initial results of the Medical Research Council Trial. Br J Urol 79 : 235-246, 1997.
PubMed
2) Holmberg L, et al : A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 : 781-789, 2002.
 
3) Bill-Axelson A, et al : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 : 1977-1984, 2005.
PubMed
4) Stamey TA, et al : Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 : 933-938, 1993.
PubMed
5) McNeal JE, et al : Patterns of progression in prostate cancer. Lancet 11 : 60-63, 1986.
 
6) Epstein JI, et al : Radical prostatectomy for impalpable prostate cancer : the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 152 : 1721-1729, 1994.
 
7) DiMarco DS, et al : Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less. Urol Oncol 21 : 439-446, 2003.
PubMed
8) Albertsen P, et al : Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280 : 975-980, 1998.
PubMed
9) Epstein JI, et al : Use of repeat sextant and transitional zone biopsies for assessing extent of prostate cancer. J Urol 158 : 1886-1890, 1997.
PubMed
10) Epstein JI, et al : Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166 : 1688-1692, 2001.
 
11) Choo R, et al : Feasibility study : watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167 : 1664-1669, 2002,
PubMed
12) Egawa S, et al : Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3 : 269-274, 2000.
PubMed
13) Vollmer RT, et al : The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma : a study of 94 Japanese men. Cancer 94 : 1692-1698, 2002.
PubMed
14) Do V, et al : The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int 89 : 703-709, 2002.
 
15) Khan MA, et al : Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170 : 2274-2278, 2003.
PubMed
P.560 掲載の参考文献
1) Lynch JH, Hofner K : Transurethral microwave thermotherapy. Eur Urol 35 (2) : 129-137, 1999.
PubMed
2) Cowles RS 3rd, et al : A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 46 (2) : 155-160, 1995.
PubMed
3) Bruskewitz R, et al : A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 159 (5) : 1588-1593, 1998.
PubMed
4) Maranzano E, et al : Comparison of two different radiotherapy schedules for spinal cord compression in the prostate cancer. Tumori 84 (4) : 472-477, 1998.
 
5) Nightengale B, et al : Strontium chloride Sr 89 for treating pain from metastatic bone disease. Am J Health Syst Pharm 52 (20) : 2189-2195, 1995.
PubMed
6) Cotten A, et al : Percutaneous vertebroplasty : state of art. Radiographics 18 (2) : 311-320, 1998.
PubMed
7) 細川豊史 : 骨転移痛に伴う症状-骨痛, 骨折, 高カルシウム血症-. 日本臨牀 65 (1) : 76-81, 2007.
Medical*Online
P.570 掲載の参考文献
1) Litwin MS, et al : Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273 (2) : 129-135, 1995.
PubMed
2) Kuwata Y, et al : Dissociation of sexual function and sexual bother following autologous sural nerve grafting during radical prostatectomy. Int J Urol 14 : 510-514, 2007.
PubMed
3) Litwin MS, et al : Difference in urologist and patient assessment of health related quality of life in men with prostate cancer : results of the CaPSURE database. J Urol 159 : 1988-1992, 1998.
PubMed
4) Litwin MS, et al : The UCLA-PCI : development, reliability, and validity of a health-related quality of life measure. Med Care 36 : 1002-1012, 1998.
 
5) Akaza H : Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer : Japanese perspective. Cancer Sci 97 : 243-247, 2006.
PubMed
6) Gomella LG : Contemporary use of hormonal therapy in prostate cancer : managing complications and addressing quality-of-life issues. BJU Int 99 : 25-29, 2007.
PubMed
7) Mizokami A, et al : Global update on defining and treatment high-risk localized prostate cancer with leuprorelin : an Asian perspective. BJU Int 99 : 6-9, 2007.
PubMed
8) Wei JT, et al : Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 : 899-905, 2000.
PubMed
9) 竹上未紗ほか : Expanded Prostate Cancer Index Composite (EPIC) 日本語版の開発 : 翻訳と文化的適合. 日泌尿会誌 96 : 657-669, 2005.
 
10) Kakehi Y, et al : Health-related QOL in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. J Urol 177 : 1856-1861, 2007.
 
11) Litwin MS, et al : Life after radical prostatectomy : A longitudinal study. J Urol 166 : 587-592, 2001.
PubMed
12) 福原俊一, 鈴鴨よしみ : SF-8日本語版マニュアル, NPO健康医療評価研究機構, 2004.
 
P.574 掲載の参考文献
1) Shanafelt TD, et al : Pathophysiology and treatment of hot flashes. Mayo Clin Proc 77 : 1207-1218, 2002.
PubMed
2) Shahinian VB, et al : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 : 154-164, 2005.
PubMed
3) Smith MR, et al : Association between androgen deprivation therapy and fracture risk : a population-based cohort study in men with non-metastatic prostate cancer. J Clin Oncol 22 (Suppl) : 4507, 2004.
 
4) Smith MR : Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 20 : 175-183, 2003.
PubMed
5) Rackley DJ : Complimentary and alternative medicine for advanced prostate cancer. Urol Clin North Am 33 : 237-246, 2006.
 
6) Di Lorenzo G, et al : Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer : the role of tamoxifen and radiotherapy, J Urol 174 : 2197-2203, 2005.
PubMed
7) Almeida OP, et al : One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29 : 1071-1081, 2004.
PubMed
8) Herr HW, O'sullivan M : Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163 : 1743-1746, 2000.
PubMed
9) Litwin MS, et al : Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 21 : 327-332, 1998.
PubMed
10) Moinpour CM, et al : Quality of life in advanced prostate cancer : results of randomized therapeutic trial. J Natl Cancer Inst 90 : 1537-1544, 1998.
 
11) Boccardo F, et al : Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients : results of an Italian Prostate Cancer Project stlldy. J Clin Oncol 17 : 2027-2038, 1999.
 
12) Chodak G, et al : Single-agent therapy with bicalutamide : a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46 : 849-855, 1995.
PubMed
13) Kakehi Y, et al : Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. J Urol 177 : 1856-1861, 2007.
PubMed
14) Oefelein MG : Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol 169 : 251-255, 2003.
PubMed
15) 吉田正貴ほか : 前立腺癌の内分泌療法がQOLに及ぼす影響. 西日泌尿 66 : 263-271, 2004.
 
P.579 掲載の参考文献
1) Namiki S, et al : Quality of life after radical prostatectomy in Japanese men : 2 year longitudinal study. Jpn J Clin Oncol 35 : 551-558, 2005.
PubMed
2) Gomha MA, Boone TB : Voiding patterns in patients with postっrostatectomy incontinence : urody-namic and demographic analysis. J Urol 169 : 1766-1769, 2003.
 
3) Namiki S, et al : Adverse effect of radical prostatectomy on nocturia and voiding frequency symptoms. Urology 65 : 147-151, 2005.
 
4) Namiki S, et al : Natural history of voiding function after radical retropubic prostatectomy. Urology 68 : 142-147, 2006.
PubMed
5) Walsh PC : Cancer control and quality of life following anatomical radical retropubic prostatectomy : results at 10 years. J Urol 152 : 1831-1836, 1994.
PubMed
6) Kaiho Y, et al : Intraoperative electrophysiological confirmation of urinary continence after radical prostatectomy. J Urol 173 : 1139-1142, 2005.
PubMed
7) Scardino PT, Kim ED : Rationale for and results of nerve grafting during radical prostatectomy. Urology 57 : 1016-1019, 2001.
PubMed
8) Saito S, et al : Impact of unilateral interposition sural nerve graft on the recovery of sexual function after radical prostatectomy in Japanese men : a preliminary study. Int J Urol 14 : 133-139, 2007.
 
9) Namiki S, et al : Impact of unilateral sural nerve graft on recovery of potency and continence following radical prostatectomy : A 3-year longitudinal study. J Urol 178 : 212-216, 2007.
PubMed
10) Kim ED, et al : Bilateral nerve grafting during radical retropubic prostatectomy : extended follow-up. Urology 58 : 983-987, 2001.
PubMed
P.582 掲載の参考文献
1) Ruiz-Deya G, et al : 0utpatient radical prostatectomy : impact of standard perineal approach on patient outcome. J Urol 166 : 581-586, 2001.
PubMed
2) 福原俊一ほか : SF-36日本語マニュアル (ver. 1.2), 財団法人パブリックヘルスリサーチセンター, 2001.
 
3) Namiki S, et al : Changes in quality of life in first year after radical prostatectomy by retropubic, laparoscopic, and perineal approach : multi-institutional longitudinal study in Japan. Urology 67 : 321-327, 2006.
PubMed
4) Litwin MS, et al : The UCLA Prostate Cancer Index : development, reliability, and validity of a health-related quality of 1ife measure. Med Care 36 : 1002-1012, 1998.
 
5) Kakehi Y, et al : Development of Japanese version of the UCLA Prostate Cancer Index : apilot validation study. Int J Clin Oncol 7 : 306-311, 2002.
 
6) Bishoff JT, et al : Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol 160 : 454-458, 1998.
 
7) Young MD, et al : Urinary continence and quality of life in the first year after radical perineal prostatectomy. J Urol 170 : 2374-2378, 2003.
PubMed
8) Gray M, et al : Urinary function after radical prostatectomy : a comparison of the retropubic and perineal approaches. Urology 53 : 881-890, 1999.
PubMed
9) Litwin MS, et al : Life after radical prostatectomy : a longitudinal study. J Urol 166 : 587-592, 2001.
PubMed
P.588 掲載の参考文献
1) 福原俊一, 鈴鴨よしみ : SF-36v2 日本語版マニュアル, NPO健康医療評価研究機構, 2004.
 
2) Isaka S, et al : Assessment of the quality of life of prostate cancer patients. Nippon Hinyokika Gakkai Zasshi 84 (9) : 1611-1617, 1993.
PubMed
3) Kakehi Y, et al : Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. J Urol 177 (5) : 1856-1861, 2007.
PubMed
4) Donovan JL, et al : Scoring the short form ICSmaleSF questionnaire. International Continence Society. J Urol 164 (6) : 1948-1955, 2000.
PubMed
5) Rosen RC, et al : Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11 (6) : 319-326, 1999.
PubMed
6) Hara I, et al : Comparison of quality of life following laparoscopic and open prostatectomy for prostate cancer. J Urol 169 (6) : 2045-2048, 2003.
PubMed
7) Ball AJ, et al : Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer : a short-term evaluation of five approaches from a single institution. J Endourol 20 (10) : 723-731, 2006.
 
8) Link RE, et al : Health related quality of life before and after laparoscopic radical prostatectomy. J Urol 173 (1) : 175-179, 2005 ; discussion 179.
PubMed
9) Namiki S, et al : Recovery of quality of life in year after laparoscopic or retropubic radical prostatectomy : a multi-institutional longitudinal study. Urology 65 (3) : 517-523, 2005.
 
10) Namiki S, et al : Changes in quality of life in first year after radical prostatectomy by retropubic, laparoscopic, and perineal apProach : Multi-institutional longitudinal study in Japan. Urology 67 (2) : 321-327, 2006.
PubMed
11) Rogers CG, et al : Age stratified functional outcomes after laparoscopic radical prostatectomy. J Urol 176 (6 Pt 1) : 2448-2452, 2006.
 
12) Soderdahl DW, et al : Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer. J Endourol 19 (3) : 318-326, 2005.
 
13) Tseng TY, et al : Prospective health-related quality-of-life assessment in an initial cohort of patients undergoing robotic radical prostatectomy. Urology 68 (5) : 1061-1066, 2006.
 
14) Wagner A, et al : Use of a validated quality of life questionnaire to assess sexual function followillg laparoscopic radical prostatectomy. Int J Impot Res 18 (1) : 69-76, 2006.
PubMed
15) Wyler SF, et al : Short-, intermediate-, and long-term quality of life after laparoscopic radical prostatectomy-does the learning curve of LRP have a negative impact on patients' quality of life? Eur Urol 51 (4) : 1004-1012, 2007；discussion 1012-1014.
 
P.592 掲載の参考文献
1) Greenlee RT, et al : Cancer statistics, 2000. CA Cancer J Clin 50 : 7-33, 2000.
PubMed
2) Stansfeld SA, et al : Assessing the validity of the SF-36 General Health Survey. Qual Life Res 6 : 217-224, 1997.
PubMed
3) Ware J : SF-36 Health Survey : Manual and lnterpretation Guide, The Health lnstitute, Boston, 1993.
 
4) Litwin MS, et al : The UCLA Prostate Cancer Index : development, reliability, and validity of a health-related quality of life measure. Med Care 36 : 1002-1012, 1998.
PubMed
5) 常義政 : 前立腺癌の治療-放射線療法-. 日本泌尿器科学会卒後・生涯教育テキスト 6 (2) : 93-100, 2001.
 
6) 常義政ほか : Stage C前立腺癌に対する高線量率組織内照射 (HDR-Brachytherapy). 泌尿器外科 15 (7) : 749-753, 2002.
 
7) Jo Y, et al : High-dose-rate iridium-192 afterloading therapy combined with external beaIn radiotherapy for T1c-T3bN0M0 prostate cancer. Urology 64 : 556-560, 2004.
PubMed
8) 常義政ほか : 特集 手術によらない限局性前立腺癌の治療 : 高線量率組織内照射 (HDR-brachytherapy). 臨床泌尿器科 59 (7) : 457-461, 2005.
 
9) 常義政ほか : Stage B, C前立腺癌に対する高線量率組織内照射 (HDR-Brachytherapy). 泌尿器外科 19 (8) : 937-941, 2006.
Medical*Online
10) 常義政ほか : 前立腺全摘除術 (RRP) と高線量率組織内照射 (HDR-Brachytherapy) 後のQOLの評価. 西日泌尿 66 : 249-254, 2004.
 
11) Jo Y, et al : Radical prostatectomy versus high-dose-rate brachytherapy for prostate cancer : effects on health-related quality of life. BJU Int 96 : 43-47, 2005.
PubMed
12) 福原俊一ほか : SF-36v2日本語版マニュアル, NPO健康医療評価研究機構, 2004.
 
13) 鈴鴨よしみほか : University of California at Los P ngeles Prostate Cancer lndex (UCLA-PCI) 日本語版作成の試み. 日泌尿会誌 93 (6) : 659-668, 2002.
 
P.596 掲載の参考文献
1) 樋之津順子ほか : 膀胱癌・前立腺癌患者用QOL調査票-FACT (Functional Assessment of Cancer Therapy) の日本語版開発におけるPilot Study-. 癌と化学療法 26 : 657-666, 1999.
 
2) 鈴鴨よしみほか : University of California at Los Angeles Prostate Cancer Index (UCLA PCI) 日本語版作成の試み. 日泌尿会誌 93 : 659-668, 2002.
 
3) Kakehi Y, et al : Development of Japanese version of the UCLA Prostate Cancer Index : a pilot validation study. Int J Clin Oncol 7 : 306-311, 2002.
PubMed
4) Wei JT, et al : Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 : 899-905, 2000.
PubMed
5) Penson DF, et al : Five-year urinary and sexual outcomes after radical prostatectomy : Results from the Prostate Cancer Outcomes Study. J Urol 173 : 1701-1705, 2005.
 
6) Litwin MS, et al : Life after radical prostatectomy : alongitudinal study. J Urol 166 : 587-592, 2001.
 
7) Walsh PC, et al : Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 55 : 58-61, 2000.
PubMed
8) Speight JL, et al : Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation : date from CaPSURE. Int J Radiat Oncol Biol Phys 60 : 1066-1075, 2004.
PubMed
9) Talcott JA, et al : Long-term treatment related complications of brachytherapy for early prostate cancer : a survey of patients previously treated. J Urol 166 : 494-499, 2001.
PubMed
10) Frank SJ, et al : An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 177 : 2151-2156, 2007.
PubMed
11) Litwin MS, et al : Sexual function and bother after radical prostatectomy or radiation for prostate cancer : multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 54 : 503-508, 1999.
 
12) Wei JT, et al : Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20 : 557-565, 2002.
PubMed
13) Krupski T, et al : Quality-of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinical localized prostate cancer. Urology 55 : 736-745, 2000.
PubMed
14) Reis F, et al : The impact of prostatectomy and brachytherapy in patients with localized prostate cancer. Int Urol Nephrol 36 : 187, 2004.
PubMed
15) Quek LM, et al : Quality of life in patients with localized prostate cancer. Urol Oncol 23 : 208-215, 2005.
 
P.603 掲載の参考文献
1) Walsh PC, Donker PJ : Impotence following radical prostatectomy : insight into etiology and prevention. J Urol 128 : 492-497, 1982.
PubMed
2) Lepor H, et al : Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa. a detailed anatomical study of the adult male pelvis. J Urol 133 : 207-212, 1985.
 
3) Walsh PC : Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life : a structured debate. J Urol 163 : 1802-1807, 2000.
 
4) Takenaka A, et al : Anatomic analysis of the neurovascular bundle supplying penile cavernous tissue to ensure a reliable nerve graft after radical prostatectomy. J Urol 172 : 1032-1035, 2004.
PubMed
5) Takenaka A, et al : Variation in the course of the cavemous nerve with special reference to details of topographic relationships near prostatic apex : histologic study using male cadavers. Urology 65 : 136-142, 2005.
 
6) Costello AJ, et al : Anatomical studies of the neurovascular bundle and cavernosal nerves. BJU Int 94 : 1071-1076, 2004.
PubMed
7) Takenaka A, et al : Pelvic autonomic nerve mapping around the prostate by intraoperative electrical stimulation with simultaneous measurement of intracavernous and intraurethral pressure. J Urol 177 : 225-229, 2007.
PubMed
8) Catalona WJ, et al : Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 162 : 433-438, 1999.
PubMed
9) Gralnek D, et al : Differences in sexual function and quality of life after nerve sparing and nonnerve sparing radical retropubic prostatectomy. J Urol 163 : 1169-1170, 2000.
 
10) Kaiho Y, et al : Intraoperative electrophysiological confirmation of urinary continence after radical prostatectomy. J Urol 173 : 1139-1142, 2005.
PubMed
11) Tewari A, et al : The proximal neurovascular plate (PNP) and tri-zonal neural architecture around the prostate grand : importance in the athermal robotic technique of nerve-sparing prostatectomy. BJU Int 98 : 314-323, 2006.
 
12) Savera AT, et al : Robotic radical prostatectomy with the "Veil of Aphrodite" technique : histologic evidence of enhanced nerve sparing. Eur Urol 49 : 1065-1074, 2006.
PubMed
13) Eichelberg C, et a1 : Nerve distribution along the prostatic capsule. Eur Urol 51 : 105-110, 2007.
 
P.609 掲載の参考文献
1) Hanks GE, et al : Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer : implications of RTOG data for patient management and trial design and stratification. Int J Radiat Oncol Biol Phys 23 : 293-298, 1992.
PubMed
2) Clark T, et al : Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169 : 145-147, 2003.
PubMed
3) Partin AW, et al : Contemporary update of prostate cancer staging nomogram (Partin table) for the new millennium. Urology 58 : 843-848, 2001.
PubMed
4) Heidenreich A, et al : Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy : High incidence of lymph node metastasis. J Urol 167 : 1681-1686, 2002.
PubMed
5) Bader P, et al : Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168 : 514-518, 2002.
PubMed
6) Catalona WJ, et al : Grading errors in prostatic needle biopsies : Relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. J Urol 127 : 919-922, 1982.
 
7) Bhatta-Dar N, et al : No difference in six-year biochemical failure rates with or without pelvic lymph-node dissection during radical prostatectomy in low risk patients with localized prostate cancer. Urology 63 : 528-531, 2004.
PubMed
8) Salomon L, et al : Nondissection of pelvic lymph-node does not influence the results of perineal radical prostatectomy in selected patients. Eur Urol 37 : 297-300, 2000.
 
9) Bader P, et al : Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance for cure? J Urol 169 : 849-854, 2003.
 
10) Han M, et al : Long-term biochemical disease free and cancer specific survival following anatomical radical retropubic prostatectomy : the 15 year Johns Hopkins experience. Urol Clin North Am 28 : 555-565, 2001.
 
11) Daneshmand S, et al : Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy : long term results. J Urol 172 : 2252-2255, 2004.
PubMed
12) Wawroschek F, et al : The sentinel lymph node concept in prostate cancer-first results of gamma probe-guided sentinel lymph node identification. Eur Urol 36 : 595-600, 1999.
PubMed
13) Takashima H, et al : Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 171 : 2268-2271, 2004.
PubMed
14) Fukuda M, et al : Detection of sentinel lymph node micrometastasis by step section and immunohistochemistry in patients with prostate cancer. J Urol 177 : 1313-1317, 2007.
PubMed
15) Weckermann D, et al : Sentinel lymph node dissection for prostate cancer : Experience with more than 1,000 patients. J Urol 177 : 916-920, 2007.
PubMed
P.615 掲載の参考文献
1) Labrie F, et al : Science behind total androgen blockade : from gene to combination therapy. Clin Invest Med 16 : 475-492, 1993.
PubMed
2) Nishiyama T, et al : Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 176 : 1387-1391, 2006.
PubMed
3) Mohler JL, et al : The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 : 440-448, 2004.
PubMed
4) Prehn RT : On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 59 : 4161-4164, 1999.
PubMed
5) Freedland SJ, et al : Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy : a search database study. J Clin Oncol 23 : 7546-7554, 2005.
PubMed
6) Xu Y, et al : Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12 : 4072-4079, 2006.
PubMed
7) Thompson IM, et al : The influence of finasteride on the development of prostate cancer. N Engl J Med 349 : 215-224, 2003.
PubMed
8) Nishiyama T, et al : The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10 : 7121-7126, 2004.
 
9) Nishiyama T, et al : The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J Urol 178 : 1282-1289, 2007.
PubMed
10) Fung KM, et al : Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 13 : 169-180, 2006.
PubMed
11) Stanbrough M, et al : Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 : 2815-2825, 2006.
PubMed
12) Ryan CJ, et al : Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal : results from a cancer and leukemia group B study. Clin Cancer Res l3 : 2030-2037, 2007.
 
13) Suzuki K, et al : Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis 10 : 301-306, 2007.
PubMed
14) Chen CD, et al : Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 : 33-39, 2004,
PubMed
15) Li R, et al : High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate : cancer patients treated with radical prostatectomy. Am J Surg Pathol 28 : 928-934, 2004.
PubMed
P.620 掲載の参考文献
1) Chan JM, et al : Plasma insulin-1ike growth factor-I and prostate cancer risk : aprospective study. Science 279 : 563-566, 1998.
 
2) Letsch M, et al : Growth hormone-releasing hormone (GHRH) antagonists inhibit the prolileration of androgen-dependent and-independent prostate cancers. Proc Natl Acad Sci USA 100 : 1250-1255, 2003.
PubMed
3) Goya M, et al : Growth inhibition of human prostate cancer cells in human adult bone implanied into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64 : 6252-6258, 2004.
PubMed
4) Garber K : IGF-1 ; old growth factor shines as new drug target. J Natl Cancer Inst 97 : 790-792, 2005.
PubMed
5) Nahta R, et al : Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65 : 11118-11128, 2005.
PubMed
6) Di Lorenzo G, et al : Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8 : 3438-3444, 2002.
PubMed
7) Craft N, et al : A mechanism for hormone-independent prostate cancer through modulation oi androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 : 280-285, 1999.
 
8) Lara PN, et al : HER-2/neu is overexpressed infrequently in patients with prostate carchoma. Results from the California Cancer Consortium Screening Trial. Cancer 94 : 2584-2589, 2002.
PubMed
9) Ziada A, et al : The use of trastuzumab in the treatment of hormone refractory prostate cmcer : phase II trial. Prostate 60 : 332-337, 2004.
 
10) Canil CM, et al : Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer : a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23 : 455-460, 2005.
 
11) de Bono JS, et al : Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25 : 257-262, 2007.
PubMed
12) Shariat SF, et al : Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22 : 1655-1663, 2004.
PubMed
13) George DJ, et al : Cancer and Leukemia Group B 9480. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7 : 1932-1936, 2001.
 
14) Shariat SF, et al : Preoperative plasma levels of transforming growth factor beta (1) (TGF-beta (1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19 : 2856-2864, 2001.
 
15) Lu T, et al : Secreted transforming growth factor beta2 activates NF-kappa B, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 101 : 7112-7117, 2004.
PubMed
P.626 掲載の参考文献
1) Schuessler WW, et al : Laparoscopic radical prostatectomy : initial short-term experience. Urology 50 : 854-857, 1997.
PubMed
2) Guillonneau B, Vallancien G : Laparoscopic radical prostatectomy : the Montsouris experience. J Urol 163 : 418-422, 2000.
PubMed
3) Paul HA, et al : Development of a surgical robot for cementless total hip arthroplasty. Clin Orthop Relat Res 285 : 57-66, 1992.
PubMed
4) Unger SW, et al : AESOP robotic arm. Surg Endosc 8 : 1131, 1994.
PubMed
5) Pasticier G, et al : Robotically assisted laparoscopic radical prostatectomy : feasibility study in men. Eur Urol 40 : 70-74, 2001.
PubMed
6) Ahlering TE, et al : Robot-assisted versus open radical prostatectomy : acomparison of one surgeon's outcomes. Urology 63 : 819-822, 2004.
 
7) Tewari A, et al : A prospective comparison of radical retropubic and robot-assisted prostatectomy : experience in one institution. BJU Int 92 : 205-210, 2003.
PubMed
8) Guillonneau B, et al : Laparoscopic radical prostatectomy : oncological evaluation after 1,000 cases a Montsouris Institute. J Urol 169 : 1261-1266, 2003.
 
9) Famham SB, et al : Intraoperative blood loss and transfUsion requirements for robotic-assisted radical prostatectomy versus radical retropubic prostatectomy. Urology 67 : 360-363, 2006.
 
10) Hull GW, et al : Cancer control with radical prostatectomy alone in 1, 000 consecutive patients. J Urol 167 : 528-534, 2002.
PubMed
11) Patel VR, et al : Robotic assisted laparoscopic radical prostatectomy : a review of the current state of affairs. Int J Clin Pract 61 : 309-314, 2007.
PubMed
12) Atug F, et al : Positive surgical margins in robotic-assisted radical prostatectomy : impact of leaming curve on oncologic outcomes. Eur Urol 49 : 866-871, 2006.
 
13) Menon M, et al : Potency following robotic radical prostatectomy : a questionnaire based analysis of outcomes after conventional nerve sparing and prostatic fascia sparing techniques. J Urol 174 : 2291-2296, 2005.
PubMed
14) Oguma J, et al : Knot-tying force during suturing and wound healing in the gastrointestinal tract. J Surg Res 140 : 129-134, 2007.
PubMed
P.631 掲載の参考文献
1) 国立がんセンターがん対策情報センター : 地域がん登録全国推計によるがん罹患データ (1975年-2001年). http://ganjoho.ncc.go.jp/professional/statistics/odjrh3000000hwsa-att/cancer_incidence(1975-2001).xls
 
2) 大野ゆう子ほか : 日本のがん罹患の将来推計. がん・統計白書-罹患/死亡/予後-2004 (大島明ほか編), p201-217, 篠原出版新社, 2004.
 
3) Silverstein AD, et al : Cost comparison of radical retropubic and radical perineal prostatectomy : single institution experience. Urology 63 : 746-750, 2004.
PubMed
4) Bruno JJ, et al : Perioperative advantage of radical perineal prostatectomy over radical retropubic prostatectomy. UroOncology 4 : 127-129, 2004.
 
5) Anderson JK, et al : Cost comparison of laparoscopic versus radical retropubic prostatectomy. Urology 66 : 557-560, 2005.
PubMed
6) Mouraviev V, et al : Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer : a single-institution experience. Urology 69 : 311-314, 2007.
PubMed
7) Konski A, et al : Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 106 : 51-57, 2006.
PubMed
8) Neymark N, et al : Estimating survival gain for economic evaluations with survival time as principal endpoint : a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 11 : 233-248, 2002.
PubMed
9) Konski A, et al : Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 66 : 408--415, 2006.
 
10) Makhlouf AA, et al : Perioperative costs and charges of prostate brachytherapy and prostatectomy. Urology 60 : 656-660, 2002.
PubMed
11) Ciezki JP, et al : Cost comparison of radical prostatectomy and transperineal brachytherapy for localized prostate cancer. Urology 55 : 68-72, 2000.
PubMed
12) Hummel S, et al : Clinical and cost-effectiveness of new and emerging technologies for early localized prostate cancer : a systematic review. Health Technol Assess 7 : iii, ix-x, 1-157, 2003.
 

書評

最近チェックした商品履歴

Loading...